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Summary 
Summary 
Results of explanatory research are recorded in this thesis. The thesis 
comprises of five following chapters: 
Chapter 1: Synthesis of pyrazolones and phthalazindiones 
Chapter 2: Synthesis of isoxazole and dihydroisoxazoles 
Chapter 3: Synthesis of oxadiazolthiones, triazo[thiones and triazolothiadiazines 
Chapter 4: Synthesis of hydrazono-isatin and N-methyl isatin derivatives 
Chapter 5: Synthesis of oxazolines and thiazolines 
The research work carried out is based on the synthesis of heterocyclic 
derivatives of selected fatty acids. All the synthesized compounds were characterized 
by IR, i H NMR, 13C NMR and mass spectra (MS). Further, synthesized compounds 
were tested for their biological activities. 
CHAPTER 1: SYNTHESIS OF PYRAZOLONES AND 
PHTHALAZINDIONES 
The novel series of long alkyl, alkenyl and hydroxyalkenyl chain substituted 
derivatives of pyrazolones and phthalazindiones, (26-34) have been synthesized by 
using selected fatty acid hydrazides (21-25), (Scheme 1). Products obtained in good 
yield and purified by column chromatography. 
All the compounds were screened for their in vitro antimicrobial activity against the 
assortment of two gram-positive bacteria, Staphylococcus aurcus SA 22, Bacillus 
subtilis MTCC 121; two gram-negative bacteria, Escherichia coli K12, Pseudomonas 
aeruginosa and fungal strain, Candida albicans LOA 109. All compounds showed 
moderate to good inhibitory activity against the tested organisms but compounds (33 
and 34) were found to be more potent antimicrobial agents. 
[i] 
Summary 
RCONHNH2 
(21-25) 
CH3COCH2CO7 Phthalic anhydride, 
glacial AcOH, E[OH, Reflux 
0 	 0 
 cc:':  Q R—C~ N—ht 	 i—ICI—R \/, CH3 	 NH 
0 
(26-30) 	 (31-34) 
Compound 	 R 
Codes 
21,26  
22, 27, 31  
HE 
23, 28, 32  
5 CH2 
OH 
24, 29, 33  
H2 
25, 30, 34 	 _ 	 H z z 
5 
OH 
Scheme 1: Synthesis of 1,3-disubstituted-1H-pyrazol-5(4H)-ones and 
2-substituted-3H-1,4-phth altizindiones 
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CHAPTER 2: SYNTHESIS OF ISOXAZOLE AND 
DIHYDROISOXAZOLES 
The novel 3,5-disubstituted isoxazole (69) has been synthesized by 1,3-dipolar 
cycloaddition of nitrile oxide to undec-l0-ynoic acid (66), (Scheme 2). Nitrile oxide 
was generated in situ from 1-nitrobutane (67) employing 1,4-phenylene diisocyanate 
(68) as dehydrating agent. Similarly, one-pot synthesis of 3,5-disubstituted-4,5-
dihydroisoxazole (74) and 3,4,5-trisubstituted-4,5-dihydroisoxazoles (75-77) 
possessing ester moiety is reported, (Scheme 3) using in situ generated nitrile oxide 
and fatty acid esters (70-73). All the newly synthesized compounds were purified by 
column chromatography and characterized by spectral data. 
COOH + 	 NO2 + OCN / \ NCO  
(66) 	 (67) 	(68) 
I Et3N, dry THE 
—+ 6 COOH 
mil) 
N 
(69) 
Scheme 2: Synthesis of 3,5-disubstituted isoxazole 
The synthesized compounds (69, 74-77) were screened for their in vitro antibacterial 
activity against different (clinical isolates) bacterial strains by disc diffusion method. 
The susceptibility was assessed on the basis of the diameter of zone of inhibition 
against gram-positive and gram-negative strains of bacteria. Inhibition zones were 
measured and compared with the controls. 
Synthesized compounds (69, 74-77) were also screened for their in vitro antifirngal 
activity against a panel of standard and clinical species of Candida. The results of 
Summary 
antimicrobial screening showed that compounds (76 and 77) exhibit excellent 
antimicrobial activity nearly equivalent to the control compounds. 
H 
 + OCN  	NCO 
/ \ 	 NO2 
Ri 	R2 
(70-73) 	(67) 	I (68) 
Et3N, dry THE 
	
Rs 	Rz 
/0 
N 
(74-77) 
Compound Rl 	 Ry 
Codes 
70, 74 	H 	H2C ' 7 COOCH3 
71,75 	H2C' 	 COOCH3 
HZ 	~ 
72, 76 	s 	 HpC' `~ \COOCH3 
OH 
73, 77 	/ "3 \CH 	
COOCHg 
Z HZ
C~ b 
OH 
Scheme 3: Synthesis of 3,5-disubstituted and 3,4,5-trisubstituted-4,5- 
dihydroisoxazoles 
[iv] 
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CHAPTER 3: SYNTHESIS OF OXADIAZOLTHIONES, 
TRIAZOLTHIONES AND TRIAZOLOTHIADIAZINES 
This chapter deals with the synthesis of long alkenyllhydroxyalkenyl chain substituted 
1,3,4-oxadiazol-2-thione (108-111) and 1,2,4-triazo]-3-thione (112-115) derivatives 
using long alkenyl/hydroxyalkenyl chain hydrazides (22-25) as cheap starting 
material, (Scheme 4). Products were purified by column chromatography and 
characterized by IR, 'H NMR, "C NMR and mass spectral data. 
Compounds (112-115) were transformed into 4-amino-5-long chain 
	
alkenyl/hydroxyalkenyl-6-phenyl-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines 	(116- 
119) derivatives by ring closure reaction using phenacyl bromide as reagent, (Scheme 
5). Structure elucidation of these compounds is based on spectral data. 
RCONHNH2 
(22-25) 	(i) CS2, KOH, EtOH, Stir CS2, KO}i, 	 (ii) Et20, Stir EtOH, Reflux ui) NZH4.2HZ0, Reflux 
N—N N—NH N—N N—NH 
R~ ~SH zS ASH R~ S O 	 O 	 N 	 N 
NH2 	 NH2 
(108-111) (112-115) 
Scheme 4: Synthesis of 5-substituted-1,3-4-oxadiazol-2-thiones and 4-
amino-5-sub stituted-1,2,4-triazol-3-thiones 
[V] 
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N—N 	 N—NH /t 
	
R // 	PhCOCHZBx EtC 
R \N SH 	N 
NH2 	 NH2 
(112-115) 
 
(116-119) 
Scheme 5: Synthesis of 3-substituted-6-phenyl-7H-1,2,4-triazolo[3,4- 
b]-1,3,4-thiadiazines 
Compound 	 R 
Codes 
22,108,112,116  
HE 
23, 109, 113, 117 	1 	- 
's CHz 
OH 
24, 110,114,118 
25, 111, 115,119 	 z 
OH 
Values of R in Scheme 4 and 5 
Furthermore, synthesized compounds were tested for in vitro anticancer activity 
against PBMCs (peripheral blood mononuclear cells) and three different human 
cancer cell lines by MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide] assay. The results of these studies showed that compounds (118 and 119) 
[vi] 
Summary 
were found to be most promising anticancer agents among all the newly synthesized 
compounds. 
CHAPTER 4: SYNTHESIS OF HYDRAZONO-ISATIN AND N- 
METHYL ISATIN DERIVATIVES 
The novel long alkyl, alkenyl, hydroxyalkenyl chain substituted hydrazono-isatin 
(144-148) and N-methyl isatin derivatives (149-153) were achieved by dehydrative 
condensation reaction of isatinlN-methyl isatin with fatty acid hydrazides (21-25) 
using ethanol as solvent containing catalytic amount of glacial acetic acid, (Scheme 
6).t Products were purified by column chromatography. The structures of all the 
newly synthesized compounds were elucidated by spectral data. 
Further, these compounds were evaluated for in vitro cytotoxicity against four 
different human cancer cell lines by MTT assay. Among all the tested compounds, 
compounds (148 and 153) were found to be most potential cytotoxic agents. 
Apoptosis induced by these two compounds was also proved by PAR? [poly(ADP-
ribose)polymerase] cleavage studies done by western blotting technique and FACS 
(fluorescence-activated cell sorting) assay results. 
R-CONHNH2 	+ I ~ 	 O 
(21-25) 
E[OH, Cat. AcOH~ 	 R': H, CH3 
(120,143) 
/ \ NNHCOR 
O 
N 
R' 
(144-153) 
(144-148), R': H; (149-153), R': CH3 
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Compound 	R 
Codes 
21,144,149  
HZ` 	CHZ 
	
22,145, I50 	 ~j~117L 
H F, 
23,146,151 	 5 	s HZ 
OII 
24,147,152 	 - 
3 	 s CHz 
25,148,153 	 — 	HZ 
z 	 s 
OH 
Scheme 6: Synthesis of novel long chain hydrazono-isatin and 1W- 
methyl isatin derivatives 
CHAPTER 5: SYNTHESIS OF OXAZOLINES AND 
TIIIAZOLINES 
The long chain dibromo derivatives (179-182) of fatty acid esters were used as 
starting material and these on reaction with urea and thiourea gave their 
corresponding 2-amino-5-substituted-l,3-oxazoline (183), 2-amino-4,5-disubstihded- 
1,3-oxazolines (184-186) and 2-amino-5-substituted-1,3-thiazoline (187), 2-amino-
4,5-disubstituted-1,3-thiazolines (188-190), respectively, (Scheme 7). Products were 
purified by column chromatography. The newly synthesized compounds were 
characterized on the basis of their spectral data. 
All the newly synthesized compounds were tested for their antimicrobial activity by 
disk diffusion assay and minimum inhibitory concentration (MIC) by broth micro 
dilution method against the representative panel of gram-positive and gram-negative 
bacteria. Also, compounds were tested for their inhibitory action against different 
fungal strains. The investigation of antimicrobial screening revealed that compounds 
[viii] 
Summary 
(185, 186, 189 and 190) were found to be better antimicrobial agents among all the 
synthesized compounds. 
R, CH—CH —R2 
Br Br 
(179-182) 
MCOH, NH2CSNI-I2 
reflux 
R1 
N 
` 	R, 
HZN 	0 
(183-186) (187-190) 
	
Compound 	R1 	R2 
Codes 
179,183,187 	lI 
HZC 	7 COOCH3 
180,184,188 	G 'CHZ 	H2C 	6 COOCH3 
H ~ 
181,185,189 	s 	Z 	H2C' ~~>000CH3 
OH 
182, 186, 190 	 COOCH3 3 CHZ HZC
~
OH 
Scheme 7: Synthesis of 2-amino-5-substituted and 2-amino-4,5- 
disubstituted oxazolines and thiazolines 
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introduction 
Introduction: 
Heterocycles comprise the major classical divisions of organic chemistry. These 
are extremely important with broad spectrum of synthetic, industrial and 
pharmaceutical applications. Compounds containing five and six membered 
heterocyclic rings in their structures possess wide range of biological activities. 
Bearing in mind the high drug-like properties of these heterocycles, medicinal 
chemists and organic chemists synthesize a large number of chemotherapeutic agents. 
In addition, most potent natural compounds, the alkaloids, arc heterocycles. 
Heterocycles are the key components of biological molecules e.g. DNA and RNA. 
Nucleotides are the building blocks of our genes and these are the derivatives of 
pyrimidines (cytosine, thymine, uracil) and purine (adenine, guanine). Pyrimidine and 
purine derivatives are monocyclic with two nitrogen containing and bicyclic four 
nitrogen containing heterocycles and they directly participate in genetic information 
encoding.. Chlorophyll and heme (oxygen carriers in plants and animals, respectively) 
are the derivatives of large porphyrin rings. Many essential amino acids (proline, 
histamine,itryptophan), hormones (kinetin, heteroauxins, cytokinins), neurotransmitter 
(serotonin)histamine) are also heterocycles. Vitamin B series (thiamine, folic acid, 
riboflavin, cyanocobalamine) are nitrogen containing heterocycles while vitamin C 
(ascorbic acid) and vitamin E (a-tocopherol) are oxygen containing heterocycles. 
The presence of sulfur, nitrogen and oxygen containing heterocycles in many 
organic compounds in pharmacology, electronics, biology, cosmetics, optics, material 
sciences, electronics, etc is very familiar. Many natural drugs (e.g. theophylline, 
atropine, etc); some dyes (e.g. mauveine), pesticides (e.g. diazinon), lumniphores (e.g. 
acridine orange) are heterocyclic in nature. Large number of synthetic heterocyclic 
compounds with important applications such as herbicides, anticorrosive agents, 
photostabilizers, agrochemicals, dyestuff, copolymer, photographic developers, 
fluorescent whiteners, sensitizers, flavouring agent and antioxidant in rubber. They 
also possess broad spectrum of therapeutic uses such as analgesic, antiinflammatory, 
muscle relaxant, antimicrobial, antimycobacterial, trypanocidal, anti HIV activity, 
antitumoral, insecticidal, antimalarial, anticancer, anticonvulsant, lipid peroxidation 
inhibitor, hypnotics, antidepressant, antileishmanial agents, etc. 
[1] 
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In the human body, all these natural and synthetic heterocyclic compounds such 
as serotonin, ATP, nucleic acids, vitamins, enzymes, co-enzymes participates in 
principle life processes such as supply of energy, metabolism, hereditary information 
transfer and nerve impulses transmission. Heterocycles are able to get involved in an 
exceptionally wide range of reaction types. They may behave as acids or bases by 
forming anions or cations depending on the pH of the medium. Some heterocycles are 
amphoteric in nature; some interact readily with electrophilic reagents while some 
react easily with nucleophilic reagents. Some are easily reduced, but resist oxidation, 
while others readily oxidized but are stable toward the action of reducing agents. 
Electronic distributions are the main reason for such versatile reactivity in 
heterocyclic molecules. 
Globally oils and fats are important raw materials for chemical industry. In 
several institutions and industries, oleochetnistry has grown a major research and 
technology division. Huge variety of products which include specialties for polymer 
applications, biodiesel, emollients for home and personal care industries, pesticides 
and biodegradable mineral oil replacements for lubricants are based on oils and fats. 
The dicarboxylic acids are industrially produced either by dimerization of oleic 
acid and linoleic acid or by ozonolysis of oleic acid to produce azelaic acid. 
Surfactants and emulsifiers are also derived from vegetable oil-based fatty alcohols 
and fatty acids. Surfactants show important applications in food sector, in mining and 
in crop protection. 
Apart from this they also show important applications in washing and cleansing 
sector, textile treatment and in cosmetics. Fatty acid derivatives of proteins and amino 
acids found significant importance in the personal care market. These are mainly used 
in surfactant based face cleansers, mild shower and bath products, cold-wave 
preparations and fixatives, mild shampoos, body wash products and in emulsifiers for 
leave-on products. Besides food uses, oils and fats have found their way into 
agrochemicals and industrial products such as plastics, inks, adhesives, coatings, 
pharmaceuticals, etc. 
In the field of lubricants, environmental and economic reasons lead to the 
utilization of plant oils and animal fats after proper chemical modification. 
Oleochemicals are more favorable than mineral oil because they are renewable, 
[2] 
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biodegradable, non-flammable, readily available all around the world and cause fewer 
health problems and allergies to the end users. Products formed from plant oils and 
animal fats are often biodegradable because of their biobased nature. Biodegradable 
fatty acid esters found applications in chain saw oil, gearbox oil, hydraulic oil and 
lubricants for off-shore crude oil exploration. OLeic acids are highly desired 
components in vegetable oils (VOs) for lubricant application because of high thermal 
stability than polyunsaturated fats. For industrial, agriculture and farming 
applications, this biobased grease with high oxidative stability can be prepared by 
using epoxy VOs. In addition, this biobased grease have better properties than mineral 
oil-based grease such as effective lubrication, wear protection, corrosion resistance, 
friction reduction, heat removal, etc. 
Literature survey reveals that long fatty acid chains substituted on heterocyclic 
rings are rare in nature. By doing the modification and derivatization of functional 
groups (i.e. terminal and internal double bond and carboxylic acid) present in the fatty 
acid chain, number of industrially useful and biologically active compounds can be 
synthesized which will be a valuable addition to the synthetic methodology available 
for the synthesis of hetero-fatty acid derivatives. 
Bearing in mind the aforementioned facts and importance of heterocycles and 
fatty acids, number of heterocyclic fatty acid analogs (hetero-fatty acids) have been 
synthesized from saturated, unsaturated (terminal and internal) and hydroxy 
unsaturated fatty acids. Further, these compounds were screened for their in vitro 
antimicrobial activity and in vitro anticancer activity. From these studies, it is 
understandable that further derivatization and heterocyclization of these hetero-
analogs of fatty acids can be served as new template for antimicrobial and anticancer 
drug discovery and could be probably leads to more potent agents in this area. 
Whole work done of this research is divided into five chapters and these are as 
follows: 
Chapter 1: Synthesis of pyrazolones and phthalazindiones 
Chapter 2: Synthesis of isoxazole and dihydroisoxazoles 
Chapter 3: Synthesis of oxadiazolthiones, triazolthiones and triazolothiadiazines 
Chapter 4: Synthesis of hydrazono-isatin and N-methyl isatin derivatives 
Chapter 5: Synthesis of oxazolines and thiazolines 
f3] 
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1.1. Theoretical 
Pyrazolone is a five membered ring lactam. It is a derivative of pyrazole with 
additional keto group. There are two possible isomers: 3-pyrazolone (1) and 5-
pyrazolone (2). Phthalhydrazidel2,3-dihydrophthala2in-1,4-dione (3) is 1,4-diketo 
derivative of tetrcrhydrophthalazine. 
(1) 	 (2) 
A variety of methods for the synthesis of pyrazolones and phthalazin-1,4-diones have 
been reported earlier A and some of them are shown here. Dohutia e1 at 5 synthesized 
3-methyl-5-pyrazolone derivative by the reaction of ethyl acetoacetate and hydrazine 
hydrate. Compound (4) reacted with hydrazine and phenyl hydrazine to give 4-[2-(1-
adamantyl)-2-oxoethyl]-3-methyl-4,5-dihydro-lH-pyrazol-5-onesb (5). 
JHNH2 
(4) 
 
 
tJ) Li.; n, ru 	 R 
Ojha et a1.' also reported the synthesis of 2-isonicotinoyl-5-methyl-2,4-dihydro-3H-
pyrazol-3-one (8) by the reaction of isoniazid (isonicotinic acid hydrazide) (6) and 
ethyl acetoacetate (7) in absolute ethanol. 
[4] 
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0 
N\ ! INHNHZ 
/ (6) 
+ 	Absolute,, 
CH3COCH2COOEt 
(7) 
Me 
(8) 
 
Abubshaits showed the synthesis of 3-(cyanomethyl)-carbonyl-phthalazin-1,4-dione 
(11) by the reaction of cyanoacetic acid hydrazide (9) with phthalic anhydride (10) in 
ethanol under reflex condition. 
NCCH2CNHNHZ + 
0 
(9) 	 (10) 
Khalil et at9 reported the synthesis of phthalazindione derivatives (14) by the reaction 
of dibenzobarellene adduct (12) and aromatic acid hydrazides (13) in 
dimethylformamide (DMF). 
	
0 	 0 
COAr 
Cage 	O + ArCONHNHZ DNW 	N 
NH 	~ l 
(12) O 	(13) 	 (14) 	 ~. 
0 Cage= 
Ar: 2-OHC6H4, 4-CIC6H4, 4-pyridyl 	/ 
[5] 
(16) 
(15) 
1Pyrazo(ones and phthafazindtones 
Nowadays, human beings are totally dependent on the medicines derived from 
heterocyclic rings. In many pharmaceutically active compounds heterocyclic rings are 
found, so heterocycles and medicines both are interrelated. The phthalazine nucleus 
has also very marked pharmacological and biological applications due to its 
antituznor10, antihypertensive I, antithrombotic 2, antidiabetic13 and antiinflanamatory5 
activities. Pyrazole ring represents an interesting template for medicinal and 
combinatorial chemistry" because they play key role in biologically active 
compounds. Indeed, several pyrazole derivatives have been reported to possess 
antimicrobials, antiviral 'b, antiandrogenic17, analgesic1e, antiinflammatory 9 , 
antidiabetic3° and antioxidant21 properties. Pyrazole and pyrazolone derivatives were 
also reported21 to possess antiinflammatory, postmenopausal, osteoporosis, 
antagonists, anticoagulants and angiotensin activities. In drug molecules such as 
celccoxib23 (15), pyrazofurinc24 (16) and many others, the pyrazole ring is the key 
moiety. 
Literature survey also reveals that (Z)-4-(4-hydroxy-3-methoxybenzylidene)-1-(3-
nitrophenyl)-3-phenyl-]H-pyrazol-5(4I-I)-one (17) (a pyrazolone derivative) was 
found to be non-steroidal Famesoid X Receptor (FXR) selective antagonist25 . 
Azclastine (18) is a potent, second-generation, selective histamine antagonist 
(histamine-Hi-receptor antagonist) and it is a member of phthalazinone family, it 
shows relevant bronchodilatory activity used for treatment of asthma2" and has also 
been reported to induce vasorelaxation in vitro assays28. 
[6] 
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:N %A  
(18) 
Commercially available drug, hydralazine (19), is one of the first antihypertensive 
drugs developed in 1950s and due to its vasodilator action it is considered as lead for 
introducing new drugs. Hydralazine belongs to phthalazine drug family and directly 
act as smooth muscle relaxant used to treat hypertension by acting as a 
vasodilator in arteries and arterioles. Slight change in the structure of hydralazine led 
to discovery of some phthalazine derivatives which were found to possess 
antiparasitic, antifunga1, antimicrobial, antipsychotic, antineoplastic activities39. Well 
known HAV 3C inhibitor (20) is also a phthalazindione derivative which has been 
found to possess inhibitory properties against hepatitis A virus 3C proteinaseJO. 
[7] 
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Pyrazolo[1,2-blphthalazindione derivatives were reported' as antiinflammatory, 
analgesic, antihypoxic and antipyretic agents. Literature survey showed that the 
structure of some drugs which are mainly based on pyrazole, pyrazolone, phthalazine 
and phthalazinone, phthalazindione nuclei (15-20) are closely related to the structure 
of the target compounds i.e. 1,3-disubstituted-1H-pyrazol-5(4H)-one and 2-
substituted-3H-1,4-phthalazindione fatty acid analogs. 
[8] 
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1.2. Synthesis and In Vitro Antimicrobial Screening of Fatty 
Pyrazolones and Phthalazin-1,4-diones*  
Compounds substituted with long alkyllalkenyllhydroxyalkenyl carboxylic acid 
chains are found to be pharmacologically active antimicrobial agents32 and these are 
also useful in the treatment of renal, cardiovascular and hepatic disorders". Also, 
some fatty acid derivatives have been found to possess antitumor activity and 
antidepressant activity34' 35.  Vital utility range of pyrazolones and phthalazindiones, 
fascinating properties of fatty acids and in continuation of our laboratory work in 
derivatization and heterocyclization of selected fatty acids3639 enthused us to 
synthesize novel series of 1,3-disubstituted-lH-pyrazol-5(4H)-one and 2-substituted-
3H-1,4-phthalazindione fatty acid analogs using selected long 
alky1/aIkenyl/hydroxyalkenyl chain hydrazides as starting materials. Furthermore, this 
synthetic methodology involves the use of cheap and readily available solvents and 
commercially available reagents, giving the desired products in good to excellent 
yield. 
1.3. Results and discussion 
1.3.1. Chemistry 
The present study is based on the synthesis and characterization of two novel series of 
pyrazolone and phthalazindione derivatives of long chain fatty acids. The reaction 
sequences leading to the formation of these two novel series of compounds are 
outlined in Scheme 1 and physiochemical parameters of all the newly synthesized 
compounds are tabulated in the Table 1. 
•Research paper entitled "Synthesis, biological screening of novel long chain derivatives of 
1,3-disubstituted-IH-pyrazoi-5(411)-one 	and 	2-substituted-3H-phthalazin-1,4-dione: 
Structure-activity relationship studies" is in press. (Aiman Ahmad, Varshney, H., Rauf, A., 
Husain, F.M., Abmad, I., 2013. J. King Saud Univ. — Sct, 
http://dx.doi.org/10.1016/j.jksus.2013.09.003) 
[9] 
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RCONHNH, 
(21-25) 
CH3COCH2COOC2H5 	Phthalic anhydride, 
glacial AcOH, EtOH, Reflux 
O 0 
R— C —N—N 	 II i —C—R 
CH3 	 NH 
0 
(26-30) 	 (31-34) 
Compound 	 R 
Codes 
21,26  
22,27,31 	Hz 	 HZ 
HE  
23, 28, 32 	 - 
CHp 
OH 
24, 29, 33 	 _ 
25, 30, 34 	 — 	 H 2 
OH 
Scheme 1: Synthesis of 1,3-disubstituted-1H-pyrazol-5(4H)-ones and 
2-substituted-3H-1,4-phth alazindio nes 
[10] 
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The fatty acid hydrazides (21-25) were used as the starting material and they were 
synthesized from corresponding fatty acids40. The derivatives of 1,3-disubstituted-1H-
pyrazol-5(4H)-ones (26-30) were synthesized by the condensation of long chain alkyl, 
alkenyl (internal and terminal) and hydroxyalkenyl carboxylic acid hydrazides (21-
25) with ethyl acetoacetate, followed by cyclization. The synthesized compounds 
were identified on the basis of IR, 'H NMR, 13C NMR and MS. The structure of 
compound (27) was confirmed by the appearance of absorption band at 1603 cm ' due 
to C=N stretch. Another absorption band for C=O was observed at 1698 cm 1. The 'H 
NMR spectrum was more informative in assigning the structure. In addition to peaks 
of fatty acid chain, the singlet at 54.18 for two protons of pyrazolone ring CH2 was 
observed and a singlet at 61.57 for CHI protons which is directly attached to the ring. 
In "C NMR, peaks at 5178.6, 5130.2, 550.8 were observed. Further evidence was 
obtained by recording mass spectrum. The mass spectrum showed characteristic 
molecular ion peak which were in accordance with the molecular formula. Similar 
type of spectral data was obtained for compounds (26, 28, 29 and 30). 
The other novel series of 2-substituted-3H-1,4-phthalazindione derivatives (31-34) 
were synthesized by the condensation of long chain alkenyl (internal and terminal) 
and hydroxyalkenyl carboxylic acid hydrazides (22-25) with phthalic anhydride in 
ethanol and catalytic amount of glacial acetic acid was used. Products were in form of 
white powder. All the newly synthesized compounds were characterized on the basis 
of IR, 'H NMR, 13C NMR and MS. Compound (31) showed IR absorption bands at 
3228 ctn' for N-H stretch, at 2925 cm' for C-H stretch and at 1599 cm' for CO 
stretch. The 'H NMR showed a singlet at 68.01 corresponding to N-H proton. Also a 
multiplet at 67.74-7.89 was observed for four aromatic protons. In "C NMR, peaks at 
5171.8, 5165.3, 6139.2, 8134.7, 5130.9, 6129.1, 5128.4, and 5127.1 were observed. 
The mass spectrum showed characteristic molecular ion peak which were in 
accordance with the molecular formula. Similar type of spectral data was obtained for 
compounds (32, 33 and 34). 
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Table 1: Structure and physico-chcmical parameters of all newly 
synthesized compounds 
Compound 
Codes 
Compound structures Molecular 	Molecular 
Formula 	Weight 
Physical 	M.P. 	%Yield 
State 
0 
26 0—x _u Q0FR602Nz 	336.49 Colorless 	_ 75 
o~cx, 
oily 
0  
27 2 N , 	 urc—v—x 
~ 
C11HZ40,N2 	26432 . Colorless 	_ 
74 
oily cx 
28 II  N—; 
o 	~ CuH3sO2N2 	362.48 Reddish brown 	- 70 
oily 
on 
29 II II 1C 	N— C22H3 O3N2 	378.48 Reddish brown 	- 71 
~ 	
11 
oily 
n 
30 N-C—N—NL 
G zH3p03NZ 	378.48 brown 	- 73  
OH 
Reddish 
 O C H Is u 	3N z 328.36 pe 	35-87 85 
31 	x'  Poowwder 
32 
CzsHze03NZ 	4262 White 	91-92 82 
° powder 
ox 
33 	s 	rtrn 	LMH3,04Ni 442.52 White 	70-72 70 
powder 
0 
C H ON 34 	 rx 	zb se a z 442.52 White 	74-76 	74 — 	 11 	~ 	 powder 
° o 
Oh 
[12] 
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1-.3.2. Biology 
1.3.2.1. Antimicrobial studies 
All the newly synthesized compounds were assessed in vitro antibacterial activity 
against an assortment of two gram-positive bacteria, Staphylococcus aureus SA 22, 
Bacillus subtilis MTCC 121, and two gram-negative bacteria, Escherichia coli K12, 
Pseudomonas aeruginosa. Doxycycline was used as standard drug for the comparison 
of the antibacterial activity results. The in vitro antimicrobial screening results are 
given in Table 2. Graphic representation of the biological screening results is 
depicted in Figure 1(A-E) in terms of diameter of zone inhibition (in mm). The newly 
synthesized compounds (26-34) have exerted significant inhibitory activity against the 
growth of the tested bacterial strains. The antibacterial screening results showed that 
among the tested bacterial strains, good inhibitory results were obtained against E. 
coli and P. aeruginosa as depicted in Figure 1(C) and 1(D). Among the tested 
compounds, compounds (33 and 34) showed more potent inhibitory activity against 
both types of bacteria. However, depending on the nature of heterocyclic moiety 
(phthalazindione/pyrazolone) and substituents (long alkanoyl/alkenoyl/hydroxy 
alkenoyl chains) attached to it exerted varying inhibitory actions. In another set of 
experiments, all the newly synthesized compounds (26-34) were also screened for in 
vitro antifungal activity against Candida albicans IOA 109. Nystatin was used as 
standard drug for the comparison of the antifungal results. The synthesized 
compounds showed moderate to excellent inhibitory results for C. albicans as seen in 
Figure 1(E). 
[13] 
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Table 2: In vitro antimicrobial screening data of the synthesized 
compounds 
Compound Concentration BS" 	SA 	EC` 	PA 	CA" 
Codes 	(pg/mL) 
26 400 - - 10 11 - 
800 - - 14 17 13 
27 400 - - 14 16 11 
800 15 14 22 19 16 
28 400 - - 13 13 10 
800 - - 17 19 14 
29 400 11 10 15 15 14 
800 13 13 22 21 18 
30 400 10 11 13 13 13 
800 13 14 19 20 17 
31 400 - - 14 13 11 
800 11 13 20 16 17 
32 400 - - 14 - 10 
800 - - 19 14 15 
33 400 13 11 18 14 13 
800 17 15 22 24 19 
34 400 11 11 15 15 14 
800 16 15 23 22 20 
Doxycycline 30 (µg/disc) 20 18 23 21 - 
Nystatin 30 (pg/disc) - - - - 18 
"BS: Bacillus subtilis, "'SA: Staphylococcus aureus, "EC: Escherichia coli, °SPA: 
Pseudomonas aeruginosa, e1CA: Candida albicans. 
[I 4] 
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Figure 1(A-E): Graphic representation of the antimicrobial 
screening results of all the newly synthesized compounds (26-34) 
in terms of diameter of inhibition zone (in mm) against various 
microbial strains. Fig. 1(A-D) shows the antibacterial activity against Bacillus 
sub/ills, Staphylococcus aureus, Escherichia coil and Pseudomonas aeruginosa, 
respectively, standard used was Doxycycline. Fig. 1(E) shows the antifungal 
activity against Candida albicans, standard used was Nystatin. 
[16] 
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1.33. Structure-activity relationship (SAR) studies 
The structure-activity studies showed that depending on the nature of heterocyclic 
skeleton and its substituent, the newly synthesized compounds (26-34) exhibit varying 
degree of microbial inhibition. From the antimicrobial screening results, it has been 
found that the phthalazindione derivatives (31-34) have shown better activity as 
compared to their corresponding pyrazolone derivatives (26-34). Within the same 
heterocyclic series that is either in phthalazindione derivatives or in pyrazolone 
derivatives, the inhibitory activity depends on the nature of substituents attached to 
them. The in vitro biological screening indicated that the presence of the hydroxy 
substituents attached to the heterocyclic moiety as in compounds (29, 30, 33 and 34) 
increased their inhibitory activities compared to other compounds. Structure-activity 
relationship. (SAR) studies cleared that, compounds with terminal alkenoyl substituent 
(27 and 31) and smaller carbon chain (Clo) have better inhibitory activity as compared 
to compounds (28 and 32) which were having internal alkenoyl substituent and longer 
carbon chain (C17). Further, SAR studies shows that heterocyclic moiety having 
alkanoyl substituent (26) which was analog of saturated fatty acid and having long 
carbon atom chain ((215) showed very small inhibitory results. 
The values of diameter of zone of inhibition (in mm) for all the newly synthesized 
compounds are pictorially represented in graphical form in Figure 1(A-E) against 
Bacillus subtilis, Staphylococcus aureus, Escherichia toll, Pseudomonas aeruginosa 
and Candida albicans, respectively. The maximum inhibition was observed in 
phthalazindione derivatives substituted with hydroxy substituent (i.e. 33 and 34) 
against P. aeruginosa with zone diameter of 14 and 15 mm, respectively (at 400 
µg/mL concentration) and also with zone diameter of 24 and 22 mm, respectively (at 
800 tglmL concentartion) as seen in Figure 1(D). These compounds (33 and 34) also 
shows good inhibitory against E. colt with zone diameter of 18 and 15 mm, 
respectively (at 400 pg/mL concentration) and with inhibition zone diameter of 22 
and 23 mm, respectively (at 800 xg/mL concentartion) as depicted in Figure 1(C). 
Hence, higher activity of compounds (29, 30, 33 and 34) may be attributed to the 
presence of hydroxy substituents. Also, the synthesized compounds with 
phthalazindione rings substituted with hydroxyl group (33 and 34) shows excellent 
activity as compared to pyrazolone rings substituted with hydroxyl group (29 and 30). 
(17] 
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Thus, the nature of substituents and the heterocyclic skeleton of molecules have 
strong influence on the extent of antibacterial and antifungal activities. 
1.3.4. Conclusion 
To the best of our knowledge these alkanoyilalkenoyllhydroxyalkenoyl pyrazolone 
and phthalazindione derivatives of some selected fatty acids have been synthesized 
for the first time. The salient features of these procedures includes mild reaction 
conditions, use of inexpensive reagents and starting material, products were obtained 
in good to excellent yields. The structure-activity studies showed that depending on 
the nature of heterocyclic skeleton and its substituent, the newly synthesized 
compounds (26-34) may exhibit varying degree of microbial inhibition. The in vitro 
biological screening results showed that compounds having hydroxy substituent 
attached to the heterocyclic moiety (29, 30, 33 and 34) were the most promising 
antimicrobial agents. The maximum inhibition was observed in phthalazindione 
derivatives substituted with hydroxy substituent (33 and 34). The synthesis will be a 
valuable addition to the synthetic methodology available for synthesis of heterocyclic 
derivatives of fatty acids which are useful biologically as well as industrially. From 
these studies it is understandable that further derivatization and heterocyclization of 
these hetero-analogs of fatty acids can be served as new template for antimicrobial 
drug discovery and could be probably leads to more potent agents in this field. 
[1 8] 
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1.4. Experimental 
1.4.1. Chemistry 
Physical and spectroscopic measurements 
(9Z, 12R)-12-Hydroxyoctadec-9-enoic and (9R, 12Z)-9-hydroxyoctadec-12-enoic 
acids were isolated from Ricinus communis and Wrighda tinctoria seed oils 
respectively following Gunstone's partition]. Undec-l0-enoic acid (Purity 98%), (Z)-
octadec-9-enoic acid (97%) and palmatic acid were purchased from Fluka Chemicals 
(Buck Switzerland). Ethylacetoacetate and phthalic anhydride were purchased from 
Merck, Mumbai, India. Thin layer chromatography (TLC) was done on glass plated 
with a layer of silica gel G (Merck, Mumbai, India 0.5 mm thickness). Column 
chromatography was carried out on silica gel (Merck, Mumbai, India, 60-120 mesh). 
IR spectra were recorded on Shimadzu 8201 PC spectrometer and absorption given in 
cm-'. 'H NMR and 13C NMR were recorded in CDCI3 on a Bruker DRX-400 
instrument. The chemical shifts (6) were measured relative to TMS as an internal 
standard and quoted in ppm. Coupling constants (J) are expressed in Hertz (Hz). The 
mass spectra were recorded on JEOL-SX 102/DA-600 mass spectrometer. 
Synthesis oft,3-disubstituted-1Hpyrazol-5(4H)-+rues, (26-30) 
Fatty acid hydrazides (21-25) previously synthesized in our laboratory40 was used as 
the starting material. A mixture of 0.01 mole of fatty acid hydrazides (21-25) and 0.1 
mole (13 mL) of ethyl acetoacetate were heated on paraffin bath. After sometime the 
reaction mixture turned into reddish oily syrup. The reaction was continued till all the 
reactants were consumed. After completion of the reaction, the reaction mixture was 
cooled and worked up with dichloromethane and water. The dichloromethane layer is 
dried over anhydrous sodium sulfate and excess solvent was removed on water bath. 
Product was purified by column chromatography. All the products were oily in nature 
and were elucidated on the basis of their spectral data. 
[ 19] 
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The spectroscopic data for the synthesized compounds (26-30) are presented below: 
1-(Hexadecanoyl)-3-arethyl-IHpyrazol-5(4H)-one, (26) 
IR (KRr, cm-'): 2920 (C-H stretching), 1680 (C=0 stretching), 1592 (C=N 
stretching). 
IIKNMR (CDC13, Sa):  4.12 (2H, s, CH2 ring), 2.25 (2H, t, J= 7.59 Hz, CH2CO), 1.95 
(2H, m, CH2CH2CO), 1.56 (3H, s, CH3 ring), 1.22 (24H, br.s, (CH2)12  chain), 0.85 
(3H, dist.t, CH3). 
'3C NMR (CDCI3, Sr): 176.9, 165.4, 127.9, 45.8, 35.6, 33.8, 33.7, 32.9, 31.8, 31.2, 
30.0, 29.9, 29.8, 29.7, 27.4, 27.0, 25.4, 23.8, 22.8, 14.09. 
MS (ESI): m/z = 359.500 found [M+Na]`, calculated [M+Na]+ — 401.470. 
1-(Undec-10'-enoyl)-3-methyl-1Hpyrazol-5(411)-one, (27) 
IR (KB,-, cm'): 2932 (C-H stretching), 1698 (C-0 stretching), 1603 (C=N 
stretching). 
1H NMR (CDCI3, bit): 5.82 (1H, tdd, j , H = 6.50 Hz, j„ = 10.30 Hz, Je_N  
17.10 Hz, CHZ=CH), 5.01 (1H, dd, J„ 	= 10.30 Hz, .t„ 4, = 2.00 Hz, HZC=CH), 
4.91 (1H, dd, r„  = 16.90 Hz, J„ 	= 2.00 Hz, HEC=CH), 4.18 (2H, s, CFI2 ring), 
2.51 (2H, t, J = 7.38 Hz, CII2CO), 2.06 (2H, m, CHi--CH-CH2), 1.71 (2H, m, 
CH2CH2CO), 1.57 (3H, s, CH3), 1.25 (10H, br.s, CH2(CH2)5). 
13CNMR (CDCI3, Sd: 178.6, 174.0, 130.2, 130.0, 129.9, 50.8, 34.4, 33.9, 31.9, 30.8, 
30.1, 29.7, 27.1, 24.2,18.0. 
MS (ESI): m/z = 287.121 found [M+Na]t , calculated [M+Na]t  = 287.310. 
[20] 
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1-f(9'Z) (Octadec-9'-enoyl)J-3-methyl-IH pyrazol-5(4H)-one, (28) 
IR (KBr, c»'): 2924 (C-H stretching), 1700 (C=O stretching), 1598 (C=N 
stretching). 
IHNMR (CDC/3, Be): 5.35 (2H, in, CH=CH), 4.20 (2H, s, CH2 ring), 2.36 (2H, t, J= 
7.52 Hz, CH2CO), 2.24 (4H, m, CHZCH CHCH2), 2.00 (2H, m, CHhCHZCO), 1.61 
(3H, s, CH,), 1.25 (20H, br.s, (CH2)10), 0.88 (3H, dist.t, CH3). 
'3CNMR (CDC13, 3J: 180.1, 165.8, 127.2, 123.1, 122.9, 48.1, 35.0, 33.1, 31.9, 30.0, 
29.7, 29.6,29.4,29.3, 29.2, 29.1, 27.1, 25.3, 25.0, 24.7, 14.2, 14.1. 
MS (ES!): m/z = 385.381 found [M+Na]', calculated [M+Na]` = 385.471. 
1((9'Z, 12'R)-12'-Hydroxyoctadec-9'-enoylJ-3-metkyl-Ifipyrazol-5(4H)-one, (29) 
IR (KBr, cm'): 3400 (0-H stretching), 2929 (C-H stretching), 1685 (CO stretching), 
1579 (C=N stretching). 
'HNMR (CDCl3. d,1): 5.34 (2H, m, CH=CH), 4.87 (1 H, m, CROH), 4.11 (2H, s, CH2 
ring), 2.27 (2H, t, J = 7.47 Hz, CH2CO), 2.21 (1H, m, CHOH), 1.96 (4H, m, 
CH,CH=CHCH2), 1.85 (2H, m, CH2CH2CO), 1.55 (3H, s, CIf3 ring), 1.21 (18H, br.s, 
(Cfl2)9), 0.80 (3H, dist.t, CH3). 
'-'CNMR (CDC13, 3d: 182.9, 173.9, 133.2, 132.8, 123.8, 72.0, 50.1, 37.4, 36.7, 34.3, 
31.9, 31.7, 30.1, 29.6, 29.5, 29.1, 28.9, 27.3, 25.6, 24.9, 15.9, 14.1. 
MS (ES!): m/z = 401.299 found [M+Na]`, calculated [M+Na]+ = 401.470. 
I-((9'R, 12'Z)-9'-Hydroxyoctadee-12'enoylJ-3-metltyl-IHpyrazol-5(4H)-one, (30) 
IR (KBr, cm '): 3391 (0-H stretching), 2933 (C-H stretching), 1680 (CO stretching), 
1570 (C=N stretching). 
[21] 
Pyrazolones antpktfafazindiones 
'HNMR (CDC13, 4zu: 5.35 (2H, m, CH=CH), 4.86 (IH, m, CHOH), 4.13 (2H, s, CH2 
ring), 2.25 (2H, t, J = 7.50 Hz, CH2CO), 2.19 (IH, m, CHOH), 1.95 (4H, m, 
CH2CH=CHCH2), 1.86 (2H, in, CH2CH2CO), 1.53 (3H, s, CH3 ring), 1.23 (18H, br.s, 
(CFI2)9), 0.82 (3H, dist.t, CHI). 
13CNMR (CDC1, 5c): 181.9, 176.9, 133.1, 132.5, 123.0, 72.9, 50.4, 38.4, 37.7, 33.3, 
31.8, 31.7, 30.2, 29.5, 29.2, 29.0, 28.6, 27.1, 25.7, 24.6, 15.9, 14.3. 
MS (ES!): m/z = 401.302 found [M-I-Na]`, calculated [M+Na]+ = 401.470. 
Synthesis of 2-substiluted-3H-1,4 phtlialazindiones, (31-34) 
0.1 Mole of fatty acid hydraxides (22-25) and 0.1 mole of phthalic anhydride in 
ethanol (5 mL) were taken in a round bottom flask and 0.005 mole of glacial acetic 
acid was added. Reaction mixture was refluxed for 10-12 hours, and then poured into 
crushed ice, a solid product was precipitated out which was washed with cold ethanol 
and then air dried. All the products were in the form of white powder and were 
elucidated on the basis of their spectral data. 
The spectroscopic data for the synthesized compounds (31-34) are presented below: 
2-(undee-10'-enoyl)-3H-1,4 phthalazindione, (31) 
IR (KBr. em'): 3228 (N-H stretching), 2925 (C-H stretching), 1599 (C=O stretching). 
'H NMR (CDC13, 6x): 8.01 (1H, s, NH), 7.74-7.89 (4H, m, ArH), 5.80 (1H, tdd, 
6.71 HZ, J„-N = 10.90 Hz, J,-', = 16.82 Hz, CH2=CH), 5.01 (1H, dd, 
J~ _y = 10.11 Hz, j,,,, = 2.20 Hz, HzC=CH), 4.93 (1H, dd, J„ _„ = 17.45 Hz, j77 
= 2,20 Hz, HEC=CH), 2.39 (2H, t, J = 7.50 Hz, CF12CO), 2.03 (2H, m, CH2=CH-
C112), 1.70 (2H, m, CFI2CH2CO), 1.28 (10H, br.s, CH2(CN2)5). 
'3CNMR (CDCh, a&: 175.1, 171.8, 165.3, 139.2, 134.7, 130.9, 129.1, 128.4, 127.1, 
124.0, 114.1, 33.9, 33.8, 29.3, 29.2, 29.0, 28.9, "one signal hidden", 25.1. 
[22] 
ctyrazotottes and phthalazindiones 
MS (ESI): m/z = 351.333 found [M+Na]4, calculated [M+Na]+ = 351.353. 
2-[(Z)-Octadec9'-enoyl]-311-1,4pkthalazindione, (32) 
IR (KBr, cm"): 3232 (N-H stretching), 2922 (C-H stretching), 1594 (C=O stretching). 
tH NMR'(CDC13, Sy): 8.36 (1H, s, NH), 7.77-7.92 (4H, m, ArH), 5.34 (2H, m, 
CH=CH), 2.41 (2H, t, J = 7.40 Hz, CH2CO), 2.22 (4H, m, CH2CH=CHCH2), 1.70 
(2H, m, CH2CH2CO), 1.29 (20H, br.s, (CH2)1o),  0.87 (3H, dist.t, CH3). 
r3CNMR (CDCI4, Ed: 174.8, 170.1, 167.2, 138.1, 134.9, 133.5, 131.9, 128.1, 127.7, 
118.4, 115.6, 36.6, 34.2, 31.5, 31.2, 30.5, "two signals hidden", 29.5, 29.2, 29.0, 28.7, 
27.5, 26.2, 24.1, 14.1. 
MS (ES!): m/z = 449.500 found [M+Na]', calculated [M+Na]+ = 449.5 10. 
2 /(9B, 12'R)-12'-Hydroxyoctadec-9'-enoylj-3H-1,4 phHilazindione, (33) 
IR (KBr, cm'): 3392 (0-H stretching), 3227 (N-H stretching), 2921 (C-H stretching), 
1585 (CO stretching). 
I H NMR (CDC13, 6,d: 8.41 (1H, s, Na 7.34-7.67 (4H, m, ArH), 5.50 (2H, m, 
CH=CH), 4.21 (IH, m, CHOH), 2.54 (2H, t, J 7.79 Hz, CH2CO), 2.19 (1H, m, 
CHOH), 1.80 (4H, m, CFI2CH—CHCH2), 1.65 (2H, m, CH2CH2C0), 1.27 (18H, br.s, 
(CH2)9), 0.88 (3H, dist.t, CH3). 
r3CNMR (CDC[3. Sc): 173.1, 168.8, 163.9, 134.9, 133.4, 132.7, 130.1, 126.7, 123.4, 
118.8, 114.7, 72.0, 38.1, 38.0, 37.2, 36.7, 35.1, 33.9, "one signal hidden", 32.1, 29.4, 
28.5, 27.6, 24.8, 23.1, 13.9. 
MS (ESI): ndz = 465.490 found [M+Na]', calculated [M+Na]+ = 465.513. 
[23] 
ejrazolones anirpkthafazingi cones 
2-[(9'R, 12'7_)-9'-Hydroxyoctadec-12'-enoylJ-3H-1,4 plat/ralazindione, (34) 
IR (KBr, cne f): 3372 (0-H stretching), 3217 (N-H stretching), 2918 (C-H stretching), 
1591 (C=O stretching). 
'H NMR (CDC(3, Sx): 8.42 (1H, s, NH), 7.29-7.57 (411, m, ArH), 5.480 (2H, in, 
CH=CH), 4.29 (1H, m, CIIOH), 2.34 (211, t, J = 7.59 Hz, CH2CO), 2.20 (1H, in, 
CHOH), 1.81 (4H, in, CH2CH=CHCH4),  1.71 (2H, m, CH2CH2CO), 1.25 (18H, br.s, 
(CH2)9), 0.81 (3H, dist.t, CH3). 
'3CNMR (CDC13, 6&: 174.5, 169.1, 162.6, 134.0, 133.9, 132.5, 131.5, 125.7, 124.4, 
119.0, 112.9, 71.0, 38.9, 38.1, 37.6, 36.7, 35.8, 33.0, `one signal hidden", 32.1, 30.0, 
295, 28.4, 26.4, 24.9, 14.4. 
MS (ESI): mlz = 465.600 found [M+Na]`, calculated [M+Na]' — 465.513. 
1.4.2. Biology 
1.4.2.1. Antibacterial studies 
A stock solution of I mg/mL was prepared by dissolving all the newly synthesized 
compounds in DMSO. Filter paper disc method42 (FPDM) was used for testing the 
antibacterial activity of all the target compounds and standard doxycycline Media 
with DMSO was set up as control. On nutrient agar all cultures were systematically 
maintained and incubated overnight at 37"C. At 1000 rpm the culture was centrifuged, 
pellets were resuspended and then diluted in sterile normal saline solution (NSS) to 
obtain viable 105 cfu/mL. On nutrient agar plates approximately 0.1 mL of diluted 
bacterial culture suspension was spread uniformly with the help of spreader. Sterile 8 
mm discs (Hi-media Pvt Ltd) were impregnated with the test compounds. Antibiotic 
disc, doxycycline (30 jig/disc Hi-Media) was used as control. The disc was placed on 
the nutrient agar plate. Each plate had one control disc impregnated with the solvent. 
The plates were then incubated for 24 hours at 37"C, and the resulting zones of 
inhibition were measured (mm). 
[241 
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1.4.2.2. Antifnngal studies 
The synthesized compounds were dissolved in DMSO. Media with DMSO was set up 
as control. All cultures were consistently maintained on SDA (sabouraud's dextrose 
agar) and incubated at 28°C. Spore formation of filamentous fungi was prepared from 
7 day old culture in sterile normal solution (8% NaCI) and approximately diluted to 
obtain 105 cfulmL. The inoculums of non-sporing fungi, C. albicans were performed 
by growing the culture in SD (sabouraud's) broth at 37°C for overnight. At 1000 rpm 
the culture was centrifuged, pellets were resuspended and then diluted in sterile 
normal saline solution (NSS) to obtain viable 105 efu/mL. On SDA plates 
approximately 0.1 mL of diluted fungal culture suspension was spread uniformly with 
the help of spreader. Sterile 8 nun discs (Hi-media Pvt Ltd) were impregnated with 
the test compounds. Antibiotic disc, nystatin (30 kg/disc Hi-Media) was used as 
control. The disc was placed onto the SDA plate. Each plate had one control disc 
impregnated with the solvent. The plates were incubated at 28°C for filamentous fungi 
for 72 hours or more, while for C. albicans plates were incubated at 37°C for 18-48 
hours. Antifungal activity was determined by measuring the diameters of the 
inhibition zone (mm). 
[25 ] 
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Iso.:gazole anddihydroisoxazots 
2.1. Theoretical 
Among the family of heterocyclic compounds the five membered isoxazoles and 
isoxazolines/dihydroisoxazoles provide a valuable scaffold in medicinal chemistry as 
well as a useful synthon in organic synthesis. In addition, isoxazoline derivatives have 
played a crucial role in the theoretical development of heterocyclic chemistry and are 
also used extensively in organic synthesis'. Isoxazole (35) is five membered 
heterocyclic ring containing nitrogen and oxygen atoms in the 1,2 positions. 
Isoxazolines/dihydroisoxazoles (36) are partially saturated analogs of isoxazole. 
(35) 	 (36) 
lsoxazole and isoxazolines have diverse useful bioactivities and are widely used as 
key intermediate in the construction of some natural products and related structures. 
So many methodologies exist towards the synthesis of isoxazoles2 3  and 
dihydroisoxazoles' and most of them endeavor nitrile oxide cycloaddition as a 
keystep5. The addition of a 1,3-dipole to an alkene/alkyne for the synthesis of 5-
membered ring is a classic reaction in organic chemistry. The general application of 
1,3-dipoles in organic chemistry was first established by Huisgen6. Isoxazole and 
isoxazoline heterocycles are derived from the [3+2] cycloaddition of a nitrile oxide to 
an alkene and alkyne, respectively'. The nitrile oxide 1,3-dipole is generated in situ in 
Mukaiyama reaction from the corresponding primary nitroalkane and phenyl 
isocyanate'. Here, nitrile oxide is generated by dehydration of primary nitroalkanes. 
This method is however the most useful due to its easy set up as described by 
Mukaiyama and coworker in 19608, 1,4-phenylene diisocyanate was used as 
dehydrating agent'. By using 1,4-phenylene diisocyanate, polyurea byproduct was 
obtained which may be removed from product by simple filtration because this 
polyurea byproduct was insoluble in the reaction solvent (benzene and 
tetrahydrofuran). 
[29] 
0 
CH3 
FF ]O%NaOH 
(42) 	EtOH 
(44) 
NH2OH.HCI, NaOAc 
Acetic acid, Reflux 
(43) 
it 4-OCH3, 3-NO2, 4-Cl, 4-CH3, 
3-Br, 4-Br, 2-NO2, 2-Cl, 4-F, 
3,4,5-trimethoxy 
(45) 
[30] 
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Bhosale et a1.10 reported the synthesis of derivatives of isoxazole (40) and 
isoxazolines (41) via 1,3-dipolar cycloaddition by reaction of aldoximes (37) with 
MagtrieveTM (CrO2) in presence of dipolarophile (38) or (39). 
OH
N
X 	 X 	 O 
Nam + / or~ Cr02' MaCN, 	O\N or \ 
R~ 80 °C,2h 
(37) 	(38) 	(39) 	 (40) R 	(41)\ 
Rt: 4-Cl-Ph; X: -Ph, -CHZ-OTBS, -CHrOTHP, CH2N(H)Boc, TMS-; 
X': -Ph, -COZEt, -CN, -Bn, -OAc 
Kadnor et al." showed the synthesis of fluorinated isoxazolines (45) by the reaction 
of fluorinated chalcones (44) and hydroxyl amine hydrochloride in presence of acetic 
acid. These fluorinated chalcones were prepared by the Claisen-Schmidts reaction of 
fluorinated ketone (42) and substituted aromatic aldehyde (43). 
CN 
/OH 
C CH 
+ ,/IJIIII::: CAT, EtOH  100 C, 3h 
Rt  
OCH3  RZ 
(46) 	 (47) 
R1, R2: H, H; H, CH3; H, OCH3; 
OCH3, OCH3; H, F; H, C1 
CAT: Chloramine-T 
IsoxazoTe anddzhiydmzso-xazo&s 
Govindappa et al.'2  outlined the synthesis of new cycloadducts, 3-aryl-5-(4-
mcthoxyphenyl)-isoxazole-4-carbonitriles (48) by the 1,3-dipolar cycloaddition 
reaction of nitrile oxides with 3-(4-methoxyphenyl)propiolonitrile (46). The nitile 
oxides were generated in situ by the oxidative dehydrogenation of aromatic aldoximes 
(47). 
Denmark and Kallemeyn13 reported sequential [3+2] cycloaddition and cross-coupling 
reactions for the synthesis of 3,4,5-trisubstituted isoxazoles. Initially, 
isoxazolylsilanols (51) were prepared by the reaction of alkynyl dimethyl silylethers 
(50) and alkyl/aryl nitrileoxides (49). In the final step, 3,4,5-trisubstituted isoxazoles 
(53) were synthesized by the cross-coupling reaction of heterocyclic silanols (51) with 
number of aryl iodides (52). 
[31] 
I 	 R3 
se 
Isoxazofe anddi(ydroisoxazofes 
R'—C= N—O 
(49) 
I. Heat 
e 	+ 	2. AcOl 
EtO—Si—C=C—R2  
Me (50) 
Rt: Ft, Ph 
R2: Me, Ph 
R': NO2, Me, OCH3 
Mayo et a1.14 carried out 1,3-dipolar cycloaddition of nitrite oxide (55) with 
unsymmetrically substituted norbornenes (56) to give isoxazoline derivatives (57). 
The nitrite oxide generated by nitromethylbenzene (54) using Hassner's method 
[(BOC)20 and DMAP]. 
NO (BOC)20, DMAP 
NO2 CHC13 
(54) 
Ph—C=N+ O 
(55) (56) 
Ph 
X: H, Hexyl, SiMc3, CO2Et 
DMAP: N,N-Dimcthyl-4-aminopyridine  
(BOC)ZO: Di-tert-butyldicazbonate 	 N 
0 
X 
(57) 
Nitrogen and oxygen containing heterocyclic compounds have received considerable 
attention due to their wide range of biological and pharmacological activities. 
Isoxazoles and isoxazolines have been reported's' 16 to possess antitubulin as well as 
antiinflammatory activity. Dihydroisoxazole derivatives are reported" as 
antinociceptive compounds. Also, medicinal activity like anxiolytic activity has been 
reported" for isoxazole derivatives. 
[32] 
Isoxazofe and fihydroisozazoles 
The isoxazole and isoxazoline derivatives19 are also largely employed in the 
therapeutics and pharmaceutical areas such as antimicrobial, antibiotic, ulcerogenic, 
insecticidal, antituberculosis and anticancer. For many years, drugs based on 
isoxazole derivatives such as sulfamethoxazole (58), sulfafurazole (59), acivicin (60), 
oxacillin (6I), leflunomide (62) and micafungin ° have been in commercial use. 
Acivicin possess antitumor and antileislnnanial activity while isoxaflutole (63) is used 
as herbicidal dtug'9. 
S 
NH 
NHz 	(58) 
O 
OH 
N~ 
H NH, Cl "--- 
(60) 
 
~OH 
F F 
F 
(62) 
[33] 
Isoxazo(e anddihydrthoiazoThs 
Isoxazole moiety is found in the COX II inhibitors20, bextra (valdecoxib) (64) and 
parecoxib (65). In several natural products such as aerothionon, homonerothionin, 
aerophobin 1, epi-flstularin-3 and calafianin, isoxazoline ring is a common feature. 
[34] 
Isoxazofe and fiifiydr000.t,azotes 
2.2. Synthesis and Characterization of Novel Long Chain 
Isoxazole and Dihydroisoxazole Derivatives: In Vitro 
Antimicrobial Activity*  
Various biological applications such as antimicrobial2t , pestitidal22, anticancer"]  and 
antifungal activities" have been reported for seed oils, long chain alkenoic acids and 
their derivatives. These observations and our interest in the chemistry of hetero-fatty 
acids prompted us to synthesize isoxazole derivatives of fatty acids with different 
substituent at 4- and 5- positions. For this reason, the present strategy for the synthesis 
of new compounds is aimed in the direction of developing new isoxazole derivatives 
to inhibit the growth of gram-positive, gram-negative bacteria and most pathogenic 
fungi. After synthesis the compounds were tested for their antimicrobial activity by 
disk diffusion assay and MIC by broth micro dilution method against bacterial and 
fungal strains. 
2.3. Results and Discussion 
2.3.1. Chemistry 
The long chain alkynoic acid and alkenoates used as the starting materials and were 
prepared from the corresponding long chain alkenoic acids. The long chain alkynoic 
acid (66) was synthesized using the procedure of ICannan et at25. The esters of fatty 
acids (70-73) were prepared by refluxing the fatty acid in methanol in the presence of 
catalytic amount of concentrated sulfuric acid. Nitrile oxide was generated in situ 
from 1-nitrobutane employing 1,4-phenylene diisocyanate. 
'Research paper entitled "Designing and Synthesis of Novel Antimicrobial Heterocyclic 
Analogs of Fatty Acids" is published. (Aiman Ahmnd, Ahmad, A., Varshney, H., Rauf, A., 
Rehan, M., Subbarao, N., Khan, A.U.. 2013. fnr. J. Med. Chen., 70, 887-900) 
[35] 
and 
The 1,3-dipolar cycloadditi a of nitrite oxide to terminal alkyne/alkene give 
isoxazole/dihydroisoxazole, respectively. On the other hand, the 1,3-dipolar 
cycloaddition of nitrile oxi a to internal alkenes gives an inseparable isomeric 
mixture of dihydroisoxazole erivatives. This transformation was most effective when 
excess base (3 equivalents o triethylamine) was employed and 1-nitrobutane added 
dropwise over 6-8 hours wh le heating. After refluxing, the reaction was quenched 
with water. The polyurea (pot mer) was removed by filtration. Products were purified 
by column chromatography d identified by using different spectral techniques. The 
signals of products in the 'H and 13C NMR spectra were successfully assigned. The 
high resolution mass (electro ionization) spectral studies have further confirmed their 
structures. The reaction scone ces are outlined in Schemes 2 and 3. 
~COOI-I 	 NO2 + OCN / \ NCO 
(66) 	 (67) 	 (68) 
Et3N, dry THE 
+ 6 COON 
(69) 
Scheme 2: Synthesis of 3,5-disubstituted isoxazole 
IR spectrum of compound (69), 5-(carboxyoctyl)-3-prapylisoxazole, revealed 
characteristic bands at 3285 (CfH stretching), 2918 (C-H stretching), 1702 (acid C=O 
stretching), 1465 (C—N stretch ).'H NMR peaks at 12.61 (1H, s, COOH), 6.98 (1H, 
s, CH ring), 2.35 (2H, t, J — 7 52 Hz, CII2COOH), two triplets merged together at 6 
2.18 were observed for four CH2 protons alpha to isoxazole ring, 1.63 (2H, m, 
CH2CH2COOH), 1.54 (2H, m, H2CH2CH3), 1.28 (10H, br.s, CH2 chain), 0.90 (311, t, 
J 7.21 Hz, CII,). In 13C NM peaks at 6176.1, 167.8, 82.1, 80.8, 44.2, 35.8, 32.6, 
29.8, 29.6, 29.3, 29.0, 27.4, 25f , 22.9, 14.1 were observed. The mass spectra showed 
characteristic molecular ion neik in accord with the molecular formula. 
[36] 
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-- H+ 	OCN \ / NCO 
	
/ 	\ 	 NO2 
R, RZ 
(70-73) 	(67) 	(68) 
Et3N, dry THE 
R, 	R2 
~0 
N 
(74-77) 
Compound Rl 	 R2 
Codes 
70,74 	fI 	 H2C' ", -COOCH3 
71,75 	H,C' \~6\COOCH3 
H2 	~/7~~ 
72,76 	 ' 	H2C "fi 'COOCH3 
OH 
COOCH3 
73, 77 	3 CH2 I32C~ 
fi 
OH 
Scheme 3: Synthesis of 3,5-disubstituted and 3,4,5-trisubstituted-4,5- 
dihydroisoxazoles 
[37] 
„ 
The structure of (74-77) i evident from their spectral data. The structure of 
compound (74) is given belo 
HE 
Structure of 5-(carbomethoxyoctyl)-3-propyl-4,5-dibydroisoxazole, (74) 
Compound (74), 5-(carbom thoxyoctyl)-3-propyl-4,5-dihyroisoxazole, showed IR 
absorption bands at 2931cm' (C-H stretching), 1740 cm' (ester C=O stretching), 
1457 (C=N stretching). The' NMR was more informative in assigning the structure. 
Diagnostic peaks for cyclic ratans were appeared at 4.46 (IH, m, CHrCH ring), 
2.91 (1H, dd, .ç 1, = 16.70 H , , 	=10.00 Hz, CH-CHz ring), 2.49 (1H, dd, j,, 
= 16.80 Hz, j,,,,, = 8.10 Hz CH-CHE ring), 2.25 (4H, two triplets partially merged, 
-CH,COOCH3, -CH2CH2C 3 ), 1.60 (6H, m, CHzCH2CH3, (CHz)5-CH2-, 
CH2CH2COOCH3), 1.25 (10 , br.s, CH2 Chain), 0.92 (3H, t, J = 7.30 Hz, CH). In 
C NMR peaks at 174.2, 15 .7, 79.9, 51.3, 42.0, 35.2, 34.0, 29.7, 29.3, 29.2, 29.1, 
29.0, 25.5, 24.8, 19.7, 13.7 ere observed. The mass spectra showed characteristic 
molecular ion peak in accord ith the molecular formula. Similarly other compounds 
were characterized from their nectral data. 
2.3.2. Biology 
2.3.2.1. Antibacterial studies 
The newly prepared compoun s were screened for their antibacterial activity against 
Escherichia coli (ATCC-259 ), Staphylococcus aureus, Pseudomonas aeruginosa 
(ATCC-27853), Streptococcus yogenes and Klebsiellapneumoniae (clinical isolates) 
bacterial strains. The susceptib lity was assessed on the basis of the diameter of zone 
of inhibition against gram-pos tive and grant-negative strains of bacteria. Inhibition 
zones were measured and corn ared with the controls (Table 3). 
[38] 
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The investigation of antibacterial screening data revealed that all the tested 
compounds showed moderate to good antibacterial activity. Among all the 
synthesized compounds, compound (76) showed highest antibacterial activity (25 
µgfmL) nearly equivalent to standard drug ciprofloxacin. Compounds (76 and 77) 
showed good inhibition against S. pyogenes, S. aureus and E. coli species. In general, 
all the compounds were more effective against gram-positive bacteria as compared to 
gram-negative bacteria. 
Table 3: Antibacterial activity of all the newly synthesized 
compounds 
Compound 
	
Diameter of zone of inhibition (mm) 
Codes 	Gram-positive 	 Gram-negative bacteria 
bacteria 
SP't 	SA 	PA` 	ICY 	EC` 
69 	21.6±0.4 	19.2±0.4 31.2±0.4 18.3+0.4 25.7±0.4 
74 	20.2±0.3 	18.1±0.4 30.1±0.4 17.1±0.3 25.1+0.3 
75 	22.3±0.4 	21.6±0.4 31.3±0.4 18.5+0.4 26.7±0.4 
76 	23.2±0.2 	22.6±0.4 32.5±0.6 19.2±0.3 27.6±0.6 
77 	22.4±0.4 	20.8±0.3 31.8±0.4 18.9±0.4 26.5±0.3 
Standard 	23.0±0,2 	22,0+0.2 32.0±0.3 19.0±0.2 27.0+0.2 
DMSO 	- 	- - - - 
SP: Streptococcus pyogenes, 	SA: Staphylococcus aureus, `IPA. Pseudomonas 
aeruginosa, 'KY: Klebsiella pneumonia, e)EC: Escherichia coli. Positive control 
(standard): ciprofloxacin; negative control: DMSO; antibacterial activity measured by 
the halo zone test (unit, mm) 
Minimum inhibitory concentrations (MICs) were determined by broth micro dilution 
method. The minimum inhibitory concentration and minimum bactericidal 
concentration are given in Table 4. 
[39] 
and 
Table 4: MIC and ry EC results of all the newly synthesized 
compounds 
Compound Gram-posith a bacteria Gram-negative bacteria 
Codes sr )  SA "1  PA `1  ICp°J EC°1  
MIC MBC IIC MBC MIC MBC MIC MBC MIC MBC 
69 50 100 50 100 100 >100 50 >100 50 100 
74 50 100 50 >100 100 >100 100 >100 100 >100 
75 25 50 5 100 25 50 25 100 25 50 
76 25 50 5 50 25 50 25 100 25 50 
77 25 50 5 100 50 100 25 100 25 100 
Standard 12.5 12.5 .25 12.5 12,5 25 6.25 25 6.25 12.5 
")SP: Streptococcus pyogenes °)SA: Staphylococcus aureus, `SPA: Pseudomonas 
aeruginosa, d1KP: Klebsiella neamania, i`EC: Lscherichia coil. MIC (µg/mL) _ 
minimum inhibitory concentra ion, i.e. the lowest concentration of the compound to 
inhibit the growth of bacteri completely; MBC (µg/mL) = minimum bacterial 
concentration, i.e., the lowest oncentration of the compound for killing the bacteria 
completely. Positive control: c p rofloxacin 
2.3.2.2. Antifungal studies 
All the newly synthesized co pounds were tested for in vitro antifungal activity 
against standard species of Ca dicta and clinical isolates of Candida which includes 
Candida albicans, Candida t opicalis and Candida parapsilosis. The results are 
presented in Tables 5 and 6. 1 the synthesized compounds had good antifungal 
effects against tested clinical sp cies of Candida. 
Among all the synthesized cc pounds, compounds (76 and 77) showed excellent 
antifungal activity (32 µg/mL against Candida tropicalis and Candida albicans, 
which were resistant to fucoi azole and itraconazole as well as against standard 
species of Candida. 
[40] 
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Table 5: In vitro antifungal activity of all the synthesized compounds 
against standard species of Candida 
Comp. Tested fungi (NUC 90% and MFC µg/mL) 
Codes CA's CT' CG l`  CPO Cr CD 
MIC MFC MIC MFC MEG MEG MEG MFC MEG MFC MW MFC 
69 >256 >256 >256 >256 128 >256 128 >256 >256 >256 128 256 
74 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 
75 128 256 128 >256 128 >256 >256 >256 >256 >256 128 >256 
76 128 256 64 >256 32 256 32 128 64 128 32 256 
77 128 >256 128 >256 64 128 32 >256 128 >256 128 >256 
Flu. >256 >256 32 256 8 128 4 32 32 >256 2 >256 
It. >256 >256 >256 >256 0.12 >256 0.6 0.5 0.6 0.12 >256 >256 
'ACA: Candida albicans, °'CT: Candida tropicalis, 1`CG: Candida glabrata, °/CP 
Candida parapsilosis, ` )CK: Candida knrzei, ')CD: Candida dubliniensis. Flu. 
Fluconazole, It. = Itraconazole 
Table 6: In vitro antifungal activity of all the synthesized compounds 
against clinical species of Candida 
Compound Tested fungi (MIC 90% and MFC pg/mL) 
Codes CA CT°I CP I` CAR CT°  
MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC 
69 >256 >256 128 >256 256 >256 >256 >256 >256 >256 
74 >256 128 >256 128 >256 >256 >256 >256 >256 >256 
75 128 >256 128 >256 128 >256 >256 >256 >256 128 
76 32 256 64 256 128 >256 128 >256 >256 >256 
77 64 256 64 >128 128 >256 >256 >256 >256 >256 
Flu. 8 >256 16 256 0.5 1 R R R R 
It. 0.12 >256 1 >256 0.25 0.5 R R R R 
a1CA: Candida albicans, " )CT: Candida tropicalis, °1CP: Candida parapsilosis, Flu. 
Fluconazole, It. = Itraconazole, * = resistant to fluconazole and itraconazole, R 
resistant 
[41] 
Also, molecular docking stu ies have been performed on peptide deformylase (PDF) 
of L•scherichia colt and CYP 450-14DM of Candida albicans to evaluate the possible 
mode of action of the molec les in the active site of the receptor. The results of the 
docking experiments for the ewly synthesized compounds (69, 74-77), with the 30s 
ribosomal subunit were fo d to be in accordance with the in vitro antimicrobial 
activity data obtained. The b ding sites of the compounds were found to be in close 
proximity to the binding site of the standard drug ciprofloxacin. It was interesting to 
observe that even though th core structure of all the compounds was the same, the 
degree of interaction and bin ing patterns were found to be different. We anticipate 
that this kind of docking and 
of novel drugs that targets n 
of the long chain isoxazole a 
of the lead molecules for Cy 
and their non-bonding inters 
14DM protein and bindin; 
antifungal agents. All the n 
these newly 
ipathogcnic screening studies would help in designing 
Dbial protein synthesis. Moreover, the mode of action 
dihydroisoxazole derivatives showed that the affinity 
nome P450-14DM was mainly attributed to hydrogen 
in with the active site residues of Cytochrome 1450-
ith the heme, which was similar to that of azoles 
is and detailed studies of the molecular docking of 
are given in the published paper. 
2.3.3. Conclusion 
The proposed method for the ynthesis of novel long chain isoxazole derivatives was 
simple and all the synthesizes compounds obtained in good yield. The report of the 
study confirms traditional r ;age of these compounds as antimicrobial agents. 
However, large data must be enerated through the pharmacognostic studies before 
going for commercialization, his present study showed that all the title compounds 
were exhibiting antibacterial ctivities. These compounds were evaluated against 
yeast. Among the synthesi ed compounds, compounds (76 and 77) showed 
antimicrobial activity against 1 tested microorganisms which is almost equivalent to 
the standard drugs ciprofloxac n and fluconazole. Also, compounds (76 and 77) had 
antifungal activity against test clinical species of Candida which were resistant to 
fluconazole as well as itracon le. It was interesting to observe that even though the 
core structure of all the compo nds was the same, the biological activities were found 
[42] 
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to be different against different microbial strains. The studies presented here provide a 
new structural type for the development of novel antimicrobial agents. 
[43] 
2.4. Experimental 
2.4.1. Chemistry 
Physical and Spectroscopic 
Anhydrous conditions were thieved by drying flasks and other-equipments in the 
oven. Reagents were of cojnniercial grade and used without further purification. 
When needed, solvents were jiried and distilled before use. The source of olefinic and 
hydroxy-olefmic fatty acids, nstru nental details of IR, NMR and mass spectrometry 
are already given in experim ntal section of chapter 1 (page number 19). The eluent 
was a mixture of petroieui4 ether and diethyl ether in different proportions for 
different compounds. I -Nitrclbutane  and 1,4-phenylene diisocyanate were purchased 
from Sigma Aldrich. Triet ylamine, tetrahydrofuran (THF) and benzene were 
purchased from Merck, Mmn ai. 
General Procedure for the S}lpthesis ofLong Chain Alkynoic Acid, (66) 
The long chain alkynoic acidl(66) used as the starting material was prepared by the 
previously reported25 method. 
Synthesis of3,5-disubstitutedlisoxazole derivative (69) of long chain alkynoic acid: 
1,4-Phenylene diisocyanate ( ) (0.003 vole) was added to long chain alkynoic acid 
(66) (0.001 mole) in dry tetr ydrofuran (THF) (20 mL). Triethylamine (0.003 mole) 
was added to the reaction nil tore and this was heated to 80'C. 1-Nitrobutane (67) 
(0.003 mole) was added in po ions over a period of 6-8 hours, and then the reaction 
was heated for additional 2 h urs. The precipitate was observed. After heating, the 
reaction mixture was cooled. The reaction was quenched with water (- 6 mL) and 
then allowed to stir at room temperature for 1 hour. The polyurea (polymer) was 
removed by filtration and was ed with THF. The solvent was evaporated on a water 
bath and then worked up with iethyl ether and water. The ether layer was dried over 
anhydrous sodium sulfate. Th excess of solvent was removed by heating on water 
[441 
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bath. Further, product (69) was purified by silica gel column with petroleum ether and 
increasing concentration of diethyl ether as eluent. 
The spectroscopic and analytical data for the synthesized compound (69) is 
presented below: 
5-(Carboxyoctyl)-3 propylisorazole, (69) 
White solid; M.P. = 79-80`C; yield: 80% 
JR (KBr, cm- ): 3285 (0-H stretching), 2918 (C-H stretching), 1702 (C=O stretching), 
1465 (C=N stretching). 
tH NMR (CDCl3. dtt: 12.61 (IH, s, COOl)), 6.98 (IH, s, CH ring), 2.35 (2H, t, J — 
7.52 Hz, CH2COOH), 2.18 (4H, two triplets merged together, (CH2)5-CH2, 
CH1CH2CH2), 1.63 (21-1, m, C112CH2COOI-I), 1.54 (2H, m, CH2CH2CH3), 1.28 (10H, 
br.s, CU2 chain), 0.90 (3H, t, J = 7.21 Hz, CH3). 
"C NM!? (CDCI1, dc): 176.1, 167.8, 82.1, 80.8, 44.2, 35.8, 32.6, 29.8, 29.6, 29.3, 
29.0, 27.4, 25.6, 22.9, 14.1. 
MS (EM): m/z = 290.210 found [M+Na]', calculated [M+Na]' = 290.308. 
Synthesis of 3,5-disubstituted anrI 3,4,5-trisubstitrded-4,5-dilrydroisDxazole 
derivatives (74-77) of long chain alkenoates: 
1,4-Phenylene diisocyanate (68) (0.03 mole), 1-nitrobutsne (67) (0.01 mole) and long 
chain alkenoates (70-73) (0.01 mole) were dissolved in dry benzene (30 mL). 
Triethylamine (25-50 drops) was added. The reaction mixture became turbid and a 
precipitate was observed. After 8 hours at reflux the reaction mixture was cooled. The 
reaction was quenched with water (= 5 mL) and allowed to stir at room temperature 
for 1 hour. The polyurea (polymer) was removed by filtration and washed with 
benzene. The solvent was evaporated on a water bath and then worked up with diethyl 
ether and water. The ether layer was dried over anhydrous sodium sulfate and excess 
[45] 
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solvent was evaporated on jater bath. Further, the products (74-77) were purified by 
silica gel column with petrol um ether and increasing concentration of diethyl ether as 
eluent. All these novel com unds were characterized from their spectral data. 
The spectroscopic and analytical data for the synthesized compounds (74-77) are 
presented below: 
(74) 
Colourless oily liquid; yield: 
IR (KBr, cm t): 2931 (C-}l stretching), 1740 (C=O stretching), 1457 (C=N 
stretching). 
'HNMR (CDCl3, Sit): 4.46 ( m, CHrCHring), 3.60 (3H, s, OCH3), 2.91 (1H, dd, 
Jx _„ 16.70 Hz, _ = 10.0 Hz, CH-CHz ring), 2.49 (1H, dd, Jf ~ = 16.80 Hz, 
= 8.10 Hz, CH-C E ring), 2.25 (4H, two triplets partially merging, 
CH2COOCH3, CH2CH2CH ), 1.60 (6H, m, CH2CH2CH,, (CH2)5-CH2, 
CH2CH2COOCH3), 1.25 (1 OH br.s, CH2 Chain), 0.92 (3H, t, J= 7.30 Hz, CH3). 
'3C NMR (CDCIj, SCJ: 174.4 158.7, 79.9, 51.3, 42.0, 35.2, 34.0, 29.7, 29.3, 29.2, 
29.1, 29.0. 25,5, 24,8, 19,7, 1317. 
MS (ESI): m/z = 305.700 fhuml [M+Na]', calculated [M+Na]` = 306.343. 
(75) 
Colourless oily liquid; yield: 
IR (KBr, cni 1): 2928 (C-1l stretching), 1743 ((>O stretching), 1462 (C=N 
stretching), 
'HNMR (CDC13, Sy): 5.26 (2, m, HC-CH ring), 3.59 (3H, s, O-CH3), 2.54 (2H, t, J 
= 7.60 Hz, CH2COOCH3), 2.4 (2H, t, J= 7.60 Hz, CH2CH2CH3), 1.95 (4H, m, H2C- 
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CH-CH-CH2), 1.70 (2H, m, CH2CH2COOCH3), 1.56 (211, m, CH2CH2CH3), 1.20 
(20H, br.s, CH2 Chain), 0.91 (3H, t, J= 7.20 Hz, CH2CH2CH3), 0.81 (311, dist.t, CHI). 
13C NMR (CDC13, Sc): 173.8, 159.2, 80.1, 52.8, 43.0, 35.5, 34.8, 33.4, 32.0, 31.2, 
30.9, 29.9, 29.8, 29.6, 29.4, 29.2, 29.1, 26.6, 25.3, 24.4, 22.7, 18.8, 13.9. 
MS (ESI): nVz = 404.190 found [M+Na]', calculated [M+Na]' = 404.504. 
5-(Carbwn eth oxyh eptyl)-4-/(2'R)-2'-hydroxyo ctylJ-3 propyl-4, 5-dihydroisoxazole, 
(76)  
Yellow oily liquid; yield: 80% 
IR (KBr. cm" ): 3328 (0-11 stretching), 2924 (C-H stretching), 1738 (C=O stretching), 
1447 (C=N stretching). 
'II NMR (CDC13, J jj): 5.32 (2H, m, HC-CH ring), 4.20 (1H, m, CH-OH), 3.60 (3H, s, 
O-Cl 3), 2.65 (2H, t, J=7.54 Hz, CH2COOCH3), 2.35 (2H, t, J = 7.45 Hz, 
CII2CH2CH3), 2.10 (4H, m, H2CHC-CHCII2), 1.80 (1H, m, CH-OH), 1.68 (2H, m, 
CH2CH2COOCH3), 1.42 (2H, m, CH2CH2CH3), 1.30 (18H, br.s, CH2 chain), 0.95 
(311, t, J— 7.25 Hz, CH2CH2CII3), 0.87 (3H, dist.t, CH3). 
'3C NMR (CDCl3, óc9: 176.4, 158.7, 80.0, 72.1, 52.8, 43.4, 39.5, 35.6, 34.8, 33.5, 
32.3, 29.9, 29.7, 29.5, 29.3, 29.2, 29.0,27.4,25.4,24.9,21.9, 19.5, 14.0. 
MS (ESI): m/z = 420.409 found [M+Na]', calculated [M+Na] = 420.503. 
5-[(8'R)-8' Uydroxy(carbonnethoxyd¢cy1)J-4 pentyl-3 propyl-4,5-dihydroisoxazole, 
(77)  
Yellow oily liquid; yield: 75% 
IR (ICBr, cm'): 3294 (0-H stretching), 2918 (C-H stretching), 1734 (C=0 stretching), 
1468 (C=N stretching). 
[47] 
and 
2HNMR (CDC13, 6y): 5.34 (H, m, HC-CH ring), 4.41 (IH, in, CH-OH), 3.69 (3H, s, 
O-CH3), 2.55 (2H, t, J = 7.45 Hz, CH2COOCH3), 2.29 (2H, t, J = 7.50 Hz, 
CH2CH2CH3), 1.98 (4H, m, 2CHC-CHCH2), 1.78 (IH, m, CH-OFI), 1.67 (2H, m, 
CH2CH2COOCH3), 1.40 (21f in, CH2CH2CH3), 1.30 (18H, br.s, CHZ chain), 0.96 
(3H, t, J= 7.25 Hz, CH2CH2 H3), 0.87 (3H, dist.t, CH3). 
'3C NMR (CDC13, 3d: 1754, 156.9, 81.0, 73.1, 51.8, 42.0, 39.0, 34.9, 34.2, 33.4, 
31.9, 29.8, 29.6, 29.4, 29.3, 2 .2, 29.0, 26.8, 24.9, 23.9, 21.9, 19.8, 13.9. 
MS (ESI): m/z = 420.347 fou d [M+Na]', calculated [M+Na]' = 420.503 
2.4.2. Biology 
2.4.2.1. Antibacterial Assay 
The antibacterial activity of t e synthesized compounds was completed by the disk 
diffusion method and measur4 by halo zone test26. 27. The susceptibility was assessed 
on the basis of the diameter f zone of inhibition against gram-positive and gram-
negative strains of bacteria. l - bition zones were measured and compared with the 
controls. 
A standard inoculums (1-2 X 0' c.fuJmL 0.5 McFarland standards) was spread onto 
the surface of sterile agar p ates. The discs measuring 6 mm in diameter were 
prepared using Whatman no. filter paper and were sterilized by dry heat at 140°C 
for 1 hour. The sterile discs p eviously soaked in a known concentration of the test 
compounds were placed in the utrient agar medium. Ciprofloxacin (30 pg) was used 
as positive control. While the d sk poured in DMSO was used as negative control. The 
plates were inverted and in bated for 24 hours at 37°C. The susceptibility was 
assessed on the basis of the di meter of the zone of inhibition against gram-positive 
and gram-negative strains ofba feria. 
The minimum inhibitory con entration (MIC) of synthesized compounds against 
bacterial strains was perform d by the micro dilution test and the results were 
observed visually and specfro hotometrically. The nutrient broth, which contained 
[48] 
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logarithmic serially two fold diluted amount of test compound and controls were 
inoculated with approximately 5 X 10 c.fu./mL of actively dividing bacteria cells. 
The cultures of the bacterial strains were incubated for 24 hours at 37C and the 
growth was monitored visually and spectrophotometrically. The lowest concentration 
(highest dilution) required to arrest the growth of bacteria was regarded as MIC. 
To obtain the minimum bacterial concentration (MBC), 0.1 mL volume was taken 
from each tube and spread on agar plates. The number of c.fu. was counted after 18-
24 hours of incubation at 35°C. MBC was defined as the lowest drug concentration at 
which 99.9% of the inoculums were killed. 
2.4.2.2. Antifungal Assay 
Bacterial and fungal strains were obtained from microbiology laboratory, Aligarh 
Muslim University, as gift, where these strains were already characterized. Sabouraud 
dextrose agar (SDA), potato dextrose agar (PDA), oatmeal, and RPMI 1640 were 
used for agar dilution and macrodilution methods. The clinical isolates of fungi 
including Candida albicans, Candida tropicalis, and Candida parapsilosis were 
purified and subcultures on SC, SCC, and PDA media before testing. To obtain the 
stock solutions of the compounds, 200 mg/mL of the compound was dissolved in 
DMSO. 
Agar dilution assay and micro dilution method were used to establish the MIC as well 
as minimum fungicidal concentration (MFC) of synthetic deriva[ives2R'z9. The 
compounds were diluted in solid and broth media to obtain a final concentration from 
0.0312 to 256 mg/mL, using PDA and RPMI 1640 media. The inocula of the yeasts 
were prepared from 1-10 days mature colonies grown. Fluconazole and itraconazole 
or griseofulvin were used as positive and the solvents of the compounds as negative 
blanks. 
[49] 
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3.1. Theoretical 
Oxadiazoles are five membered heterocycles possessing one oxygen atom and two 
nitrogen atoms. Oxadiazoles exist in different isomeric forms such as 1,2,4- (78), 
1,2,5- (79), 1,2,3- (80) and 1,3,4-oxadiazoles (81). 1,3,4-Oxadiazole is derived from 
furan by substitution of two methylene groups (=CH) with two (-N=) of pyridine type 
nitrogens. Out of these isomers, 1,3,4- and 1,2,4- oxadiazoles are more widely studied 
due to their significant chemical and biological and importance. 
4 	3 	4 	3 	4 	3 	4 	3 
~N~ 
5 o N 2 s N o/N 2 s 	 (~ o N 2 5 0 z 
(78) 	(79) 	(R0) 	(81) 
The presence of three nitrogen atoms in five membered ring compounds describes an 
important class of heterocycles, the triazoles. The two isomers of triazole are 1,2,3- 
(82) and 1,2,4-triazole (83). 
HI 
N 
5 ` 	 2 
4 	3 
(82) 
HI 
2 
1\N / 
4 	3 
(83) 
1,2,4-Triazole is very stable nucleus shown by different chemical reactions and it can 
be considered as aromatic, stabilized by resonance as shown below: 
HN~N 
	
N HN~~ HNC 
N) N 
RN 
o 	e 
e 
o/N 'N~ ~N 
[53] 
O.todtozo£thiones, triazotthianw and tttazotothtttfitazines 
Further, 4-amino-1,2,4-triazol-3-thiones were found to be useful synthon or tools for 
the synthesis of triazolothiadiazines'. For the synthesis of condensed heterocyclic 
structures, the mercapto and amino groups are good nucleophilic centres. 
Banday and Rauf reported the synthesis of 1,2,4-trioazole derivatives (86) by the 
intermolecular cyclization of thiosemicarbazides (85) in alkaline medium. These 
thiosemicarbazides were prepared by the reaction of fatty acid hydrazides (22-25) and 
phenylisothiocyanate (84) in dry benzene. 
RCONHNH + Ph-N=C=S ~ benzene 	 NaOH s 	RCONHNHCSNHPh 
(22-25) 	(84) 	
reflux 
(85) 	
iDA-Ic  
N—NH 
R: CH2=CH(CH2)8, 	 / 
CH3(CH2) CH=CH(CH2)7, 	 R 	 S 
CH3(CH2)5CHOHCH2CH=CH(CH2)7, 	 N 
CH3(CH2)4CH=CH(CH2)2CHOH(CH2)7 
IPh 
(86) 
Padmavathi et aL3 synthesized 1,3,4-oxadiazole derivatives (90, 91) by the reaction of 
acid hydrazides (87, 88) and carboxylic acids (89) in presence of 
phosphonnsoxye]iloride. Further, these oxadiazole derivatives on reaction with excess 
hydrazine produce 3-(arylsulfonylmethyl)-5-phenyl-4H-1,2,4-triazol-4-amines (92) 
and 3-(aryhmethanesulfonylmethyl)-5-phenyl-4H-I,2,4-tria2oI-4-amines (93). 
[54] 
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C6H,R' 
RC6HyS~/CONHNHZ 00 OX 
RC6H 	— 	II n 	 A~ / 8 	 ----  (87,88)  
	
+ 	 3 	(90,91) 	N,/ -;r79 
R'C6H4COOH H2.NNH2. 	
o .............../... 
H2O/''`. ' 	 J, 
(89) 	 n-butanol  
H2N 
n = 0 (87, 90, 92) 	 \ 	C6H4R' 
n=I( 	 \ /O N~ 
R, R': 	
H; 
4- 1, H,, 
	
/ 2-C1I ;4-C1, H; 	RC6H4 	
n 
S\/ 	\ vim~ /I1N 
 (92, 93) 
Banday et at4 reported the synthesis of 2-amino-I,3,4-oxadiazole (94) and 2-alkenyl- 
5-phenyl-1,3,4-oxadiazole (95) using cyanogens bromide and benzoyl chloride or 
benzoic acid as reagents, respectively. 
RCONHNH2 
i)CNBr, Me OH i) PhCOOHIPhCOCI 
ii)Nal-IC03 	(22-25) 	ii) POCI3, C2H4C1z 
R_/O~NI"IZ Ph 
(94) 
\N—N 	 11N—N 
(95) 
R: CH2=CH(CH2)3, 
CH3(CH2)7CH=CH(CH2)7, 
CH3(CH2) 5 CHOHCH2CH=CH(CH2},, 
CH3 (CH2 )4CH=CH(CH2)2CHOH(CH2)7 
Lotfi et als reported the synthesis of 2,5-disubstituted-I,3,4-oxadiazoles (96) by 
electrocyclization of semicarbazone (97). 
[55] 
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H ~NH 
C=N 
RI
~ 
	
	CH30H _ 
LiC104,-2e 
(96) (97) 
R: 4-OMe, H, 4-Me, 4-Cl, 4-NO2, 2,6-Cl, 3-OMe, 4-OH, 
3-Ethoxybenzene, 4-OMe 
Deohate6 outlined the synthesis of 6,7-disubstituted-phenyl-3-pyridin-4-yl-5H-[ 1,2,4]-
triazolo[3,4-b]-[1,3,4]-thiadiazines (100) by reacting 4-amino-3-mercapto-5-pyridin-
4-yl-4H-[1,2,4]-triazole (98) with substituted benzoins (99) in presence of potassium 
hydroxide. 
N—N 
HSC ) /N 
N 
NHZ (98) 
+ 	KOH, EtOH 
RCOCHOHR 
(99) 
R: ph HO \ I \ 
OH 
p 
H3CO H3CO 
CI 	 OH 
Singh and Singh° described the synthesis of 6,7-diphenyl-3,5-disubstituted-s- 
triazolo[3,4-b][1,3,4]-thiadiazine (103) by the reaction of compound (102) with 
hydroxyl ketone in the presence of potassium hydroxide using triazole (101) as 
starting material. 
[56] 
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NN 	Isonicotinic acid 
Ar_LN 	
hydrazide 
N SR 
NHZ 
(101) 
Ar: 4-methyl phenyl, 
4-nitrophenyl, 
4-chlorophenyl, 
4-methoxyphenyl 
(102) 
PhCHOHCOPh, 
KOH 
(103) 
Nitrogen, oxygen and sulfur containing compounds are the most common 
heterocycles which serve as the core component of a large number of biochemical 
materials which are essential to life such as nucleic acids. Oxadiazoles are used as 
support on which pharmacophores are placed to provide potent and selective 
medicines'. During the past few years, considerable evidence has been accumulated 
that demonstrates the efficacy of 1,3,4-oxadiazoles including insecticidal, analgesic, 
diuretic, CNS depressant, antiviral, herbicidal, antihypertensive, pesticidal activities 
and these are cited in literature9. Oxadiazoles also possess antitubercular °, 
antimalarial", antileishmanial12 and anticancer13 activities. 
The 1,2,4-triazole derivatives possess a broad spectrum of activity including 
antimalarial, anticancer and antitubercular°' 15 and also having a wide range of 
therapeutic properties like analgesic insecticidal", hypoglycemic, antiparasitic, 
herbicidal19 and plant growth activities20. The 1,2,4-triazole nucleus is extensively 
used in medicines2 '. The substituted 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine derivatives 
have been reported to possess antimicrobial activity mainly due to N-C-S linkage in 
the skeleton of triazolothiadiazine and also possess anticancer activity22-15.  These 
[57] 
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biheterocyclic triazolothiadiazine derivatives also possess broad spectrum of 
pharmacological activities26 27 
Zibotentan (104) and raltegravir (105) are two examples of compounds that are used 
in clinical medicine which contains 1,3,4-oxadiazole unit's. Also, triazole moiety is 
present in many antifungal drugs such as fluconazole (106) and voriconazole (107). 
(104) 
0 
O 	 N 
0 	 (105) O 
 
(106) 
N 
 
(107) 
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3.2. Synthesis and Anticancer Activity of Long Chain 
Substituted 1,3,4-Oxadiazol-2-thione, 1,2,4-Triazol-3-thione 
and 1,2,4-Triazolo[3,4-b]-1,3,4-thiadiazine Derivatives 
The literature survey29' 30 reveals that there are many examples of triazole fused with 
pyridines, pyridazines, pyrimidines, pyrazines and triazines but triazolothiadiazines 
are not very common moieties. Earlier works31' 31  showed that these heterocycles were 
synthesized from different substituted carboxylic acids and hydrazides (other than 
long chain alkenyl/hydroxyalkenyl hydrazides). Literature survey33 also reveals that 
minor change in the structure of 1,3,4-oxadiazoles, 1,2,4-triazoles and 1,2,4-
triazoto[3,4-b]-1,3,4-thiadiazines can lead to quantitative and qualitative changes in 
biological activity. Recently, stearic acid (a saturated fatty acid) analogs having 1,3,4-
oxadiazole, 1,2,4-triazole and 1,2,4-triazolo-[3,4-b]1,3,4-thiadiazole were reported14 
as antidepressant and antimicrobial agents. Also, the usage of fatty acids shows an 
increasing trend in the treatment of neuropsychological disorders such as depression 
and schizophrenia35' 36  Despite this, some of the fatty acids have been found to play a•
regulatory role in tumor growth progression and were reported as effective anticancer 
agents37. Keeping in view the significance, the aforementioned facts of long chain 
alkenyl/hydroxyalkenyl carboxylic acids as potential pharmacophores and in 
continuation of earlier research work in our laboratory on the synthesis of novel series 
of biologically active heterocyclic derivatives of fatty acids38, the synthesis of three 
different novel series of biologically important heterocyclic fatty acid analogs 
described in this chapter. 
.Research paper entitled "Synthesis and anticancer activity of long chain substituted 1,3,4-
oxadiazol-2-thione, 1,2,4-triazol-3-thione and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazinc 
derivatives" is in press. (Alman Ahmad, Varshney, H., Rauf, A., Sherwani, A., Owais, M., 
2014. Arab. J. C/tent., http:/Idxdoi.org/lO.101ófjsrabjc. 2014.01.015) 
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After synthesis, all the newly synthesized compounds were characterized by different 
spectral techniques and further evaluated for in vitro anticancer activity against three 
different human cancer cell lines and peripheral blood mononuclear cells (PBMCs), 
normal human cells. The salient features of the procedure described in this chapter are 
taking short reaction time, not require elevated temperatures, the use of cheap 
reagents and easily available starting materials. 
3.3. Results and discussion 
3.3.1. Chemistry 
Earlier in our laboratory it has been reported4 that some other 1,3,4-oxadiazoles 
substituted with fatty acid chain possess antibacterial activity. Due to the biological 
importance of heterocyclic fatty acid analogs, synthesis of target compounds (108-
119) and evaluation of anticancer activity was reported in this chapter. All reactions 
are outlined in Scheme 4 and 5. The physicochemical parameters of all the newly 
synthesized compounds are tabulated in Table 7. Three novel series of 
oxadiazolthiones, (108-111); triazolthiones, (112-115) and triazolothiadizines, (116-
119) were synthesized from the corresponding unsaturated/hydroxy-unsaturated fatty 
acid hydrazides, (22-25). These fatty acid hydrazides used as starting materials and 
were synthesized from the corresponding fatty acids'9. The cyclization reaction of 
carbon disulfide with fatty acid hydrazides gave a novel series of 5-long chain 
alkenyl/hydmxyalkenyl-1,3,4-oxadiazol-2-thiones, (108-111). 4-Amino-5-long chain 
alkenyllhydroxyalkenyl-1,2,4-triazol-3-thiones, (112-115) were synthesized by the 
reaction of carbon disulfide and fatty acid hydrazides on treatment with hydrazine 
hydrate. Furthermore, biheterocyclic derivatives of fatty acids i.e. 4-amino-5-long 
chain alkenyl)hydroxyalkenyl-6-phenyl-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines, 
(116-119) were synthesized from corresponding compounds (112-115) and phenacyl 
bromide by ring closure reaction. 
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RCONHNH2 
(22-25) 	(i) CS2, KOFH, EtOH, Stir 
CS2, KOH, 	 (ii) Et20, Stir EtOH 	ux (, Refl iii) NZH4.2H2O, Reflux 
N—N N—NH N—N N—NH 
R 	 SH R~ ~S R~ ~S O 0 	 N 	 N 
NI-I2 	 NH2 
(108-111) (112-115) 
Compound 	 R 
Codes 
22, 108,112  
H E 
23,109,113 
5 CH2 
OH 
24, 110,114  
n 	H2 
25,111, 115 	 — 	 H 
2 
~ 	 s 
OH 
Scheme 4: Synthesis of 5-substituted-1,3-4-oxadiazol-2-thiones 
and 4-amino-5-substituted-1,2,4-triazol-3-thiones 
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Reflux 
(116-119) 
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N—NH 
N—N~SH R/ 
/
\N~ R 	N  
I 	 I 
NH2 NH2 
(112-115) 
Compound 	R 
Codes 
112,116  
H E 
113,117 	- 
H2 
OH 
114,118 	 - 
3 	s H2 
115,119 	— 	HZ 
s 
OH 
Scheme 5: Synthesis of 3-substituted-6-phenyl-7H-1,2,4-triazolo[3,4- 
b]-1,3,4-thiadiazines 
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Table 7: Physico-chemical properties of all the newly synthesized 
compounds, (108-119) 
S. No. Compound R Molecular Physical M.P. %Yield Motec. 
Code Formula State (C) Wt. 
1 IUS 	11` ~//~(~/ C1,H20N_OS Whitepowdcr g6-88 90 240.157 
H, 
2 112 
H~\  CI]H22N4S While powder 80.86 90 254.358 
H'\ 	/ CDrown~H36N4S Drown slickYq liquid 65 355.470 3 116 j~~~  
4 109 C19H34N,OS White powder 67-89 BO 338.492 
C19HMN4S Whft powder 76-77 85 352319 
6 117 , 	BgH40N4S Bmwn sticky liquid 	- 62 452.631 
C19Ii3 N_O:S Y0Iiilsolid 	76.78 go 354,431 7 110 
OH 
C]gH26N40S vs1lu. solid 	62-64 7g 368.518 
8 114 
OH 
Is'7H4pN4OS Brown sticky 	- 60 463.630 
Y IIR 	\' 	 ' 
OH 
IC 111 Ct,HhMQ2s Yet1ovaolid 	
75-76 84 354431 
OH 
Yellow solid 	64-66 80 368.518 
11 115 C1,HMN'OS 
OH 
12 119 C,,Ht,N4OS Brown stcky liquid 	- 60 466.630 
Oa 
M.P.: Melting poiat 
The 1,3,4-oxadiazole-2-thiones and 1,2,4-triazol-3-thiones may exist in thiol-thione 
tautomeric forms, but in solid state thione form dominates. Such observations are also 
[63] 
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reported in literaturez. Structure of compound (109) appeared in literature ° also, but 
without spectral data. All reactions were monitored by using TLC time by time. 
Products were purified by column chromatography. The structure of all the newly 
synthesized compounds was determined on the basis of their IR,'H NMR, 13C NMR 
and mass spectral data. Characteristic [M+Na]' ion peaks were observed for all the 
compounds under study. The detailed spectral description for compounds (108, 112 
and 116) is discussed below. 
IR spectrum of compound 5-(dec-9'-enyl)-(311)-1,3,4-oxadiazol-2-thione, (108) 
revealed characteristic bands at 3215 cm"' for N-H stretching, 2921 cni' for C-H 
stretching and the detection of C=N stretching band at 1613 cnf', GS stretching 
band at 1165 cm 1  and C-O-C absorption band at 1054 cm" for evidence of ring 
closure of 1,3,4-oxadiazol-2-thione ring. No peak was observed around 2600-2550 
em" for Ihiol group, further confirmed the structure of compound (108). In the 'H 
NMR spectrum of compound (108), characteristic peak was observed for N-H proton 
at S 10.30 as singlet, in addition to peaks of fatty acid chains. The 13C NMR 
characteristic peaks for compound (108) were observed at 6 166.8, 165.4, 123.0 and 
122.3. Further evidence for the formation of (108) was obtained by recording the 
mass spectrum which showed the [M+Na]` ion peak at m/z 262.880. Similarly, the 
structures of compounds (109-111) were confirmed from their spectral data given in 
experimental section (3.4.1). 
The structure of compound 4-amino-5-(dec-9'-enyl)-1,2,4-triazol-3-thione, (112) was 
confirmed by the appearance of absorption bands at 3228 cm" for N-H stretching, 
2924 em-' for C-H stretching, 1599 cm ' for C=N stretching and for C=S stretch, the 
absorption band appeared at 1186 cm". No peak was observed around 2600-2550 
cm" for thiol group, further confirmed the thione structure of compound (112). The 
'H NMR characteristic peaks were observed at 8 11.60 as singlet for N-H proton, 3 
4.57 as broad singlet for NH2 protons. The 13C NMR characteristic peaks for 
compound (112) were observed at 5 167.0, 160.5, 139.1 and 121.2. In addition, 
evidence for the formation of (112) was obtained by recording the mass spectrum 
which showed the [M+Na]' ion peak at m/z 276.830. Similarly, the structures of 
compounds (113-115) were confirmed from their spectral data given in experimental 
section (3.4.1). 
[64] 
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The structure of compound 3-(dec-9'-enyl)-6-phenyl-7H-1,2,4-triazolo[3,4-b]-1,3,4-
thiadiazine, (116) was confirmed by the appearance of absorption bands at 2923 cm t 
for C-H stretching, 1604 cm 1 for C=N stretching, 1125 cm' for C-N stretching, 652 
cm' for C-S-C. The disappearance of absorption peaks for N-H and C=S stretching 
was further confirmed the structure of compound (116). The 'H NMR characteristic 
peaks were observed at 6 7.55-7.39 as multiple[ for five aromatic protons, S 4.12 as 
singlet for two ring protons. The disappearance of 'H NMR peak for N-H proton 
further confirmed the structure of compound (116). The °C NMR characteristic peaks 
for compound (116) were observed at S 168.1, 165.4, 160.8, 134.8, 132.9, 132.5, 
131.1, 130.5, 124.8, 122.5, 115.4 and 36.2. Confirmation for the formation of (116) 
was also obtained by recording the mass spectrum which showed the [M+Na] ion 
peak at n✓z 378.041. Similarly, the structures of compounds (117-119) were 
confirmed from their spectral data given in experimental section (3.4.1). 
3.3.2. Biology 
3.3.2.1. In vitro cytotoxicity evaluation 
In vitro cytotoxicity of all the newly synthesized compounds (108-119) was measured 
by Mn [3-(4,5-dirnethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] assay against 
a panel of three different human cancer cell lines namely; human hepatoceI1uIaz 
carcinoma (Hep3 B), human breast adenocarcinoma (MCF 7) and human cervical 
carcinoma (HeLa). These cell lines are procured from Cell Repository—National 
Centre for Cell Science, Pune (India). Normal human cells (PBMCs) were also used 
for the determination of cytotoxicity of synthesized compounds. The MTT assay is a 
colorimetric assay for measuring the cellular growth that reduces the tetrazolium 
yellow dye MTT, to its insoluble formazan (purple colour) by mitochondrial 
dehydrogenases of living cells. MU is used to determine the cytotoxicity of potential 
drugs and other toxic compounds. The insoluble purple formazan product is dissolved 
into a coloured solution by the addition of a suitable solvent. At certain wavelength, 
the absorbance of this coloured solution can be measured. The potency of the drug in 
causing cell death can be concluded through the production of dose-response curves 
when the purple formazan produced by untreated control cells. Curves of dose- 
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dependent effects of (108-119) on cell viability of different human cancer cell lines 
(Hep3 B, MCF 7, HeLa) and normal human cells (PBMCs) are displayed in Figure 2. 
Doxorubicin and S-fluorouracil were used as standard drugs. Experiment was 
performed in a triplicate. For each of the tested drug ICso was calculated and the 
results are summarized in Table 8. Experiments revealed that there was substantial 
increase in cytotoxicity in cancer cell lines with increasing exposure to compound 
concentration i.e. showing low ICS values and the in-house synthesized compounds 
were not showing marked effects on normal human cells (PBMCs) i.e. showing high 
IC50 values. None of the synthesized compound showed cytotoxicity to normal human 
cells (PBMCs). Present study showed that among the three human cancer cell lines 
tested, Hep3 B cells were found to be sensitive to all the tested compounds while 
HeLa and MCF 7 cells were found to be sensitive to some selected compounds. The 
obtained results were revealed that compound (108, 110, 111, 112, 114, 115, 116, 
117, 118 and 119) showed remarkable inhibitory activities against different human 
cancer cell lines and were also comparable to the standard drugs. 
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Figure 2: Dose-response effect of all the synthesized compounds (108- 
119) on cell-viability of Hep3 B, MCF 7, HeLa and PBMCs. Data 
expressed here is meantstandard deviation of three independent experiments. 
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Table 8: Anticancer data (IC50 values in ItM) of all the synthesized 
compounds and standard drugs against three different human cancer 
cell lines and normal human cells 
S.No. Compound Hep3 B MCF 7 HeLa PBMC 
codes 
1 108 08.9412.5 13.60±2.5 11.90±1.3 35.32±3.1 
2 109 16.42+1.5 19.00±2.5 17.60±2.3 39.12+1.7 
3 110 09.00±1.6 15.90±1.6 12.90±1.3 45.42±4.1 
4 111 10.10+2.6 16.83±2.6 13.30±3.3 41.38+2.5 
5 112 09.20±0.8 14.00}0.6 11.10±2.1 39.12±1.6 
6 113 16.60±1.2 19.90+0.7 18.80+1.3 43.83±1.9 
7 114 09.48±1.4 13.20±0.5 16.20±2.4 33.5712.3 
8 115 09.96±2.8 14.50±1.6 15.82+3.1 35.25±1.9 
9 116 07.40±2.2 10.30±2.7 08.01±1.3 32.78±2.9 
10 117 09.49±1.5 11.27±2.4 10.03+1.7 >50 
11 118 06.50±2.4 08.59±1.5 08.83±1.4 >50 
I2 119 07.36+1.6 08.80±2.1 06.00}3.1 39.12±3.1 
Doxo°  02.35±1.2 03.12±1.7 03.56±2.7 09.23+2.6 
5-Fu" 03.54±2.1 04.12±2.3 02.78±2.6 08.91±1.9 
Standard drugs used for reference: a: Doxombicin, b: 5-Fluorouracil 
3.3.3. Structure-activity relationship (SAR) studies 
On the basis of structure-activity relationship, it could be concluded that 1,2,4-triazole 
fused with 1,3,4-thiadiazine ring were found to have better antitumor activity than 
those of 1,2,4-triazoles and 1,3,4-oxadiazoles. The structural activity study shows that 
anticancer activity may also dependent on the nature of alkenyYhydroxyalkenyl fatty 
acid chain. From IC50  values a number of correlations can be made. It is apparent 
from the IC50 values that, all the tested compounds showed moderate to good 
cytotoxicity against different human cancer cell lines. For Cio terminal alkenyl fatty 
acid chain residue which is substituted at 5-position of 1,3,4-oxadiazol-2-thione 
(compound, 108) and at 5-position of 1,2,4-triazol-3-thione (compound, 112) lead to 
remarkable increase in potency against human hepatocellular carcinoma cells (IC50 
[71] 
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value of 08.94f2.50 pM and 09.20±1.5 .tM, respectively). Incorporation of 1,3,4-
thiadiazine ring with 1,2,4-triazole ring having Cio terminalalkenyl fatty acid chain 
residue at 3-position of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazine (compound, 116) lead 
to increase in cytotoxicity against all the three human cancer cell lines; IC50  values of 
07.40±2.2 µM (against Hep3 B cells), 10.30±2.7 µM (against MCF 7 cells), 
08.01±1.3 pM (against HeLa cells). Increase in carbon chain length (C17) of internal 
alkenyl fatty acid chain residue at 5-position of 1,3,4-oxadiazol-2-tlilone (compound, 
109) and at 5-position of 1,2,4-triazol-3-thione (compound, 113) lead to high IC50 
values i.e. IC50  value was above 16.42 pM against all the three tested human cancer 
cells. In case of 1,2,4-triazolo-[3,4-b)-1,3,4-thiadiazine ring system, even the chain 
length of the internal alkenyl substituent at 3-position (compound, 117) was increased 
(C17) still it displayed good antitumor activity against all the three cancer cell lines 
(IC5o value of 09.49±1.5 µM against Hep3 B cells, 11.27±2.4 µM against MCF 7 cells 
and 10.03±1.7 µM against HeLa cells), this may be due to the fused ring system. 
Presence of hydroxyl group on alkenyl fatty acid chain residue which is attached to 
1,3,4-oxadiazol-2-thione at 5-position (compounds, 110 and 111) was responsible for 
increase in potency against hepatocellular carcinoma cells (ICso values of 09.00±1.60 
µM and 10.10±2.6 µM, respectively). Also, in case of 1,2,4-triazole, the presence of 
hydroxyl group on the alkenyl fatty acid chain residue at 5-position was responsible 
for increased cytotoxicity of compounds (114 and 115) against Hep3 B cells (IC50 
value of 09.48±1.4 µM and 09.96±2.8 AM, respectively). For compounds (118 and 
119), there may be two reasons for increased in potency against all the three cancer 
cell lines: the presence of hydroxyl group on the alkenyl fatty acid substituent and the 
other was the presence of fused ring system i.e. incorporation of thiadiazine with 
hiazole ring (IC50 values of 06.50±2.4 }iM against Hep3 B cells, 08.59±1.5 pM 
against MCF 7 cells, 08.83±1.4 1sM against HeLa cells and 07.36±1.6 µM against 
Hep3 B cells, 08.80±2.1 µM against MCF 7 cells, 06.00±3.1 pM against HeLa cells, 
respectively). These initial findings lead to further derivatization of heterocyclic fatty 
acids. 
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3.3.4. Conclusion 
In conclusion, the synthesis of novel heterocyclic fatty acid analogs and in vitro 
anticancer activity evaluation of synthesized compounds against different human 
cancer cell lines and PBMCs by MTT assay were described. Anticancer activity 
results revealed that the synthesized compounds were non-toxic to the normal human 
cells. The results of cytotoxic study also showed that, all compounds possess 
moderate to good activity but compounds (118 and 119) were the most promising 
cytotoxic agent with IC50  values below 08.83±1.4 tM against all the three tested 
human cancer cells (Hep3 B, MCF 7, HeLa cells) may be due to the presence of 
hydroxyl group on fatty acid chain and fused ring system (triazolothiadiazine 
nucleus). From this study, it can be concluded that the potency of drugs depend on the 
nature of fatty acid chain and the heterocyclic ring system. From these studies, it is 
comprehensible that further derivatization of different heterocyclic analogs of fatty 
acids can be serve as new templates for antitumor chemotherapy and could be 
probably lead to more active molecules in the area of cancer chemotherapy. 
[73] 
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3.4. Experimental 
3.4.1. Chemistry 
Physical and spectroscopic measurements 
Anhydrous conditions were achieved by drying flasks and other equipments in the 
oven. Reagents were of commercial grade and were used without further purification. 
When required, solvents were dried and distilled before use. The source of olefinic 
and hydroxy-olefinic fatty acids, instrumental details of IR, NMR and mass 
spectrometry are already detailed in experimental section of chapter 1 (page number 
19). Long chain alkenyl/hydroxyalkenyl hydrazide used as starting material which 
was synthesized from the corresponding fatty acids'9. All the products were purified 
by column chromatography. Carbon disulfide, potassium hydroxide, phenacyl 
bromide, hydrazine hydrate were purchased from Merck, Mumbai, India. TLC was 
performed on glass plates with a layer of silica gel G (Merck, Mumbai, India, 0.55 
min thickness). Developing solvents used were the mixture of petroleum ether-diethyl 
ether-acetic acid (75:25:1; v/v). 
Synthesis of novel series of 5-long chain alkenyl/lrydToxyalkenyl-1,3,4-oxadiazol-2- 
11dones, (108-111) 
A mixture of 0.01 mole of long chain alkenyl/hydroxyalkenyl hydrazide39 (22-25), 
0.01 mole of potassium hydroxide and 10 mL of carbon disulfide were refluxed (80-
90°C) in 50 mL ethanol for 8 hours. The reaction mixture was concentrated on water 
bath, then cooled to room temperature, acidified with dilute HCl at 0'C and the solid 
product was separated out. After that the product was filtered and washed with cold 
water. The solid products (108-111) were then air dried. Further, the products (108-
111) were purified by silica gel column chromatography with petroleum ether and 
diethyl ether as eluent. The products were identified by spectral data. 
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The spectroscopic data for the synthesized compounds (108-111) are presented 
below: 
5-(Dec-9'-enyt)-(3H)-1,3,4-oxadiazol-2-thione, (108) 
IX (KBr, cm 1): 3215 (N-H stretching), 2921 (C-H stretching), 1613 (C=N stretching), 
1165 (C=S stretching), 1054 (C-O-C). 
'HNNIR (CDC1j, S,:): 10.30 (1H, s, NH), 5.81 (1H, tdd, ,tr ,rH = 6.48 Hz, j, = 
10.31 Hz, Je _H = 17.24 Hz, CH2=CH), 5.01 (1H, dd, t 	= 10.31 Hz, j 	=2.00 
Hz, HzC=CH), 4.92 (1 H, dd, •J 1 r" = 16.91 Hz, 7,, W —2.00 Hz, HC=CH), 2.69 
(2H, t, J= 7.50 Hz, CH2 a to ring), 2.01 (2H, m, CH2—CH-CH2), 1.74 (2H, m, CII2 (i 
to ring), 1.30 (10H, br.s, (CH2)5). 
13C NNIR (CD Ch, Sc): 166.8, 165.4, 123.0, 122.3, 30.9, 30.8, 30.1, 29.9, 28.5, 27.1, 
26.2, 24.2. 
MS (ESI): m/z = 262.880 found [M+Na]`, calculated [M+Na]' = 263.146. 
5-(Heptadec-8'-enyl)-(3H)-1,3,4-oxadiazol-2-thione, (109) 
IR (KBr, cm"'): 3218 (N-H stretching), 2925 (C-H stretching), 1615 (C=N stretching), 
1166 (C=S stretching) 1059 (C-O-C). 
'H NMR (CDCI3, 8g): 10.85 (IH, s, NH), 5.35 (2H, m, CH=CH), 2.69 (2H, t, J = 
7.58 Hz, CH2 a to ring), 2.01 (4H, m, CH2CH=CHCH2), 1.75 (2H, m, CH2 3 to ring), 
1.31 (20H, br.s, (CH2)10),  0.88 (3H, dist.t, Cllj). 
13C NMR (CDC13, Se): 165.3, 163.2, 126.0, 125.8, 35.0, 33.9, 31.0, 29.4, 28.9, 28.7, 
28.0, 27.3, 26.8, 25.8, 23.7, 23.4, 23.0, 22.0, 14.0. 
MS (ESI): mtz = 362.231 found [M+Na]4, calculated [M+Na]' = 361.481. 
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5-[(8'Z, Il'R)-11'-Hydroxyheptadec-8'-euylJ-(3H)-1,3,4-oxadiazo1-2-tbione, (110) 
IR (KSr, cm-'): 3398 (0-H stretching), 3121 (N-H stretching), 2923 (C-H stretching), 
1625 (FN stretching), 1159 (C=S stretching), 1056 (C-O-C). 
rH NMR (CDCI3, Sy): 12.34 (11-1, s, Na), 5.47 (2H, m, CH—CH), 3.68 (IH, m, 
CHOH), 2.68 (2H, t, J= 7.49 Hz, CH2 a to ring), 2.28 (1H, m, CHOH), 2.04 (4H, m, 
CH2CH=CHCH2), 1.72 (2H, m, CH2 (t to ring), 1.28 (18H, br.s, (CH2)9), 0.88 (3H, 
dist.t, C113). 
13CNMR (CDCdr, 8d: 168.3, 164.2, 133.2, 125.1, 72.0, 37.3, 36.6, 35.1, 31.8, 30.1, 
29.7,29.6,29.1,28.9,27.2,25.4,24.0,23.4,14.2. 
MS (ESI): tn/z = 376.689 found [M+Na]', calculated [M+Na]' = 377.420. 
5-[(8'R,11'Z)-8'-Hydroxyheptadec-11'-euylJ-(3H)-1,3,4-oxadiazol-2-thioue, (111) 
Lk (KBr, crri t): 3353 (0-H stretching), 3159 (N-H stretching), 2921 (C-H stretching), 
1619 (C=N stretching), 1152 (C=S stretching), 1051 (C-O-C). 
'H NMR (CDC13, 8H):  11.56 (IH, s, NH), 5.37 (2H, m, CH=CH), 3.59 (1H, m, 
CHOH), 2.70 (2H, t, J= 7.50 Hz, CH2 a to ring), 2.25 (1H, iii, CHOH), 2.00 (4H, m, 
CHICH=CHCH2), 1.72 (2H, m, CHz (i to ring), 1.29 (18H, br.s, (CH2)9),  0.87 (3H, 
dist.t, CH3). 
13CNMR (CDCI3, 6c): 167.5, 165.8, 133.0, 125.9, 71.9, 37.1, 36.4, 35.1, 32.8, 31.4, 
30.9, 29.9, 282, 27.6, 26.9, 25.2, 24.6, 23.1, 14.0. 
MS (ESI): mfz = 376.450 found [M+Na]', calculated [M+Na]' = 377.420. 
Synthesis of novel series of 4-amino-5-long chain alkenyuhydroxyalkenyl-1,2,4-
triazol-3-thiones, (112-115) 
To a solution of 0.01 mole of potassium hydroxide in 50 mL absolute ethanol, 0.01 
mole of long chain alkenyl/hydroxyalkenyl hydrazide, (22-25) and 0.013 mole of 
[76] 
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carbon disulfide was added. The reaction mixture was stirred for 8 hours at room 
temperature. The reaction mixture was then diluted with 30 mL diethyl-ether and 
stirred for additional 1 hour. The potassium salt without further purification was used 
for the next step. 0.02 Mole of hydrazine hydrate in 20 mL water was gradually added 
to the above potassium salt with constant stirring and then the reaction mixture was 
refluxed for 4 hours. During refluxing, H2S gas released and the reaction mixture 
colour changed to light pink. The reaction mixture then cooled and acidified with 
concentrated HCI. The white solid product was separated out which was then filtered 
and washed with water. The solid products (112-115) were then air dried. The 
products (112-115) were purified by silica gel column chromatography with 
petroleum ether and diethyl ether as eluent. The products were identified-by-spectraL 
data. 	 / ,' 
The spectroscopic data for rite synthesized compounds (112-1T5JYdr¢:prweHteel t 
below:  
4-Amino-5-(dec-9'-enyl)-1,2,4-triazol-3-thione, (112) 
IR (KBr, cm-5: 3228 (N-H stretching), 2924 (C-H stretching), 1599 (C=44 stretching), 
1186 (C=S stretching). 
'HNMR (CDCI3, dy): 11.60 (1H, s, NH), 5.79 (1H, tdd, .~H ,rU = 6.70 Hz, J„_„ = 
10.10 Hz, j,,.,, = 17.20 Hz, CH2—CH), 5.01 (1H, dd, i,, _„ = 10.10 Hz, j', = 1.30 
Hz, HzC=CH), 4.94 (1H, dd, .;„ = 17.20 Hz, j,, -,, = 1.30 Hz, HEC=CH), 4.57 
(211, br.s, NH2), 2.74 (2H, t, J 7.50 Hz, CH1 a to ring), 2.02 (21-1, m, CH2=CH-CH2), 
1.70 (2H, m, CH2 3 to ring), 1.29 (10H, br.s, (CH2)5). 
13CNMR (CDCl3, 3d: 167.0, 160.5, 139.1, 121.2, 33.7, 31.8, 29.5, 29.4, 28.8, 27.2, 
26.1, 24.8. 
MS (ES!): m/z = 276.830 found [M+Na]`, calculated [M+Na]' = 277.347. 
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4-Amino-5-[(8'Z)-heptadec-8'-enylJ-1,2,4-triazol-3-tliione, (113) 
IR (((Hr. cni '): 3224 (N-H stretching), 2924 (C-H stretching), 1595 (C=N stretching), 
1179 (C=S stretching). 
'H NMR (CDC13, JR): 11.32 (1H, s, NH), 5.35 (21-1, m, CH=CFI), 4.55 (2H, bcs, 
Nllz), 2.75 (2H, t, J = 7.50 Hz, CHz a to ring), 2.03 (4H, m, CHICH=CHCH2), 1.68 
(2H, m, CH2 Q to ring), 1.29 (20H, br.s, (CH2)ie), 0.88 (3H, dist.t, CH3). 
13CNMR (CDCJJ, dc): 167.3, 165.6, 134.6, 122.1, 36.5, 34.1, 30.9, 29.2, 29.0, 28.9, 
28.6, 27.4, 26.0, 25.9, 24.6, 24.1, 23.2, 22.4, 14.2. 
MS (ESI): ails 374.912 found [M+Na]', calculated [M+Na]+ = 375.508. 
4 Amino-5 /(8'Z, 11'R)-11'-1ydroxyGeptarIec-8'-enyll-1,2,4-triazol-3-tlrione, (114) 
IR (KBr, cm 1): 3380 (0-H stretching), 3214 (N-H stretching), 2924 (C-lI stretching), 
1622 (C=N stretching), 1162 (C=S stretching). 
'H NMR (CDC13, 3p): 12.17 (IH, s, NH), 5.41 (2H, m, CH=CH), 4.51 (211, br.s, 
NH,), 3.69 (1H, m, CHOH), 2.70 (2H, t, J 7.51 Hz, CH2 a to ring), 2.26 (1H, m, 
CHOH), 2.02 (4H, m, CH2CH CHCHz), 1.67 (2H, m, CH2 J3 to ring), 1.29 (18H, br.s, 
(CH2)9), 0.89 (3H, dist.t, CH3). 
f3C NMR (CDC13, Sc): 168.0, 163.2, 135.1, 121.9, 71.9, 37.3, 36.2, 34.9, 32.8, 30.1, 
29.9, 29.6, 29.1,28.2, 28.0, 27.8, 25.4, 24.0, 13.9. 
MS (ESI): m/z = 392.014 found [M+Na]', calculated [M+Na]+ = 391.507. 
4 fbnino-5-[(8'R, Il'Z)-8'-hydroxyheptadeall'-e,:y1J-1,2,4-triazol-3-thione, (115) 
IR (KBr, cm"1): 3376 (0-H stretching), 3217 (N-H stretching), 2921 (C-H stretching), 
1619 (C=N stretching), 1164 (C=S stretching). 
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'H NMR (CDCI3, 8y): 12.09 (111, s,.NH), 5.47 (2H, m, CH=CH), 4.56 (2H, br.s, 
NH2), 3.68 (1 H, m, CHOH), 2.72 (2H, t, J=7.50 Hz, CH2 a to ring), 2.27 (IH, m, 
CHOH), 2.04 (4H, m, CHICH=CHCH2), 1.69 (2H, m, CHz (i to ring), 1.28 (18H, br.s, 
(CH2)9), 0.87 (3H, dist.t, CH3). 
t3CNMR (CDC13, dc): 167.8, 164.4, 135.2, 122.5, 70.4, 37.2, 36.9, 34.0, 32.4, 30.1, 
29.8, 29.5, 29.2, 28.7, 28.0, 27.6, 25.4, 23.5, 14.2. 
MS (ES!): m/z = 392.210 found [M+Na]~, calculated [M+Na]' = 391.507. 
Synthesis of novel series of 3-long chain alkenyl/hydroxyalkenyl-6phenyl-7H-
1,2,4-triazolof3,4-bJ-1,3,4-thiadiazines, (116-119) 
To a solution of 0.0025 mole of 4-amino-5-long chain alkenyl/hydroxyalkenyl-1,2,4-
triazol-3-thiones, (112-115) in 15 mL absolute ethanol, 0.0025 mole of phenacyl 
bromide was added and the reaction mixture was refluxed at 90°C for 12 hours on oil 
bath. When all the triazole was consumed the reaction mixture was neutralized by 
ammonium hydroxide. The product was extracted with dichloromethane and washed 
with water. The organic layer dried over anhydrous sodium sulfate. The solvent was 
evaporated on water bath from the oily product (116-119). Further, the products (116-
119) were purified by silica gel column chromatography with petroleum ether and 
diethyl ether as eluent. The products were identified by spectral data. 
The spectroscopic data for the synthesized compounds (116-119) are presented 
below: 
3-(Dec-9'-enyl)-6-phenyl-7H-1,2,4-triazolo(3,4-b]-1,3,4-thiadiazine, (116) 
IR (KBr, cm"'): 2923 (C-H stretching), 1604 (C=N stretching), 1125 (C-N stretching), 
652 (C-S-C). 
I H NMR (CDC(?, 8y): 7.55-7.39 (5H, m, ArH), 5.78 (1H, tdd, J 	— 6.72 Hz, N-R CN, 
= 10.00 Hz, J„ 	17.24 Hz, CH2=CH), 5.01 (1H, dd, j,,. -, = 10.12 Hz, j,,,-,,   
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= 1.35 Hz, HzC=CH), 4.94 (IH, dd, ✓„ ,, = 17.23 Hz, ✓x -„ = 1.34 Hz, HLC=CH), 
4.12 (2H, s, CH2 ring), 2.75 (2H, t, J = 7.50 Hz, CHZ a to ring), 2.04 (2H, m, 
CH2=CH-CH2), 1.69 (2H, m, CH2 p to ring), 1.28 (IOH, br.s, (CH2)5). 
13CNMR (CDC13, Scd: 168.1, 165.4, 160.8, 134.8, 132.9, 132.5, 131.1, 130.5, 124.8, 
122.5, 115.4, 36.2, 34.2, 33.9, 32.8, 32.1, 31.7, 30.9, 29.4, 25.0. 
MS (ES!): mlz = 378.041 found [M+Na]+, calculated [M+Nar = 377.459. 
3-[(8'Z)-Heptadec-8'-eny1J-6 phenyl-7H-1,2,4-triazolo[3,4-bJ-1,3,4-thiadiazine, 
(117) 
IR (KBr, cm- ): 2926 (C-H stretching), 1599 (C=N stretching), 1120 (C-N stretching), 
660 (C-S-C). 
'HNMR (CDCI3, ö): 7.62-7.40 (511, m, ArH), 5.35 (2H, m, CH=CH), 4.09 (2H, S. 
CH2 ring), 2.67 (2H, t, J = 7.54 Hz, CHs a to ring), 2.03 (4H, m, CFI2CH=CHCH2), 
1.64 (211, m, CH2 [3 to ring), 1.25 (20H, br.s, (CH2)10), 0.87 (3H, dist.t, CH,). 
13CNMR (CD C13, hr): 168.3, 165.6, 160.5, 134.5, 132.5, 132.0, 131.5, 130.8, 129.7, 
125.0, 122.1, 35.5, 34.0, 32.5, 30.5, 29.0, 28.9, 28.4, 28.0, 27.2, 26.6, 25.5, 24.4, 
24.0, 23.1, 21.4, 14.3. 
MS (ESI): ink = 474.971 found [M+Na]', calculated [M+Na]~ = 475.620. 
3-[(8'Z,11'R)-11'-Hydrazyheptadec-8'-enylJ-6 pherry47H-1,2,4-triazoto[3,4-bJ-
1,3,4-thiadiazfne, (118) 
IR (KBr, cm'): 3360 (0-H stretching), 2922 (C-H stretching), 1613 (C=N stretching), 
1115 (C-N stretching), 665 (C-S-C). 
'HNNTR (CDCI3, h,): 7.60-7.35 (5H, m, ArH), 5.40 (2H, m, CH=CH), 4.10 (2H, s, 
CHtring), 3.62 (1H, m, CHOH), 2.72 (2H, t, J= 7.50 Hz, CH2a to ring), 2.28 (1H, m, 
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CHOH), 2.01 (414, in, CH2CH=CHCH2), 1.68 (2H, m, CH2 [i to ring), 1.29 (1814, br.s, 
(CH2)9), 0.87 (314, dist.t, CH3). 
'3CNMR (CDCI, bc): 167.0, 164.1, 163.8, 135.1, 132.7, 132.2, 131.4, 130.1, 123.4, 
123.0, 121.9, 112.8, 36.3, 34.8, 33.9, 32.4, 30.3, 29,9, 29.5, 29.2, 28.7, 28.3, 27.8, 
26.6, 24.7, 24.4, 14.2. 
MS (ESI): mlz = 492.106 found [M+Na]', calculated [M+Na]` = 491.619. 
3-[(S'R,11'Z)-8'-Hydroxybeptadeo-ll'-enylJ-6phenyl-7H-1,2,4-1riazolo[3,4-b]-
1,3,4-t6iadiazine, (119) 
II? (KRr. cm I): 3382 (0-H stretching), 2924 (C-H stretching), 1615 (C=N stretching), 
1122 (C-N stretching), 667 (C-S-C). 
'H NMR (CDCI3, c,j): 7.58-7.35 (514, in, ArH), 5.37 (2H, m, CH=CII), 4.19 (214, s, 
CH2 ring), 3.64 (1H, m, CHOH), 2.69 (211, t, J= 7.50 Hz, CH, a to ring), 2.28 (1H, 
m, CHOP), 2.04 (411, m, CHICH=CHCH2), 1.65 (2H, m, CH2 (i to ring), 1.28 (1814, 
br.s, (CH2)9),  0.87 (311, dist,7, CH 3). 
I3C NMR (CDC13, Sd: 167.8, 166.2, 164.4, 133.2, 132.6, 131.9, 131.5, 130.6, 129.6, 
123.1, 122.5, 70.2, 37.1, 36.5, 32.8, 32.6, 30.3, 29.8,29.4,29.1,29.5, 28.0, 27.8, 27.2, 
25.8, 23.9, 14.1. 
MS (ESI): m/z = 492.110 found [M+Na]`, calculated [M+Na]` = 491.619 
3.4.2. Biology 
3.4.2.1. In vitro anticancer activity 
3.4.2.1.1. Peripheral blood mononuclear cell isolation 
Fresh blood (20-15 mL) was kindly provided by blood bank, Jawaharlal Nehru 
Medical College, Aligarh Muslim University, Aligarh. The blood sample was diluted 
with the same volume of phosphate buffersaline (PBS). After that, the diluted blood 
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sample was carefully layered on Ficoll-Histopaque (Sigma Aldrich, .USA). The 
mixture was centrifuged under at 400xg for 30 minutes at 20-22"C. The undisturbed 
lymphocyte layer was carefully transferred out. The lymphocyte was washed and 
pelleted down with three volumes of PBS for twice and resuspended RPMI-1640 
media (Sigma Aldrich, USA) with antibiotic and antimycotic solution (Sigma Aldrich, 
USA) 10%, viv fetal calf serum (FCS) (Sigma Aldrich, USA). Cell counting was 
performed to determine the PBMC cell number with equal volume of trypan blue61,42. 
3.4.2.1.2. MTT assay 
The PBMCsIHeLa/Hep3 B/MCF 7 cell lines were maintained in RPMI 1640 (Sigma 
Aldrich) culture medium supplemented with 10% heat-inactivated fetal calf serum 
and antibiotic antimycotic solution (Sigma Aldrich). The cells were plated at a density 
of 5 x  103 cells per well in a 96-well plate, and cultured for 24 hours at 3TC. The 
cells were subsequently exposed to drugs. The plates were incubated for 48 hours, and 
cell proliferation was measured by adding 20 µL of MTT (Sigma Aldrich) dye (5 
mglmL in phosphate-buffered saline) per well. The plates were incubated for a further 
4 hours at 37'C in a humidified chamber containing 5% CO2.  Formezan crystals 
formed due to reduction of dye by viable cells in each well were dissolved in 150 µL 
dimethyl sulfoxide (DMSO), and absorbance was read at 570 nm. The absorption 
values were expressed as the cell viability (%), according to the control group as 
100%. The concentration required for 50% inhibition of cell viability (ICs,)  was 
calculated using the software "Prism 3.0". 
[82] 
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CONHNHZ 
+ 	 Alcohol 
NH2  
(121) 	(122) 
(123) 
?fytrazono-isatin andN-metiyLisatin terivatiyes 
4.1. Theoretical 
Isatin is an indole derivative i.e. IH-indole-2,3-dione (120). In 1841, isatin was 
obtained as a product from the oxidation of indigo dye by nitric acid and chromic acid 
by Erdman and Laurent for the first time. 
5 
6 
(120) 
For the synthesis of large number of heterocyclic compounds such as indole 
derivatives, quinoline derivatives and raw material for drug synthesis, isatin nucleus 
can be used. Because of this mentioned fact isatins are synthetically versatile nuclei'. 
Sammaiah at al.' reported the synthesis of 2-aminobenzoic acid(2-oxo-1,2-dihydro-
indol-3-ylidcne)hydrazides (123) by the reaction of suitable isatin (121) and 2-amino 
benzoic acid hydrazide (122) in alcohol containing few drops of acetic acid. 
R: H, 5-CH3, 5-Cl, 5-NO2, 5-COOH, 7-COOCH3, 
S-Br, 7-Cl, 7-CH3, 6-Br, 5-I, S-F, S-COOCH3, 
4-C1.5-F, 7-NO2  
[86] 
OH + 
SH (124) 
~O—R 
~A 
H2N (125) O 
microwave 
a' 
\H2N (126) 
H2, Et; 
(CH2)2, Me 
Oydrazono-isatin and%-methyfisatin derivatives 
Spiro thiazolidinone-isatin conjugates (128) were prepared by Kaminskyy et a(.° by 
the reaction of isatin, appropriate amine (126), acetic acid and thioglycolic acid (124) 
under reflux conditions. Also, microwave assisted organic synthesis approach was 
used for the synthesis of target compounds (127) by reacting thioglycolic acid (124), 
isatin (120) and amine derivative (125). 
N4-Aryl substituted-5-trifluoromethoxy isatin-3-thiosemicarbazones (131) were 
prepared by Pervez et a1.5 by the reaction of trifluoromethoxy isatin (129) with 
different aryl thiosemicarbazides (130) in aqueous ethanol containing few drops of 
acetic acid. 
[87] 
m 
(132) 
N—N 
NH2  Cl 	Cl 
?Cydiazono-isatin anti m-metfiyEisatin derivatives 
0 
F3CO 
0 
(129) H 
RNI-ICSNHNI-I2  
(130)  
NNHCSNHR 
PS CO 
iIIII1::::f 	== 0 
(131) H 
50% ag. EtOH`  
AcOH 
R: C6H5, 4-C2H5C6H4, 2-FC6H4, 3-FC6H4, 4-C6H4, 4-CIC6H4, 4-BrC6H4, 4-IC6H4, 
2-F3CC6H4, 3-F3CC6H4, 4-F3CC6H4, 4-F3C0C6H4, 2,4-(CH30)2C6H3, 2,4-F,C6H3, 
2,6-F2C6H3, 3,5-F2C61-I3, 2-F-4-BrC6H3, 2,4-C12C6H3, 3,4-C12C6H3, 2-CH3-5-CIC6H3, 
2,4,6-C13C6H2  
The synthesis of 3-substituted isatin derivatives (134) were described by Nagarajan et 
at6 by the reaction of substituted isatin (132) with amino derivatives of lamotrigine 
(133). 
N—N 
H2N—j\ / \ / 
\N 
(133) NH2  CI 	Cl 
R: H, CI, Br 	 (134) 
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Bis-Schif bases isatin and its derivatives (137 and 139) were prepared by Jarrahpour 
et al.7 by the reaction of isatin, 5-fluoroisatin and benzyl isatin (120 and 135) with 
aromatic diamines (136 and 138) in the presence of catalytic amount of glacial acetic 
acid in ethanol. 
	
O 	 Y 	 Y 
1j 	 NH2 
(135) 	 (136) 	W 
EtOH, reflux 
X: CH2, 0, CO; Y: H. Cl; Z—H, Et; W: H, Et; R': H, Bn; R2: H, F 
[89] 
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H2N / NH2  
(120) 	
ELOH, reflux 
	(138) 
Panda et al.s reported the green chemistry approach for the synthesis of Schiff bases 
of isatin derivatives (141) by the condensation of keto group of isatin (120) with 
different aromatic primary amines (140) under microwave heating method. 
+ R-NH2 EtOH 
microwave 
(140) 
R: Phenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-chlorophenyl, 
4-chlorophenyl, 4-bromophenyl, 4-fluorophenyl, 3-CI-4-F-phenyl, 
2,6-dichlorophenyl 
In most of the developed countries after cardiovascular diseases, cancer represents 
one of the leading causes of mortality. The mainstay in the treatment of malignancies 
is the use of chemical agents to destroy cancer cells i.e. chemotherapy. Chemotherapy 
is used to treat widespread or metastatic cancers whereas radiation therapies and 
surgery are limited to treating cancers that are restricted to specific areas. Nowadays, 
significant research work is dedicated to introduce more affective anticancer agent 
[90] 
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while minimizing their toxic side effects, although many antineoplastic agents have 
been successfully identified and used in cancer treatments. Several drug delivery 
approaches have been modified to intensify the effectiveness of anticancer agents due 
to invariant advancements achieved in the field of chemistry, nanotechnology, soft 
matter science and in the understanding of biological mechanisms of cancer. Most of 
the drugs works by interfering with the cellular functions by microtubule assembly 
inhibition, by intercalation of DNA with groove binding, by proteins and nucleic acids 
alkylation, by topoisomerase II inhibition and by microtubules polymerization 
stabilization or by biosynthesis prevention or by normal cellular metabolites 
utilization. Microtubules are a sensitive target for the development of anticancer drugs 
because drugs that bind to tubulin act by interfering with the mitosis of cells during 
the M-phase resulting in mitotic arrest and ultimately leading to apoptosis9. In 2006, 
for the treatment of gastro intestinal stromal tumors and advanced renal cell 
carcinoma, SUI 1248 (Sutent), a 5-fluoro-3-substituted-2-oxoindole IUPAC name: N-
(2-diethylaminoehtyl)-5-[(Z)-(5-fluoro-2-oxo-I H-indol-3-ylidene)methyl]-2,4- 
dimethyl-lH-pyrrole-3-carboxamide, (142) was approved by the US FDA1° ... 
I 
Some halogenated derivatives of isatin were found to exhibit antileukemic activity 
against P388 lymphocytic leukemia in mice and 5-bromo-3-o-nitrophenyl isatin 
hydrazone was found to be active intramuscularly against Walker carcinorna-25612. 
In multicellular organisms, there are two patterns of cell death: necrosis and 
apoptosis. Apoptosis also known as programmed cell death, is a type of cell death that 
occurs during various pathological situations in multicellular organisms and help to 
cause replacement of cells, damaged cells removal under normal conditions and 
[91] 
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remodeling of tissue. In normal cellular processes including maintenance of the 
immune system, fetal development and tissue homeostasis, apoptosis plays a 
significant role. In pathological conditions such as allograft rejection, 
cardiomyopathy, neurodegenration, ischemia-reperfusion injury and sepsis, abnormal 
apoptosis has been found. These all are cited in the literature". Apoptosis is 
characterized by well known cytological and molecular events which include a 
change in the refractive index of cells, cytoplasmic blebbing, nuclear shrinkage and 
condensation of chromatin, shape irregularity of cells, retraction of processes, 
intemucleosomal DNA fragmentation, cleavage of poly(ADP-ribose)polymerase 
(PAR?) and apoptotic bodies formation 1.. 15. In pharmaceutical industry, the synthesis 
of novel drugs that can stop the process of apoptosis has been one of the most 
important and significant area of research. 
On the other hand literature survey also reveals that isatin structural motif can be 
found in a broad range of natural and synthetically derived biologically and 
pharmacologically active compounds". Isatin derivatives have been also found to 
possess antimicrobial, antiviral, anticonvulsant, antitubercular, antioxidant, anti HIV, 
anthelmintic, antiplasmodial, antiinflammatory and analgesic activities'7. 
[92] 
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4.2. Synthesis and Studies Involving Apoptosis Induced by 
Novel Isatin/N-Methyl Isatin Derivatives of Fatty Acid 
Hydrazones* 
Recently, some of the hydrazone derivatives have been reported1e as antituhercular 
agents whose mechanism of action was same as already known drug: isoniazid 
derivatives. Nowadays, in the treatment of neuropsychological disorders such as 
depression and schizophrenia, fatty acid derivatives are used"' 2°. Some of the fatty 
acid derivatives were reported as potent antitumor agents which plays important role 
in tumor growth progression2t . Also, the heterocyclic derivatives of saturated fatty 
acid i.e. stearic acid heterocyclic derivatives have been found to possess 
antidepressant and antimicrobial activities". Few years back, in our laboratory 
number of novel series of heterocyclic analogs of selected fatty acids (saturated, 
hydroxy-unsaturated, non hydroxy-unsaturated) have been synthesized and were 
found to be biologically active23-~. It has been described in reviews21, zr that isatin 
derivatives possessing important biological activities as well as the isatin analogs 
were also found to possess antimalarial28, antitubercularz9, antimicrobial30, etc. These 
aforementioned facts about the heterocyclic analogs of fatty acids and isatin 
derivatives prompted us to design and synthesize a series of novel compounds based 
on heterocyclic indole scaffold nucleus to assess their cytotoxicity profile. In this 
chapter, novel hydrazono-isatin analogs of fatty acids were synthesized by using fatty 
acid hydrazides as starting material for the first time. On the molecular design level, 
different fatty acid hydrazides were condensed at position 3 of isatinlN-inethyl isatin 
nucleus and impact of this performed manipulation was studied from the obtained 
cytotoxicity assessment and apoptotsis induction using MTT assay, propidium iodide 
(PI) staining, PAR? cleavage and fluorescence-activated cell sorting (FACS) assay 
studies of the synthesized compounds against different human cancer cell lines. 
`Research paper entitled "Synthesis and Studies Involving Apoptosis Induced by Novel 
Isatin/N-Methyl Isatin Derivatives of Fatty Acid Hydrazones" is communicated. (Aiman 
Ahmad, Varshney, H., Rauf, A. Arab. J. Chem.) 
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4.3. Results and discussion- 
4.3.1. Chemistry 
The synthesis of the hitherto unreported long chain title compounds and anticancer 
properties is described in this chapter. The long chain substituted hydrazono-isatin 
derivatives (144-148) were achieved in excellent yield using condensation reaction 
(dehydration) with isatin and fatty acid hydrazides (21-25) in ethanol as solvent 
containing catalytic amount of glacial acetic acid. Similarly, long chain substituted 
hydrazono-N-methyl isatin derivatives (149-153) were achieved in excellent yield in 
the same way as discussed above for N-methyl isatin. The schematic representation of 
the synthetic route of these novel title compounds is shown in Scheme 6. The 
structures of all the newly synthesized compounds were elucidated by IR, 'H NMR, 
13C NMR and mass spectral studies. 
For instance, IR absorption bands at 3398 (hetem N-H) and 3063 (amide N-H) were 
obtained for 3-(undec-10'-enoyl hydrazono) isatin (145). Also, bands at 1690 and 
1657 cm 1 were observed for CO stretching vibrations and a band at 1593 cm' for 
C=N was observed. 'H NMR spectra showed singlet for two N-H protons at 811.78 
and at 9.65. The spectrum also shows a multiplet for four aromatic protons at 57.62-
7.00. For a methine proton at C-10, a triplet of doublet of doublet was observed at 
55.80. C-1I methylene protons designated as Hz and HE which gave two values of S 
after coupling with adjacent C-10 methine protons. Two doublets of doublet were 
obtained for Hz  and HE at 55.00 and 4.92, respectively. °C NMR also confirmed the 
structure of (145). The characteristic signals for C=O, C=N and aromatic carbons 
were observed at 6176.8, 171.2, 163.2, 142.8 and 141.4-131.7, respectively. The 
structure of compound (145) was further supported by the mass spectrum which 
showed a molecular ion peak at m/z 349.368 consistent with the molecular formula. 
For 3-(undec-10'-enoyl hydrazono)-N-methyl isatin, (150), in addition to the peaks of 
compound (145) as discussed above, a singlet was observed at 53.23 for methyl 
protons which is substituted at nitrogen of indole moiety. A broad singlet which was 
the evidence of N-H proton of indole in compounds (144-148) was disappeared in the 
'H NMR spectra of compounds (149-153). 
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R-CONHNH2 
(21-25) 
EtOH, Cat. AcOH,~ 
A 
O 
R': H, CH3 
(120, 143) 
/ \ NNHCOR 
0 
N 
R' 
(144-153) 
(144-148), R': H; (149-153), R': CHI 
Compound 	 R 
Codes 
21, 144,149 
tt 	z 
22,145, 150 ~//~,YCHZ 
HE 
23, 146, 151 	 s 	 5 I-I2 
OH 
24, 147,152 	 } 	 5 CH2 
25,148,153 — 	Hz 
2 	 5 
OH 
Scheme 6: Synthesis of novel long chain hydrazono-isatin and N- 
methyl isatin derivatives 
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4.3.2. Biology 
The synthesized compounds were tested for in vitro cytotoxicity by MTT assay 
against HeLa (cervical carcinoma) cells. Compounds (148 and 153) were found to 
show best results for cytotoxicity against HeLa cells, so these two compounds were 
further tested for in vitro cylotoxicity against MCF 7 (breast carcinoma), Hep G2 
(hepatocarcinoma) and U20S (osteosarcoma) cell lines. In addition, the induction of 
apoptosis by these two compounds is evidenced by the PARP cleavage studies 
through western blotting technique, FACS assay and Pt staining results31a4. 
4.3.2.1. In vitro cytotoxicity 
In vitro cytotoxicity of the newly synthesized compounds (144-146, 148-151 and 153) 
was determined by MTT assay against HeLa cells. The general description of MTT 
assay and cytotoxicity is given in chapter 3 (page number 65, 66), in section 3.3.2.1. 
Experiment was performed in a triplicate. For each of the tested compounds IC50 was 
calculated and the results are summarized in Table 9. Further, cytotoxicity of two 
selected compounds (148 and 153) was carried out against Hep 02, MCF 7 and U20S 
cells by MTT assay. Selection of these compounds was based on low IC50 value 
among all the tested compounds against HeLa cells. 
[96] 
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Table 9: Anticancer data (IC50 values in tg/mL) of the synthesized 
compounds against four different human cancer cell lines. Data 
expressed here is meanfstandard deviation of three independent experiments. 
S.No. Compound HeLa MCF 7 U20S Hep G2 
Codes 
1 144 >50 N.T. N.T. N.T. 
2 145 19.07±1.5 N.T. N.T. N.T. 
3 146 >50 N.T. N.T. N.T. 
4 148 16.1911.7 15.30±25 21.80±2.4 19.63±1.8 
5 149 >50 N.T. N.T. N.T. 
6 150 32.75k0.9 N.T. N.T. N.T. 
7 151 >50 N.T. N.T. N.T. 
8 153 12.2111.6 18.14±2.1 17.27±3.1 10.64±2.8 
N.T.: Not Tested 
4.3.2.2. Propidium iodide (PI) nuclear staining 
Fluorescence microscopic investigations showed that test compounds induced cell 
death in Hela cell lines by apoptosis (Figure 3). Phenotypically, apoptosis is 
identified by cell shrinkage, chromatin compaction, blebbing of plasma membrane, 
fragmentation of DNA and cell collapse into small intact fragments (apoptotic 
bodies). Figure 3 shows the morphology of Hela cells treated with compounds (148 
and 153) and stained with PI. The fluorescent images showed structure and shape of 
control cells, untreated cells possessed intact nuclei, cells treated with compound (148 
and 153) at different concentrations caused the formation of clear apoptotic bodies 
and membrane blebbing which leads to cell death. 
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Figure 3: Fluorescence microscopic study of test compounds on Hela 
cell line stained with 25 pg/mL propidium iodide. (a) Un-stimulated (b) 5 
pg/mL Doxoruhicin treated (c) 10 pg/mL (148) treated (d) 20 µg/mL (148) 
treated (e) 10 pglmL (153) treated (1) 20 Itg/mL (153) treated 
4.3.2.3. Flow cytometry analysis of cell viability by PI uptake 
In apoptosis, membrane bound apoptotic bodies are formed by articulated breakdown 
of the cells. To determine the live and dead cell caused by compound (148 and 153) in 
Hela cells, the FACS assay was done using PI staining. PI can be used to stain dead 
cells so that they may be excluded from analysis in standard live cell surface staining 
protocols. These dyes cannot pass through intact cell membranes, but may freely enter 
cells with compromised cell membranes. Upon catering dead cells, PI will intercalate 
into double-stranded DNA or double-stranded RNA in a stoichiometric manner. As 
shown in Figure 4, after 72 hours treatment with compounds (148 and 153) at 10 and 
20 pg/mI, the number of apoptotic cells was increased in concentration dependent 
manner. 
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Figure 4: Flow cytometry analysis using PI staining showing live and 
dead cell percentage. (a) untreated (b) 5 pg/mL doxorubicin treated, (c) 10 
pg/mL (148) treated, (d) 20 pg/mL (148) treated, (e) 10 pg/nrL (153) treated, (1) 
20 pg/mL (153) treated 
4.3.2.4. Apoptosis induction via PARP cleavage 
Apoptosis involves the caspases activation and is also implicated in physiological and 
pathological processes. PARP cleavage has been served as one of the hallmark of 
apoptosis and caspase activation. To confirm the apoptosis induction by compounds 
(148 and 153), the expression of cleaved PARP was investigated by western blotting 
technique35. As shown in Figure 5, the cleaved PARP was significantly increased 
after treatment of Hela cells with compounds (148 and 153) at concentrations of 10 
and 20 µp/mL after 72 hours. These results together indicate that compounds (148 and 
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153) caused Hela cancer cell death via apoptosis by increasing the level of cleaved 
PARP. 
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Figure 5: Western blot analysis of PARP cleavage. Both full length and 
cleaved forms (p89) of PARP are shown. 
4.3.3. Structure-activity relationship (SAR) studies 
The synthesized compounds, (144-146, 148-151and 153) were tested for cytotoxicity 
assay against HeLa cells. Previously some fatty acid derivatives were also tested for 
anticancer activities and they were found to possess anticancer properties36, ». 
Compounds (147 and 152) have not tested for cytotoxicity because these are the 
structural-position isomers of compounds (148 and 153), respectively; they differ only 
in position of double bond and hydroxyl group with each other and it is already 
known that position isomers show same chemical properties and slightly different 
physical properties. From cytotoxicity assay results it has been found that, compounds 
(144, 146,149 and 151) were not showing significant cytotoxicity against HeLa cells, 
except compounds (145, 148, 150 and 153) which show cytotoxicity against HeLa 
cells. The difference in biological activities of all the tested compounds may be 
related to their structures. So by analyzing the IC5o values it may be said that isatinlN-
methyl isatin derivatives substituted with saturated long fatty acid hydrazone chain 
(C16) (144 and 149) were not showing significant cytotoxicity. On the other hand, 
presence of terminal double bond in the fatty acid hydrazone chain (Cl t) substituted 
to isatin/N-methyl isatin derivatives (145 and I50) lead to show some cytotoxicity 
against Hela cells. Further, the cytotoxicity assay of compounds (146 and 151) show 
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inconsiderable results and it may be said that as the number of carbon atoms of fatty 
acid hydrazone substituted to isatin/N-methyl isatin derivatives (146 and 151) 
increases (C18) and the terminal double bond changes to internal double bond lead to 
insignificant cytotoxicity against HeLa cells. Cytotoxicity assay results showed that 
introduction of hydroxyl group to internal alkenyl chain (Cl 8) substituted to isatinlN-
methyl isatin derivatives (148 and 153) leads to remarkable increase in cytotoxicity 
(having low ICso  value). Among compounds (148 and 153), compound (153) shows 
better cytotoxicity against cancerous cell lines and we have also found that compound 
(153) was the better apoptosis inducing agent than compound (148), may be due to 
presence of N-methyl substituted isatin. 
4.3.4. Conclusion 
In summary, two novel series of isatin and N-methyl isatin derivatives of fatty acid 
hydrazones (144-153) were successfully synthesized and characterized in this chapter. 
Additionally, these compounds were evaluated for in vitro cytotoxicity against four 
different human cancer cell lines by MTT assay. Further, the apoptotsis induction by 
the compounds was also proved by PARP cleavage studies done by western blotting 
technique, FACS assay and PI staining results. From the current investigation, 
structural-activity relationship of these compounds suggests that the nature of fatty 
acid hydrazone chain (saturated/unsaturated: terminallintemal double bond) and 
presence of hydroxyl group on fatty acid hydrazone chain may be responsible for 
difference in biological activities of the synthesized compounds (144-153). 
Compounds (148 and 153) with hydroxyl group substituted on fatty acid hydrazone 
chain were found to be most potent cytotoxic compounds and apoptosis inducing 
agents. Compound (153) was found to be better cytotoxic compound and potentially 
better apoptosis inducing agent compared to (148) may be due to substitution of N-
atom of isatin. 
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4.4. Experimental 
4.4.1. Chemistry 
Physical and Spectroscopic Measurements 
The source of olefinic and hydroxy-olefutic fatty acids, instrumental details of IR, 
NMR and mass spectrometry are already detailed in experimental section of chapter I 
(page number 19). Isatin and N-methyl isatin were purchased from Sigma Aldrich. All 
the reactions were monitored by thin layer chromatography (TLC). The developing 
solvent used were the mixtures of petrol-acetone-acetic acid (90:10:1; v/v). 
Anhydrous conditions were achieved by drying flasks and other equipments in the 
oven. Reagents were of commercial grade and used without further purification. 
When needed, solvents were dried and distilled before use. 
General procedure for the synthesis of long chain alkyl/alkenybhydroxyalkenyl 
hydrazides, (21-25) 
The long chain alkylalkenyUhydroxyalkenyl hydrazides (21-25) were synthesized by 
following the method"" and these selected fatty acid hydrazides were used as the 
starting material for the synthesis of long chain alkanoyllalkenoyl/hydroxyalkenoyl 
hydrazono-isatin/N-methyl isatin derivatives (144-153). 
Synthesis of 3-subsdtuted long chain alkanoyl/alkenoyVhydroxyalkenoyl 
hydra zono-isatin/N-methyl isatin derivatives, (144-153) 
A mixture of long chain alkyl/alkeny]/hydroxyalkenyl hydrazides (21-25) (0.01 mole) 
and isatiniN-methyl isatin (0.01 mole) in ethanol (50 mL) containing 5-8 drops of 
glacial acetic acid was refluxed on oil bath for 6-8 hours and left over night at room 
temperature. Excess solvent was evaporated and the reaction mixture was poured into 
crushed ice after consumption of all reactants. The product was washed with cold 
ethanol several times. Products were purified by column chromatography. All the 
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newly synthesized compounds (144-153) were characterized on the basis of their 
spectral data (fR,'H NMR, 13C NMR and mass spectra). 
Tire spectroscopic and analytical data for the synthesized compounds (144-153) are 
presented below: 
3-(Hexadecanoyl hydruzono) isatin, (144) 
Yellow powder; yield: 90%; m.p.: 91-94°C 
IR (KBr, cm'): 3409 (hetero N-H stretching), 3066 (amide N-H stretching), 2919 (C-
H stretching), 1688, 1660 (C=O stretching), 1588 (C=N stretching). 
'HNMR (CDC13, SH):  12.98 (1H, s, NHindole), 9.38 (IH, s, NH), 7.36-7.10 (4H, m, 
ArH), 2.83 (2H, t, J = 7.61 Hz, CH2CO), 1.74 (2H, m, CH2CH2CO), 1.25 (24H, br.s, 
(CH2 )1 2 chain), 0.87 (3H, dist.t, CH3). 
'3CNMR (CDC13, dc): 177.1, 170.4, 163.2, 141.9, 139.1, 133.2, 131.7, 131.2, 129.0, 
33.8, 32.0, 31.9, 31.6, 29.6, 29.5, 29.3, 29.1, 28.9, 25.2, 24.5, 22.6, 21.9, 21.5, 14.1. 
MS (ESI): m/z = 423.087 found [M+Na]', calculated [M+Na]4 = 422.494. 
3-(Undee-1o'-enoyl hydrazono) isatin, (145) 
Yellow powder; yield: 85%; m.p.: 88-89°C 
IR (KBr, cm'): 3398 (betero N-H stretching), 3063 (amide N-H stretching), 2920 (C-
H stretching), 1690, 1657 (CO stretching), 1593 (C=N stretching). 
'HNMR (CDC13, 8H): 11.78 (IH, s, NHindole), 9.65 (1H, s, NH), 7.62-7.00 (4H, m, 
ATH), 5.80 (1H, tdd, J„ 	— 6.6 Hz, .I„_ — 10.1 Hz, J 	= 17.2 HZ, CHz=CH), 
5.00 (IH, dd, j,, = 10.1 Hz, j,,,_,,  = 1.4 Hz, H2C=CH), 4.92 (IH, dd, J„ H  = 17.2 
Hz, j, 	— 1.4 Hz, H,C=CH), 2.79 (211, t, J = 7.60 Hz, CH2CO), 2.03 (2H, m, 
CH2=CH-CH2), 1.72 (2H, m, CH2CH2CO), 1.31 (1OH, br.s, CH2(CH2)5 chain). 
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'IC NMR (CDC13, 6c): 176.8, 171.2, 163.2, 142.8, 141.4, 139.7, 137.3, 133.2, 131.7, 
123.3, 123.0, 33.9, 33.1, 32.0, 31.7, 29.5, 25.1, 24.5, 22.6. 
MS (ESI): m/z = 349.368 found [M+Na]', calculated [M+Na]f = 350.367. 
3 ((9'Z)-Octadee-9'-enoyl hydrazono] Lvatin, (146) 
Yellow powder; yield: 80%; m.p.: 95-96'C 
IR (KRr, cm- ): 3372 (hetero N-H stretching), 3044 (amide N-H stretching), 2920 (C-
H stretching), 1682, 1669 (C=O stretching), 1599 (C=N stretching). 
'HNMR (CDC?;, 8&: 12.10 (1H, s, NHindole), 9.65 (1H, s, NH), 7.56-6.90 (4H, m, 
ArH), 5.30 (2H, m, CII=CII), 2.76 (2H, t, J = 7.60 Hz, CH2CO), 1.99 (4H, m, 
CH2CH=CHCH2), 1.64 (2H, m, CH2CH2CO), 1.27 (20H, brs, (CH2)lo chain), 0.86 
(31-I, dist.t, CH3). 
rJCNMR (CDCI3, Sc): 175.8, 174.9; 161.5, 143.0, 142.9, 135.0, 131.4, 130.9, 129.2, 
125.3, 123.6, 35.6, 32.0, 31.8, 31.2, 31.0, 30.9, 30.7, 30.2, 29.6, 29.5, 29.3, 29.0, 28.9, 
27.3, 14.2. 
MS (ESI): m/z = 449.740 found [M+Na]', calculated [M+Na]t = 448.528. 
3-1(97, 12'R)-12'-Hydrozyoctadec-9'-enoyl hydrazono] isatin, (147) 
Yellow solid, yield: 75%; m.p.: 85-8CC 
IR (KBr, c11): 3410 (0-H stretching), 3368 (hetero N-H stretching), 3105 (amide N-
H stretching), 2918 (C-H stretching), 1691, 1654 (C=0 stretching), 1585 (C=N 
stretching). 
'HNMR (CDC13, hp): 12.53 (1H, s, NH indole), 9.11 (1H, s, NH), 7.54-6.70 (4H, m, 
Ar!), 5.35 (2H, m, CI-I=CH), 4.18 (IH, m, CHOH), 2.74 (2H, t, J = 7.57 Hz, 
CH2CO), 2.23 (4H, m, CH2CH=CHCH2), 1.70 (IH, m, CHOH), 1.56 (2H, m, 
CII2CH2CO), 1.28 (18H, br.s, (CH2)9 chain), 0.73 (3H, dist.t, CH3). 
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I3CNMR (CD Cl3, Sr): 175.0, 172.6, 171.0, 142.3, 142.1, 133.9, 130.7, 130.0,126.2, 
124.9, 69.9, 39.5, 36.4, 33.3, 33.0, 32.4, 31.3, 30.8, 29.6, 29.4, 29.1, 28.9, 28.7, 28.3, 
28.2, 14.0. 
MS (ESI): mIz = 464.319 found [M+Na]', calculated [M+Na] =464.527. 
3-[(9'R, 12'Z)-Y-Hyrtracyoctadec-12'-enoyt hydrazono] isatin, (148) 
Yellow solid, yield: 78%; m.p.: 88-89°C 
IR (KB#, en t): 3422 (0-H stretching), 3340 (hetero N-H stretching), 3100 (amide N-
H stretching), 2921 (C-I-I stretching), 1685, 1660 (C=O stretching), 1580 (C=N 
stretching). 
'HNMR (CDCI3, 51 ): 12.00 (IH, s, NH indole), 9.51 (IH, s, NH), 7.22-6.45 (4H, m, 
ArH), 5.32 (21-1, m, CFI—CH), 4.20 (1H, m, CHOH), 2.71 (2H, t, J = 7.45 Hz, 
CH2CO), 2.10 (4H, m, CH2CH=CHCH2), 1.75 (1H, in, CEO/I), 1.45 (2H, m, 
CH2CH=CO), 1.27 (1SH, br.s, (CH2)9 chain), 0.77 (3H, dist.t, CH,). 
'3C NMR (CDC13, ad: 176.2, 173.8, 172.7, 143.3, 141.3, 134.2, 132.5, 131.8, 127.9, 
70.1, 39.3, 35.9, 33.9, 33.6, 33.2, 32.7, 31.6, 31.6, 29.9, 29.7, 29.4, 29.0, 28.8, 28.6, 
28.4, 14.2. 
MS (ESI): m/z = 464.408 found [M+Na]+, calculated [M+Na]t = 464.527 
3-(Hexodecanoyl hydrazono)-N-methyl isatin, (149) 
Orange powder, yield: 80%; m.p.: 89-91'C 
Hi (KBr, cni'): 3071 (N-H stretching), 2921 (C-H stretching), 1682, 1651 (C=O 
stretching), 1575 (C=N stretching). 
'HNMR (CDC13, Op): 9.40 (1H, s, NH), 7.58-6.85 (4H, m, ArH), 3.28 (3H, s, CH3), 
2.80 (2H, t, J= 7.52 Hz, CH2CO), 1.72 (2H, m, CH2CH2CO), 1.30 (24H, br.s, (CH2)12 
chain), 0.87 (3H, dist.t, CFFJ. 
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'3CNMR (CDCL3, 6,): 176.5, 171.0, 161.4, 160.1, 131.2, 130.9, 123.5, 123.1, 121.8, 
36.0, 33.4, 31.8, 31.7, 29.5, 29.3, 29.0, 28.9, 25.6, 25.3, 24.4, 23.6, 23.2, 22.8, 22.4, 
14.0. 
MS (ESI): mlz = 436.390 found [M+Na]`, calculated [M+Na]+= 436.517. 
3-(pndec-IO'-enoyl kyrlrazono)-N-met/ry1 isatin, (150) 
Orange powder; yield: 75%; m.p.: 85-86'C 
IR (KBr, cm'): 3047 (N-H stretching), 2923 (C-H stretching), 1698, 1660 (C=O 
stretching), 1598 (C=N stretching). 
'H NMR (CDCl3, SpJ: 9.42 (1H, s, NH), 7.57-6.87 (4H, m, ArH), 5.80 (1H, tdd, 
= 6.4 Hz, j,_,, = 10.3 Hz, J„_„e = 17.1 Hz, CH2=CH), 4.99 (1H, dd, j,,r_.. = 
10.3 Hz, j,,, = 1.3 Hz, HzC=CH), 4.91 (1FI, dd, j,,,, = 17.1 Hz, Jx „ = 1.3 Hz, 
HEC=CH), 3.23 (311, s, CH,), 2.82 (2H, t, J = 7.60 Hz, CH2CO), 2.02 (2H, m, 
CH2 =CH-CH2), 1.74 (2H, m, CH2CH2CO), 1.32 (10H, br.s, (CH2)5 chain). 
3`C NMR (CDCI3, Sr): 176.7, 170.1, 161.5, 160.4, 136.3, 132.2, 131.4, 130.1, 123.7, 
123.6, 121.5, 35.7, 33.6, 3 1.0, 29.6, 29.4, 25.9, 24.4, 22.9, 22.6. 
MS (ESI): m/z = 364.109 found [M+Na]`, calculated [M+Na]" = 364.390. 
3-((9'Z)-Octadec-9'-enoyl hydra zonoJ-N-methyl isatin, (151) 
Orange powder; yield: 80%; m.p.: 83-85C 
II? (KBr, cm '): 3089 (N-H stretching), 2924 (C-H stretching), 1668, 1646 (C=O 
stretching), 1596 (C=N stretching). 
rH NMR (CDC13, Sy): 9.96 (1H, s, NH), 7.50-6.92 (4H, m, ArH), 5.40 (2H, m, 
CIFCH), 2.78 (2H, t, J — 7.56 Hz, CH2CO), 2.00 (4H, m, C112CH=CHCH2), 1.65 
(2H, m, CH2CH2CO), 1.28 (20H, br.s, (CH2)10  chain), 0.88 (3H, dist.t, CH3). 
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I3C NMR (CDC13, 6c): 177.0, 172.4, 160.8, 159A, 134.8, 133.6, 133.4, 128.9, 128.5, 
123.8, 123.4, 35.0, 32.8, 32.4, 32.0, 30.9, 30.4, 30.2, 29.9, 29.8, 29.4, 28.7, 28.0, 25.4, 
22.3, 22.0, 13.9. 
MS (ESI): m/z = 462.230 found [M+Na]+, calculated [M+Na]' = 462.551. 
3-[(9'Z, 12'R)-12'-Hydroxyoctadec-9'-enoyl hydrazonoj-N-methyl isatin, (152) 
Orange sticky oil; yield: 70% 
IR (KBr, cm-): 3405 (O-H stretching), 3094 (N-H stretching), 2926 (C-H stretching), 
1684, 1662 (C=O stretching), 1599 (C=N stretching). 
'H NMR (CDCI j, S,d: 9.45 (1H, s, NH), 7.60-6.84 (4H, in, ArM), 5.41 (2H, m, 
CH—CH), 4.09 (IH, m, CHOII), 3.23 (3H, s, Cl13 ) 2.81 (2H, t, J= 7.57 Hz, CH2CO), 
2.17 (4H, m, CH2CH=CHCH2), 1.74 (IH, m, CHOH), 1.62 (2H, m, CH2CH2CO), 
1.28 (18H, br.s, (CH2)9 chain), 0.89 (3H, dist.t, CH3). 
r3C NMR (CDCh, dd: 176.4, 173.9, 161.5, 160.8, 143.3, 134.0, 133.1, 132.5, 131.4, 
125.3, 123.6, 71.9, 37.4, 36.8, 33.9, 31.8, 31.6, 31.4, 30.6, 30.0, 29.9, 29.8, 29.7, 29.1, 
28.4, 27.3, 14.0. 
MS (ESI): m/z — 478.419 found [M+Na]', calculated [M+Na]T — 478.550. 
3-[(9'R, 12 'Z) -9'-Hydroxyoctadec-12'-en oyl hydrazonoJ-N-methyl isatin, (153) 
Orange sticky oil; yield: 65% 
IR (KBr, cm I): 3395 (O-H stretching), 3090 (N-H stretching), 2923 (C-H stretching), 
1679,1658(0=0 stretching), 1593 (C=N stretching). 
1H.NMR (CDCl3, 6&: 9.30 (IH, s, NH), 7.49-6.69 (4H, m, ArH), 5.40 (2H, m, 
CINCH), 4.28 (1H, m, CHOH), 3.15 (3N, s, CH3) 2.75 (2H, t, J— 7.53 Hz, CII2CO), 
2.20 (4H, m, CH2CH=CHCH2), 1.78 (1H, m, CHOH), 1.68 (2H, m, CH2CH2CO), 
1.30 (18H, br.s, (CH2)9 chain), 0.76 (3H, dist.t, CH3). 
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rJCNJYIR (CDCI3, &r): 175.8, 173.6, 162.5, 161.0, 142.4, 133.2, 133.1, 132.8, 131.3, 
124.3, 123.8, 71.6, 36.1, 36.0, 33.7, 31.8, 31.5, 31.2, 30.5, 30.1, 29.9, 29.6, 29.4, 29.1, 
28.3, 27.5, 14.1. 
MS (PSI): m/z = 478.325 found [M+Na]~, calculated [M+Na]t = 478.550. 
4.4.2. Biology 
4.4.2.1. Chemicals used in studies 
MTT was purchased from Affymetrix (USB), PI was purchased from Molecular 
Probes (Eugene, OR, USA), anti-rabbit PARP-1/2 (Santa Cruz Biotechnology, CA, 
USA), monoclonal anti-mouse alpha tubulin (Sigma, St. Louis, MO, USA). 
4.4.2.2. Human cancer cell lines and culture 
Hep 62, U2OS, HeLa and MCF 7 cells were obtained from American Type Culture 
Collection (Manassas, VA). They were cultured in RPMI-1640 or DMEM medium 
along with 10% fetal bovine serum (FBS) and antibiotics (100 U/mL penicillin and 
100 tg/mL streptomycin). Cells were maintained in humidified incubator at 37°C in 
5% CO2-95% air. 
4.4.2.3. IViTT assay 
The cells were incubated with tested compounds at different concentrations for 72 
hours at 37°C in a 96 well plate in triplicates. After incubation, MTT dye (5 mg/mL in 
PBS) was added to each well and kept it for 2 hours at 37'C until blue coloured 
product developed. Then extraction buffer (20% SDS in 50% dimethylformamide, 
DMF) was added and incubates it for overnight. The absorbance was measured at 570 
ran by mulfiscanner autoreader (Coda, Bio Rad). The absorption values were 
expressed as the cell viability (%), according to the control group as 100%. The 
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concentration required for 50% inhibition of cell viability (IC5o)  was calculated using 
the software "Prism 3.0". 
4.4.2.4. Flow Cytometry (FACS) 
0.5 X 106 Hela cells were treated with different concentrations of the test compounds 
for 24 hours. After an incubation period, cells were harvested, washed with phosphate 
buffer saline (PBS), and stained with PI (2 µg/mL in PBS) for 2 minutes at room 
temperature. Under these conditions, live cells exclude dye, and only nonviable cells 
are stained. Live versus dead cells were analyzed by flow cytometry (BD FACS Aria 
Ill). 
4.4.2.5. PI Nuclear Staining 
For PI staining, cells were fixed in 80% methanol for 6 hours, washed with PBS and 
then stained with PI (25 µg/mL in PBS). Fluorescence microscopy was done to check 
nuclear integrity 
4.4.2.6. Western Blotting Protocol 
1 X 106 Hela cells were cultured on six 60 mm culture dishes (coming) and then was 
treated with increasing concentration of compounds (148 and 153) (10 and 20 µg/mL) 
and whole cell extract was prepared by the following method. Briefly, cells were 
suspended in lysis buffer (1M HEPES, 1M Nacl, 10% NP-40, 0.5M EDTA) PMSF (1 
mM), OTT (10 µg/mL), aprotinin (5 tg/mL) and leupeptin (5 µg/mL). The 
suspension was vortexed five times in interval of 10 minutes and was centrifuged at 
14,000 rpm for 10 minutes and supernatant was collected in a chilled fresh microfuge 
tubes. The 50 µg of protein from each cell extracts were resolved in a denaturing 12% 
SDS-PAGE gel and after completion of the run, the gel was over laid on a 
nitrocellulose paper cut to the size of gel and kept in the blotting cassette in the 
presence of blotting buffer. Finally, the cassette was put in the mini transblot 
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apparatus (Bio Rad) and blotting was done for 3 hours at a constant voltage of 80-V. 
After that, the membrane was taken out and rinsed in Phosphate Buffer Saline—
Twee, (PBS-T) for 5 minutes by gentle shaking. Later, the membrane was immersed 
in 5% non-fat milk solution in PBS-T with gentle shaking for 1 hour at 37°C. The 
membrane was washed off from the traces of the fat free milk with PBS-T and the 
membrane was over laid with primary antibody (anti-PARP 1/2) diluted in PBS-T 
(1:5000) for 3 hours at shaking; After incubation the membrane was washed with 
PBS-T thrice for 5 minutes each and layered with anti-rabbit secondary antibody 
(conjugated with horse-radish peroxidase) diluted in 5% fat free milk solution in PBS-
T (1:5000) and incubated for 45 minutes at room temperature. The membrane was 
washed thrice after incubation and processed for the protein bands of interest using 
ECL-plus detection reagent followed by development of the bands using X-ray film 
(Hyperfilm-ECL, Amersham Biosciences). To ensure equal loading of extracted 
protein, the blot was reprobed with antitubulin antibody. 
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Otazolsnes and tfiiazoCines 
5.1. Theoretical 
Oxazolines are five membered cyclic compounds having imino-ether linkage (-N=C-
O-) group. In terms of saturation, oxazoline (155) exists between oxazole (154) and 
oxazolidine (156). The first successful synthesis of oxazoline was reported in 1889'. 
Oxazolines (also called oxazolyls) have been found to possess wide range of chemical 
applications, specialy for carboxylic acids 'as protecting group and in asymmetric 
catalysis as ligands. Depending on the position of double bond, three structural 
isomers of oxazoline are possible, despite that only 2-oxazolines (155) are common. 
4-Oxazolines (158) are rare and 3-oxazolines (157) are even less common. 
	
o 
\ % 4 	t 
22 Q4Q24Q2  
N 	N 	N 	N 	 i 3 H 3 
R 
(154) 	(155) 	(156) 	(157) 	(158) 
R: Organyl group 
Similarly, thiazoline is the, structural analogue of oxazoline where the oxygen is 
replaced by sulfur. Thiazoline (160) exists between thiazole (159) and thiazolidine 
(161) with reference to saturation. Like oxazolines, depending on the location of the 
double bond existence of three different thiazoline rings are possible i.e. 2-thiazoline 
(160), 3-thiazoline (162) and 4-thiazoline (163). Thiazoline was first prepared by 
dialkylation of thioamides2. 
5 	1 	 5 
	4 
Q4Q29402 
 \
/r 
/ 2 
N 	 N 	 N 	 N 	 N 3 
3 H 
R 
(159) 	(160) 	(161) 	(162) 	(163) 
R: Organyl group 
M 
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Numerous methods have been discovered for the synthesis of oxazoline and thiazoline 
derivatives3-8. Padmavathi et at 9 reported the synthesis of oxazoline and thiazoline 
derivatives (165, 166) by treatment of arylethenesulfonylacetic acid methyl ester 
(164) with 2-amino ethanol or 2-amino-ethanthiol in the presence of n-butyllithium 
and anhydrous samarium (III) chloride in toluene, respectively. 
O 
O/S~o COZMe 
R 16 
NH2CH2CH2OH 	HSCH2CHZ NH2 
Sm(Ill)C13 	 Sm(III)C13 
n-BuLi, Toluene 	n-BuLi, Toluene 
(166) 
Katritzky et aL'° outlined the microwave reactions for the synthesis of 2-substituted-
2-oxazolines (169) and 2-substituted-2-thiazolines (171) by the treatment of 2-amino-
2-methyl-l-propanol (168) or 2-amino-ethanthiol hydrochloride (170) with N-
acylbenzotriazoles (167) in the presence of thionylchloride. 
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RCOBt + 	 microwaves  
HO 	NHZ 
R 
(167) 	 (168) 	 (169) 
R: 4-CH3C6H4, 4-CH3OC6H4, 4-NO2C6H4, 4-CIC6H4, 2-CIC6H4, phenyl, 
1-naphthyl, 2-fury!, 2-phenylethenyl, 1-(6-methoxy-2-naphthyl)ethyl 
N, 
Bt: I 	I'N 
~ N 
	
RCOBt + /C\ 	microwaves 
HS 	NHZ HCl 
R N 
(167) 	(170) (171) 
R: 4-CH3C6H4, 4-CH3OC6H4, 4-NO,C6H4, 4-CIC6H4, 2-CIC6H4, 
phenyl, 2-fury!, 2-phenylethenyl 
Dowex-50W-hydrogen ion exchange resin was used by Bazgir et al.'s as reusable 
catalyst for the synthesis of oxazoline and thiazotine derivatives (174) through aryl 
nitriles (172) and 2-amino-alcohol or 2-amino-ethanthiol (173) condensation reaction. 
H2N 	N 
dowex-SOW 
ArCN ± Ar 
HX 	
solvent-freel80°C 
(172) 	(173) (174) 
Ar, X: C6H5, 0; 4-Cl-C6114, 0; 3-C1-C6H4, 0; 4-Me-CJI14, 0; 4-CN-C6H4, 0; 
C6115, S; 4-C1-05H4, S; 4-Me-05114, S; 4-CN-C6H4, S; 4-MeO-C6H4, S; 
4-NO2-C6IIq, S 
Nitrogen containing heterocycles have gained importance because they possess many 
biological activities and pharmaceutical properties. The use of fatty acid substrates as 
starting material has become significant because of their own biological activities 
such as pesticidal, antimicrobial, antidepressant, antitumor activities1",. Significant 
biological activities exhibited by oxazolines, thiazolines and their corresponding 
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oxidized derivatives i.e. oxazoles and thiazotes which are commonly found in marine 
sources. The summary of four years literature survey in the review" showed the 
isolation, synthetic and biological studies of these natural products. Among them, the 
derivatives of oxazoline and thiazoline have been used as therapeutic agents and have 
biological properties such as antihypertensive17, antidiabetic's, antitumor 9' 20, 
antialzheimer21, antihypercholesterolemic22 and antiinflammatoryz3 activities. 2-
Oxazolines and thiazolines are important substructures in a large number of 
biologically active natural products24-21. Micacocidin (175) is an antibiotic having 
potent antimycoplasma activity containing two thiazoline and one thiazolidine rings. 
Micacocidin was isolated from the culture broth of Pseudomonas sp. no. 57-25021. 
lu J) 
Agyemang et al.29 for the first time reported the presence of 2-ethyl-4-methyl-3-
thiazoline (176) and 2-isopropyl-4-methyl-3-thiazoline (177) with other components 
in nature through an analysis of sesame seed oil. The thiazoline derivatives also play 
important role in pharmaceutical drug discovery30. 
S 	 S  
(176) 	 (177) 
Dmg aminorex/aminoxafen (2-amino-5-aryl oxazoline) (178) having oxazoline 
moiety. Aminorex is a weight loss (anorectic) stimulant drug. Frump31 outlined the 
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applications of oxazolines in the field of protective coatings, surface active agents, 
gasoline and lube oil additives, corrosion inhibitors, antifoam agents, textile 
chemicals, adhesives and binders, stabilizers for chlorinated hydrocarbons, stabilizers 
for aqueous formaldehyde solutions, protective films in polish formulations, foam 
stabilizers, photography, plasticizers and agriculture. 
IIN 
(178) 
Enteric bacterial infections are responsible for morbidity and mortality globally in 
developing countries and areas such as the Indian sub-continent, part of South 
America and tropical part of Africa32' 33. In case of E. colt infection amoxicillin, 
norfloxacin and ciprofloxacin are generally used but have harsh side effects34  
Toxicity and resistance to the drugs also play important role in the treatment failure35. 
For this reason the present stratagem for the synthesis of new compounds was aimed 
in the direction of developing new oxazoline and thiazoline derivatives that inhibits 
the growth of gram-positive, gram-negative bacteria and fungi. 
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5.2. Synthesis, Characterization of Long Chain Oxazolines 
and Thiazolines: In Vitro Antimicrobial Activity 
Many of the previously known methods involve expensive reagents, long reaction 
time, low yield, strong acidic conditions and use of toxic organic solvents. Therefore 
to avoid these limitations and due to biological importance36' " of oxazoline and 
thiazoline derivatives as mentioned ea-lier, the synthesis of new compounds was 
aimed in the direction of developing new oxazoline and thiazoline fatty acid ester 
derivatives that inhibits the growth of gram-positive, grain-negative bacteria and 
fungi. The method described here have advantages like short reaction time, high 
yields of products, usage of cheap starting material for the synthesis of these novel 
hetero-fatty acid ester analogs. 
5.3. Results and discussion 
5.3.1. Chemistry 
Previously in our laboratory, fatty acids and their derivatives have been reported as 
antimicrobial agents.s' 39.  It has been suggested that the incorporation of the fatty acid 
chain may increase antimicrobial activity of certain organic moieties40. The synthesis, 
characterization and antimicrobial activities of oxazoline and thiazoline derivatives of 
fatty acid esters are described in this chapter. The synthesis of 2-amino-5-substituted 
and 2-amino-4,5-disubstituted oxazolines (183-186) and thiazolines (187-190) were 
carried out by refluxing urea and thiourea, respectively, with dibromo derivatives 
(179-182) of olefinic and hydroxy-olefinic fatty acid esters in methanol (Scheme 7). 
All reactions were monitored by thin layer chromatography. The nucleophilic 
substitution of area and thiourea to dibromo derivatives of olefinic and hydroxy-
olefinic fatty acid esters gives inseparable isomeric mixture of oxazolines and 
thiazolines, respectively. The products (183-190) were purified on silica gel column 
with petroleum ether and diethyl ether as eluent. The synthesized compounds were 
identified on the basis of IR,'H NMR, 13C NMR and mass spectra. 
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R1 —CH —CH —R2 
Br Br 
(179-182) 
	
NH2CONHZ 1 QH 	McOH, NHZCSNH2 
reflux 	reflux 
R~ 
N 
R, 
HZN 	O 
(183-186) (187-190) 
Compound 	R1 	Rz 
Codes 
179, 183,187 	H H,C 	COOCH3 
180,184,188 	' n 'CHy 	HxC "6 'COOCH3 
181,185,189 	5 T 	H2C 	6 COOCH3 
OH 
182, 186,190 HzC 	
COOCH3 
3 CH2 ~ 
e 
OH 
Scheme 7: Synthesis of 2-amino-5-substituted and 2-amino-4,5- 
disubstituted oxazolines and thiazolines 
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The structure of compound (183) is given below: 
CH2(CI-12)7COOCH3 
H2N 
Structure of 2-amino-5-(carbomethoxyoctyl)-1,3-oxazoline (183) 
A detailed spectral description for compound (183) is discussed below: 
IR spectrum of compound (183) revealed 3320 cm -' (N-H stretching), 1739 cm 1 
(C=O in ester), 1437 (C—N ring stretching), 1362 (C-O-C). In the 'H NMR, the cyclic 
protons CH2-CH were observed at Su 4.16 (tdd, 1H, j 	= 6.6 Hz, ,t,_,, = 10.2 
Hz, .t„_,,, = 17.1 Hz, CH2-CFI-), 3.85 (dd, 1H, i,111  = 10.2 Hz, iH _„ = 1.2 Hz, HC-
CH), 3.64 (dd, 111, x _„ = 17.1 Hz, ç,, = 3.6 Hz, HFC-CH), a sharp singlet at 3.66 
was observed for three methyl ester protons and the two amine protons were observed 
at 811 2.32 as a singlet. The structure of compound (183) was further confirmed by °C 
NMR spectral data which showed peaks at 6c 179.8, 163.4, 79.2, 64.7, 51.4, 36.3, 
35.9, 34.0, 29.8, 29.1, 28.7, 26.7, 24.9. The mass spectra showed characteristic 
molecular ion peak in accord with the molecular formula. 
Similarly, other compounds were characterized from their spectral data. 
5.3.2. Biology 
5.3.2.1. Antibacterial studies 
The newly prepared compounds were screened for their antibacterial activity against 
Escherichia coli (ATCC-25922), Methicillin resistant Staphylococcus aureus (MRSA 
+Ve), Psedomonas aeraginosa (ATCC-27853), Streptococcus pyogenes and 
Kiebsiella pneumoniae (Clinical isolate) bacterial strains by disc diffusion method and 
measured by halo zone test41 92. The MIC of synthesized compounds against bacterial 
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strains was performed by micro dilution test and results were observed visually and 
spectrophotometrically. The susceptibility was assessed on the basis of diameter of 
zone of inhibition against gam-positive and gram-negative strains of bacteria. 
Inhibition zones were measured and compared with the controls. The bacterial zones 
of inhibition values are given in Table 10. The minimum inhibitory concentration and 
minimum bactericidal concentration are given in Table 11. All the compounds 
showed moderate to good inhibitory action against both types of bacteria. Compounds 
(185, 186, 189 and 190) showed good inhibition against S. pyogenes, S. aureus and E. 
eoli species. Compound (186) showed stronger antibacterial activity nearly equivalent 
to that of ciprofloxacin against the methicillin-resistant Staphylococcus aureus 
(MRSA). In general, all the compounds were more effective against gram-positive 
bacteria as compared to gram-negative bacteria. 
Table 10: Antibacterial activity of oxazoline and thiazoline 
derivatives of fatty acid esters 
Compound Diameter of zone of inhibition (mm) 
Codes Gram-positive bacteria Gram-negative bacteria 
Sp" MRSA PA` 1p" EC` 
183 14.1±0.3 12.5±0.2 14.9±0.3 13.1±0.4 12.9+0.2 
184 14.1±0.2 13.5±0.2 16.2+0.6 12.2±0.6 13.6}0.2 
185 17.1±0.3 16.4±0.2 19.1 f 0.3 16.2±0.3 16.5+0.2 
186 20.3±0.2 19.4±0.4 26.1±0.4 20.3+0.4 22.2±0.4 
187 12.9±0.4 12.1±0.4 14.1±0.2 11.9±0.6 10.9±0.3 
188 14.1±0.3 12.9±0.4 15.8+0.2 13.2+0.3 13.2±0.6 
189 15.1±0.3 14.5±0.6 17.2±0.3 13.2±0.3 14.6±0.3 
190 16.1±0.4 16.5±0.3 18.2±0.5 15.1±0.2 16.5+0.5 
Standard 23.0±0.2 22.0t0.2 32.0+0.3 19.0±0.2 27.0t0.2 
DMSO - - - - - 
SP: Streptococcus pyogenes, "' MRSA: methicillin resistant Staphylococcus aureus, 
1`  PA: Pseudomonas aeruginosa, d) KP: KIebsiel!a pneumonia, `I EC: Escherichia coli. 
Positive control (standard): ciprofloxacin and negative control (DMSO) measured by 
the halo zone test (unit, mm). 
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Table 11: ARC and MBC results of oxazoline and thiazoline 
derivatives of fatty acid esters 
Comp. 	Gram-positive bacteria 	Gram-negative bacteria 
Codes 	Spa) 	MRSA 1 	PA `1 	1(0 	EC 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
183 50 100 50 >100 100 >100 50 >100 50 >100 
184 25 100 25 100 50 100 50 >100 50 >100 
185 25 50 25 50 25 50 25 50 25 50 
186 25 50 25 50 12.5 50 12.5 25 25 50 
187 50 100 50 >100 50 >100 100 >100 100 >100 
188 50 100 50 100 50 >100 50 >100 50 >100 
189 50 100 25 100 50 100 50 100 50 >100 
190 50 100 25 50 25 50 50 100 50 100 
Standard 12.5 12.5 6.25 12.5 12.5 25 6.25 25 6.25 12.5 
';SP: Streptococcus pyogenes, °~MRSA: methicillin resistant Staphylococcus aureus, 7` PA: 
Pseudomonas aeruginosa, °)KP: Klebsiella pneumonia, )`EC: Escherichia coil. NEC 
(µg/mL) — minimum inhibitory concentration, i.e. the lowest concentration of the 
compound to inhibit the growth of bacteria completely; MBC (gg/mL) = minimum 
bacterial concentration, i.e, the lowest concentration of the compound for killing the 
bacteria completely. Positive control (standard): ciprofloxacin. 
5.3.2.2. Antifungal studies 
Antifungal activity was also done by disk diffusion method'' 4°. For assaying 
antifungal activity Candida albicans, Aspergillus fumigatus, Penicillium marneffei 
and Trichophyton mentagrophytes (recultured) in DMSO strains were used. The 
fungal activity of each compound was compared with griseofulvin as standard drug. 
Inhibition zones were measured and compared with the controls. The MIC of 
synthesized compounds against fungal strains was performed by micro dilution test 
and results were observed visually and spectrophotometrically. The fungal zones of 
inhibition values are given in Table 12. The minimum inhibitory concentration and 
minimum fungicidal concentration are given in Table 13. All the compounds showed 
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moderate to good inhibitory activity against the four strains of fungus. Among all the 
screened compounds, compounds (185, 186, 189 and 190) showed excellent 
antifungal activity, nearly equivalent to the control compound against C. albicans, P. 
marnefei and A. fumigates fungal strains. The MIC of few compounds was found to 
be the same as MIC but in most of the compounds it was two or three or four folds 
higher than the corresponding MIC results. Compound (186) exhibited stronger 
antifungal activity against Candida albicans strains. 
Table 12: Antifungal activity of oxazoline and thiazoline derivatives 
of fatty acid esters 
Compound Diameter of zone of inhibition (mm) 
Codes CO AF TM` PM 
183 21.1±0.3 16.8±0.4 14.3+0.9 13.1±0.6 
184 17.5+0.3 13.2+0.4 10.7±0.6 09.1±0.5 
185 22.9±0.2 18.9±0.3 16.9±0.2 13.810.8 
186 28.2±0.2 23.8±0.2 20.4±0.8 16.2±0.4 
187 19.3±0.3 16.6±0.4 14.1±1.2 12.9+0.6 
188 17.8+0.6 13.9+1.2 11.9±0.4 10.7±0.3 
189 24.8±0.5 20.3±0.2 18,1±0.4 15.2+0.6 
190 26.9±0.3 21.9+0.4 18.8±0.2 15.8±0.2 
Standard 30.0}0.2 27.0±0.2 24.0±0.3 20.0±0.5 
DMSO - - - - 
'ACA: Candida albicans, " )AF: Aspetgillus ftmigatus, `JPM: Trichophyton 
mentagrophytes, d1PM: Penicillium marneffei. Positive control (griseofulvin) and 
negative control (DMSO) measured by the halo zone test (unit, mm). 
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Table 13: MIC and MFC of oxazoline and thiazoline derivatives of 
fatty acid esters 
Compound CA°1  AFb)  TM` PM°) 
Codes MIC MFC MIC MFC MIC MFC MIC MFC 
183 25 50 25 50 25 100 25 100 
184 25 100 50 100 50 100 50 >100 
185 12.5 50 25 50 25 100 25 100 
186 6.25 12.5 12.5 12.5 6.25 25 12.5 25 
187 25 50 50 100 50 100 50 100 
188 25 100 50 100 25 100 50 100 
189 12.5 25 12.5 20 25 50 25 50 
190 6.25 12.5 12.5 25 12.5 25 12.5 50 
Standard 6.25 25 12.5 12.5 6.25 25 12.5 25 
°ACA: Candida albicans, °'AF: Aspergillus fumigatus, I`TM; Trichophyton 
mentagrophytes, d)PM: Penic/Ilium marneffei. MIC (pg/mL) = minimum inhibitory 
concentration, i.e. the lowest concentration of the compound to inhibit the growth of 
fungus completely; MFC (µglmL) = minimum fungicidal concentration, i.e., the 
lowest concentration of the compound for killing the fungus completely. 
5.3.3. Conclusion 
For the first time, the synthesis of 2-amino-5-substituted and 2-amino-4,5-
disubstituted oxazoline and thiazoline derivatives of olefinic and hydroxy-olefinic 
fatty acid esters by nucleophilic substitution of urea and thiourea to the dibromo 
derivatives of olefinicnd hydroxy-olefinic fatty acid esters is reported in this 
chapter. In vitro antimicrobial activity of the tested compounds shows that all these 
novel compounds were found to be active against different bacterial and fungal 
strains. Compounds (185, 186, 189 and 190) showed good antimicrobial activity 
nearly equivalent to that of ciprofloxacin and griseofulvin. The present study showed 
that the synthesized compounds can be used as template for future development 
through modification and derivatization to design more potent antimicrobial agents. 
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5.4. Experimental 
5.4.1. Chemistry 
Physical and Spectroscopic Measurements 
The sources of all the fatty acids and instrumentation details are the same as chapter I 
(page number 19). All reagents were generally used as received from commercial 
suppliers. When needed, solvents were dried and distilled before used. The esters of 
fatty acids (long chain alkenoates) were prepared by refluxing the fatty acid in 
methanol in the presence of catalytic amount of concentrated sulfuric acid. The 
dibromo derivatives of fatty acid esters were prepared following the literature 
method45. Reactions were monitored by TLC. Mixture of petroleum ether and diethyl 
ether was used as developing solvents in different proportions for different 
compounds and was visualized in an iodine chamber. Products were purified by 
column chromatography and the synthesized compounds were identified on the basis 
of Qt, 'Fl NMR, 13C NMR and mass spectra. 
General procedure for preparation of dibrotno derivatives (179-182) of fatty acid 
esters: 
Fatty acid ester (0.1 mole) was dissolved in carbon tetrachloride and an equimolar 
amount of bromine (added drop wise to the reaction mixture) at 0°C. The reaction was 
stirred until all the fatty acid ester was used. 
Synthesis of oxazoline (183-186) and tbiazoine (187-190) derivatives ofJatty acid 
esters: 
0.1 Mole of dibromo derivative of fatty acid ester (119-182) dissolved in methanol 
and equimolar amount of urea/thiourea was added. The mixture was refluxed on a 
paraffin bath. Reaction was continued till all reactants were consumed. After 
completion, excess of solvent was evaporated on a water bath and then worked up 
with diethyl ether-water. The organic layer was dried over anhydrous sodium sulfate 
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and excess of solvent was removed by heating on water bath. Product was purified by 
column chromatography. All these novel compounds were yellow oily liquid and 
were characterized from their spectral data. 
The spectroscopic and analytical data for the synthesized compounds (183-190) are 
presented below: 
2 Amino-5-(cm•bometl,oxyoctyl)-1,3-oxazoline, (183) 
Yield: 85% 
IR (KBr, cm'): 3320 (N-H stretching), 2931(C-H stretching), 1739 (C=0 in ester), 
1437(C=N ring), 1362(C-O-C). 
'H NMR (CDCI3, r5&: 4.16 (tdd, 1 H, f H 	= 6.6 Hz, j,1 ,, = 10.2 Hz, y 	= 17.1 
Hz, CH2-CH-), 3.85 (dd, IH, j 11 = 10.2 Hz, j,, ,,=  1.2 Hz, H2C-CH), 3.66 (s, 3H, -
OCH3), 3.64 (dd, 111, j,,,,= 17.1 Hz, Je y = 3.6 Hz, HEC-CH), 2.32 (s, 2H, NH2), 
2.30 (t, J= 7.52 Hz, 2H, -CH2COOCH3), 2.12 (m, 2H, -CII2CH2COOCIh), 1.76 (m, 
2H, -CH2(CH2 )5-), 1.31 (br.s,10H, (CH2)5). 
13CNMR (CDC13, 6c).• 8 179.8, 163.4, 79.2, 64.7, 51.4, 36.3, 35.9, 34.0, 29.8, 29.1, 
28.7, 26.7, 24.9. 
MS (ESI): m/z = 279.151found [M+Na]' , Calculated [M+Na]' = 279.287. 
2 Amino-4-octyl-5-(carbomethoxyheptyl)-1,3-oxazoline, (184) 
Yield: 80% 
IR (KB,-, cm"): 3322 (N -H stretching), 2927 (C-H stretching), 1740 (C=O in ester), 
1461 (C=N ring), 1366 (C-O-C). 
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'H NMR (CDCt3, 6&: 4.20 (m, 2H, CH-CH ring), 3.65 (s, 3H, -OCH3), 2.31 (s, 2H, 
NH2), 2.24 (t, 2H, J= 7.75 Hz, CH2COOCH3), 1.56 (m, 4H, CH2-CHCH-CH2), 1.44 
(m, 2H, CfI2CH2COOCH3), 1.30 (br.s, 18H, (CII2)9),  0.87 (dis.t, 3H, Cl-I3). 
'3C NMR (CDCl3, S&: 178.7, 164.2, 79.0, 63.8, 51.3, 37.3, 34.0, 31.9, 30.7, 29.9, 
29.7, 29.3, 28.7, 28.3, 26.5, 25.8, 24,5, 24.1, 22.7, 14.1. 
MS (ESI): m/.z = 377.301 found [M+Na]u, calculated [M+Na]+ = 377.448. 
2-Amino-4-(2'R)(2'-hydroxyoclyl)-5-(carbome[Goxydeptyl)-1,3-axazoline, (185) 
Yield: 82% 
II? (Kilt-, cm'): 3461-3315 (0-H, N-H stretching), 2928 (C-H stretching), 1740 (C=0 
in ester), 1459 (C=N ring), 1363 (C-CD-C). 
'HNMR (CDC13, 6H): 4.05 (m, 1H, CH-OH), 3.98 (m, 2H, CFI-CH ring), 3.66 (s, 3H, 
-OCH3), 2.32 (s, 2H, NH7),  2.20 (t, 2H, J = 7.14 Hz, CH2COOCH3), 2,06 (m, 1H, 
CH-OH), 1.59 (in, 4H, CH2-CHCH-CH2), 1.49 (m, 2H, CH2CH2COOCH3), 1.43 (br.s, 
1 SH, (CH2)9),  0.88 (dist.t, 3H, CIl3). 
t3C NMR (CDC13, 6c): 179.2, 162.9, 79.1, 72.4, 65.1, 52.9, 42.3, 36.1, 35.2, 34.6, 
33.9, 31.7, 29.9, 29A, 29.0, 28.8, 28.6, 27.7, 25.8, 14.1. 
MS (ESI): ink = 393.352 found [M+Na]', calculated [M+Na]' = 393.447. 
2Anina-4 pcnsyl-5-[(8'R)-8'-hydroxy(corboweNhoxydecyf)-1,3-oxazoline, (186) 
Yield: 65% 
IR (KRr, cm"'): 3475-3314(0-H, N-H stretching), 2925 (C-H stretching), 1739 (C-0 
in ester), 1455 (C=N ring), 1362 (C-0-C). 
'IINMR (CDCI3, Sy): 4.12 (m, 1H, CH-OH), 3.85 (m, 2H, CH-CHring), 3.65 (s, 3H, 
-OCH3), 2.33 (s, 211, NH2), 2.18 (t, 2H, J= 7.32 Hz, CH2COOCH3), 2.02 (m, 111, 
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CH-OH), 1.60 (m, 4H, CH2-CHCH-C112),1.53 (m, 2H, CH=CH=C00CH3), 1.38 (br.s, 
1811, (CH2)9), 0.84 (dist.t, 3H, CH3). 
t3C NMR (CDC13, 5c9: 178.8, 164.7, 78.4, 73.2, 63.6, 52.9, 41.8, 37.3, 34.7, 33.4, 
31.3, 29.8, 29.0, 28.7, 28.5, 28.4, 28.3, 26.9, 25.8, 14.0. 
MS (ESI): m/z = 393 .3 89 found [M+Na]`, calculated [M+Na]t  = 393.447. 
2-Amino-5-(carbomethoxyoctyl)-1,3-thiazoline, (187) 
Yield: 83% 
IR (KBr, cm- ): 3324 (N-H stretching), 2929 (C-H stretching), 1738 ((>0 in ester), 
1435 (C=N ring), 1359 (C-S-C). 
'HNMR (CD 03, 6&: 4.16 (tdd, 111, J„ ,„ - 6.6 Hz, r,„ ° 10.2 Hz, r„_ „t = 17.1 
Hz, CH2-CH-), 3.85 (dd, I H, 'H H= 10.2 Hz, j,, ,, = 1.2 Hz, HZC-CH), 3.66 (s, 3H, -
OCH3), 3.64 (dd, IH, j„ = 17.1 Hz, j„a _,r = 3.6 Hz, NEC-CH), 2.32 (s, 2H, NH2), 
2.30 (t, J=7.52 Hz, 2H, CH2COOCH3), 2.12 (m, 2H, CH2CH2COOCH3), 1.76 (m, 
2H, CH2(CH2)5), 1.31 (br.s, IOH, (CH2),). 
t3CNMR (CDC13, 	: 6 177.2, 165.9, 79.5, 62.2, 50.8, 35.8, 34.3, 33.8, 28.8, 28.6, 
28.3, 25.8, 24.2. 
MS (ESI): m/z — 294.99 found [M+Na]', calculated [M+Na]` = 295.354. 
1Amino-4-octyl-5-(carbomethoxylieptyl)-1,3-thiazoline, (188) 
Yield: 80% 
IR (KBr, cm'): 3323 (N-H stretching), 2926 (C-H stretching), 1740 ((>O stretching), 
1461(C=N ring), 1355 (C-S-C). 
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IH NMR (CDC13, bid: 4.20 (m, 2H, CH-CH ring), 3.66 (s, 3H, -OCH3), 2.32 (s, 2H, 
NHh), 2.30 (t, 2H, J = 7.45 Hz, CH2COOCH3), 1.57 (m, 4H, CH2-CHCH-C112), 1.43 
(m, 214, CH2CH2COOCH3), 1.29 (br.s, 18H, (CH2)9), 0.89 (dist.t, 311, CH3). 
'3C NMR (CDC13, Sd: 3 177.5, 164.9. 79.1, 63.9, 52.0, 36.3, 33.8, 31.5, 30.2, 29.9, 
29.7, 29.5, 28.8, 28.7, 28.1, 28.0, 25.1, 24.6, 22.6, 14.0. 
MS (CSI): m/z = 393.321 found [M+Na]`, calculated [M+Na]' = 393.515. 
2-Amino-4-(2 '1?) (2'-Jiydroxyoctyi)-5-(carbomethoxyheptyl)-1,3-thiazoline,  (189) 
Yield: 83% 
IR (KBr. cm r): 3493-3318 (0-H, N-H stretching), 2930 (C-H stretching), 1738 (CO 
in ester), 1461 (C=N ring), 1358 (C-S-C). 
1HNMR (CDCh, Sid: 4.02 (m, IH, CH-OH), 3.95 (m, 2H, CH-CH ring), 3.66 (s, 3H, 
-OCH3), 2.32 (s, 2H, NH,),  2.20 (t, 2H, J = 7.46 Hz, CH2COOH), 2.00 (m, 1H, CH-
OH), 1.62 (m, 4H, CH=-CHCH-CH,), 1.38 (m, 2H, CH2CH2COOCH3), 1.36 (br.s, 
18H, (CH2)9), 0.79 (dist.t, 3H, CH3). 
13C NMR (CDCI,, 6c)'  178.8, 164.2, 79.8, 71.8, 62.7, 51.8, 38.8, 35.0, 34.8, 33.5, 
31.4,29.9,29.5, 28.8, 28.7, 28.5, 28.0, 27.7, 25.8, 14.0. 
MS (ES!): mlz = 409.012 found [M+Na]+, calculated [M+Na]+ = 409.514. 
2 Amino-4 pentyl-5-[(8'R)-8'-Irydroxy(carbometboxydecyl)-1,3-tlziazoline, (190) 
Yield: 68% 
IR (KBr, cm- ): 3493-3317 (0-H, N-H stretching), 2927 (C-H stretching), 1712 (C=O 
in ester), 1452 (C=N ring), 1340 (C-S-C). 
'HNMR (CDCls, bid: 4.20 (m, 1H, CH-OH), 3.83 (in, 2H, CH-CH ring), 3.66 (s, 3H, 
-OCH3), 2.33 (s, 2H, NH,),  2.30 (t, 2H, J = 7.32 Hz, CH2COOCH3), 2.14 (m, IH, 
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CH-OH), 1.58 (m, 4H, C112-CHCH-CH2), 1.49 (m, 2H, CH2CH2COOCH3), 1.37 (br.s, 
18H, (CH2)9),  0.89 (dist.t, 3H, CH3). 
J3C AMR (CDClr, Sr): 178.9, 163.4, 79.1, 70.9, 63.1, 51.4, 38.4, 35.1, 34.5, 34.2, 
33.4, 31.3, 29.0, 28.9, 28.6, 28.5, 28.3, 26.9, 25.7, 14.0. 
MS (ESI): mlz = 409.139 found [M+Na]', calculated [M+Na]4 = 409.514. 
5.4.2. Biology 
5.4.2.1. Antibacterial assay 
A standard inoculums (1-2 X 101c.fu./mL 0.5 McFarland standards) was introduced 
on to the surface of sterile agar plates, and a sterile glass spreader was used for even 
distribution of the inoculums. The discs measuring 6 mm in diameter were prepared 
from Whatman no. I filter paper and sterilized by dry heat at 140"C for 1 hour. The 
sterile discs previously soaked in a known concentration of the test compounds were 
placed in nutrient agar medium. Solvent and growth controls were kept. Ciprofloxacin 
(30 pig) was used as positive control. While the disk poured in DMSO was used as 
negative control. The plates were inverted and incubated for 24 hours at 37`C. The 
susceptibility was assessed on the basis of diameter of zone of inhibition against 
gram-positive and gram-negative strains of bacteria. Inhibition zones were measured 
and compared with the controls. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The nutrient broth, which contained logarithmic serially two fold diluted 
amount of test compound and controls were inoculated with approximately 5 X 105 
c.f u.hnL of actively dividing bacteria cells. The cultures were incubated for 24 hours 
at 37°C and the growth was monitored visually and spectrophotometrically. The 
lowest concentration (highest dilution) required to arrest the growth of bacteria was 
regarded as minimum inhibitory concentration (MIC). To obtain the minimum 
bacterial concentration (MBC), 0.1 mL volume was taken from each tube and spread 
on agar plates. The number of c.f.u. was counted after 18-24 hours of incubation at 
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35°C. MBC was defined as the lowest drug concentration at which 99.9% of the 
inoculums were killed. 
5.4.2.2. Antifungal assay 
Antifungal activity was also done by disk diffusion method Sabourands agar media 
was prepared by dissolving peptone (1 g), D-glucose (4 g) and agar (2 g) in distilled 
water (100 mL) and adjusting pH to 5.7. Normal saline was used to make a 
suspension of spore of fungal strain for lawning. A loopful of particular fungal strain 
was transferred to 3 mL saline to get a suspension of corresponding species. Twenty 
milliliters of agar media was poured into each petridish. Excess of suspension was 
decanted aid the plates were dried by placing in an incubator at 37t for 1 hour using 
an agar punch, wells were made and each well was labeled. A control was also 
prepared in triplicate and maintained at 37C for 3-4 days. The fungal activity of each 
compound was compared with standard drug. Inhibition zones were measured and 
compared with the controls. 
The nutrient broth, which contained logarithmic serially two fold diluted amount of 
test compound and controls was inoculated with approximately 1.6 X 10° -6 X 10°  
c.f.u./mL. The cultures were incubated for 48 hours at 35°C and the growth was 
monitored. The lowest concentration (highest dilution) required to arrest the growth of 
fungus was regarded as minimum inhibitory concentration (MIC). To obtain the 
minimum fungicidal concentration (MFC), 0.1 mL volume was taken from each tube 
and spread on agar plates. The number of c.f.u. was counted after 48 hours of 
incubation at 35`C. MFC was defined as the lowest drug concentration at which 
99.9% of the inoculums were killed. 
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development for Orphan/Neglected Diseases held on 26"-281' Feb 2013 at 
Central Drug Research Institute, Lucknow. 
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REYWORBS 	 Abstract The main purpose of this study is to synthesize novel heterocyclic derivatives of fatty 
Pymzoiones; acids which are also biologapy important. The simple, efficient and one-pot synthesis of two novel 
PhJhestazmdiDna,; 	 series of 1-bug chain dlkuuoyl/slkenayl/pydruxyalkevuyl-3-methyl-IH-pynuzol-5(4H)-Dues 2(a-e) 
Fatty adds; and 2-long chain alkanyMhydroxyalheno)1-3H-phthala'rin-l.4diones 3(b-e) is achieved by the 
Biological screening; 	 reaction of ethyla toacelatc(phthafic anhydride and long chain a)kyl/alkenyl/hydroxJ'alkenyl 
StructorraCGVity - 	hydrazides 1(n-e). Although some method, are available for the synthesis of phrbalazindiones 
rt suonslup 	 and pyruzoloves, the development of e, new synthetic method for the efficacious buildup of heleco- 
cycles (phthalazindiones and pyrazolones) substituted with long alkanoyl(alkennyllhydroxyalke- 
nayl chain is an interesting challenge in the field of synthesis of novel compounds of fatly adds 
that includes helerocyclization and derivatization of fatty acids. Compounds 2(a-e) were syntbe-
sixd by the ageIizatian reaction betwaa e[hylealoacetDte and long alkylfalkenyl@ydwxyulkanyl 
chain hydrazides 1(a-e). Compounds 3(b-e) were synthesized by the reaction ofphthalic anhydride 
and long alkcnyl/hydTaxy.lkenyl chain hydrazidw l(b a) in absolute ethanol/glacial AcOH. Struc-
tuxes of at the newly synthesized compounds have been elucidated by mean. of IR, H NMR, I3C 
NMR and MS. Newly synthesized compounds were evaluated for in vitro antibacterial and anti-
rungal activities and their swctuco-acdvity relationship studies have been carried out. 
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1. Tvtrodaction 
Nowadays, human beings arc totally dependent on the medi-
cines derived from heterocyclic rings. In many pharmaceuti-
cally active compounds heterocyclic rings are found, because 
both heterocycles and medicines are interrelated. The phHral-
aane nucleus also has very marked pharmacological and bio-
logical applications due to its antitumour (Loh et al., 2005), 
atutypec[msive (Dcrvirayak et al., 2004), antithromhotic 
(Johnsen et aL, 2003), acirdiabetic (Lenz et al., 2002) and anti-
inflammatory (Dogma et al., 2004) activities. Pyrazole ring 
represents an interesting template for medicinal and combina-
torial chemistry (Pevarello et al., 2006) because they play a key 
role in biologically active compounds. Indeed, several pyrazole 
derivatives have been reported to possess antimicrobial (Vije-
she et al., 2011), antiviral (Narule, 2011), antiandrogenic 
(Amr et al., 2006), analgesic (Parashar et al., 2010), aninflcm-
matory (Doliulia et al., 2013), antidiabetic (Das et al., 2005) 
and antioxidant (Mohan and Ananthan, 2011) properties. Pyr-
azale and pyraeolone derivatives were also reported to possess 
ananaammatory, postmenopausal, osteoporosis, antagonists, 
anticoagulants and angiotensin activities (Lee et al., 2003). In 
drug molecules such as celecoxib (a) (Singh et al., 2004), pyra-
znfudnc (b) (DHmling and Ugj, 2000) and many others, the 
pyrvzole ring is the key moiety. Literature survey also reveals 
that (Z)4-(4-hydroxy-3-methoxy benzylidcne)--(3-nitro-
phenyl)-3-pbenyl-lH-pyrazol-S(411)-one (c) (a pyrazolone 
derivative) was found to be a non-steraidal Fernesoid X 
Receptor (FXR) selective antagonist (Huang et aL, 2012; Ma 
et al., 2010). Azelastine (d) is a potent, second-generation, 
selective histamine antagonist (histamine-Ht-receptor antago-
nist) and it is a member or the phthalazinone family, it shows 
relevant bronchodlatory activity used for treatment of asthma 
(McTavish and Sorkin, 1989) and has also been reported to 
induce vasorelaxatian in vitro assays (Lee at al., 1990). Com-
mercially availahle drug, hydralaane (e), is one of the fast 
antihyperteasive drugs developed is 1950s and due to its vaso- 
dilator action it is considered as lead for introducing new 
drugs. Hydra)azine belongs to phthalazine drug family and 
directly acts as a smooth muscle relaxant used to treat 
hypertension by acting as a vasodilator in arteries and arteri- 
ales. A slight change in the structure of hydrapedoc led to 
the discovery of some phthalazcne derivatives which were 
Figure 1 Structurally related drugs to the target compounds. 
found to possess antiparasitie, antifungal, antimicrobial, anti-
psychotic, antineoplaslic activities (Ohms et al., 2006). The well 
know. HAV 3C inhibitor (I) is also a phthalazindiove deriva- 
tive which has been found to possess inhibitory properties 
against hepatitis A virus 3C proteinase (lain and Vederas, 
2004). Pyrazolo[l,2-b]pbthalazine-dione derivatives were 
reported as antdnflarumatory, analgesic, antihypoxic and 
antipyretic agents (Al-Assar et al., 2002). Our investigations 
show That the structure of some drugs which are mainly based 
on pyrazole, pymzolone, phthalazine and phthalazinone, 
phthalazindione nuclei (Fig. 1) is closely related to the 
structure of the target compounds i.e., 1,3-disubstituted-1H-
pyrazol-5(4H)-one and 2substituted-3H-I,4-phihalazindione 
fatty acid analogues. 
Carboxylic acids having long alkyI(alkeny1/hydrnxyalkenyl 
chains are found to be pharmacologically active antimicrobial 
agents (Haul and Parveen, 2005) and these are also useful in 
the ti-oatmeal of renal, cardiovascular and hepatic disorders 
((ireetings et al., 211413). Also, some fatty acid derivatives have 
been found to possess antitumor activity and antidepressant 
activity (Khan et aL, 2011; Jubie et al., 2D12). Vital utility 
range of pymmlons and phthalaziadions, fascinating 
properties of fatty acids and in continuation of our work in 
derivaliealion and heterocycl nation of selected fatty acids 
(Parshori at al., 2010, 701 lab: Varshney at al., 1013) enthused 
us to design a simple, efficacious and one-pot synthetic route 
for the synthesis of two novel series of 1,3-disubstituled-IH- 
pyra2ol-5(4H)-one and 2subsututed-3H-t,4-ph1hnianbldion 
fatty acid analogues using selected long alky1fa1keny1/hydroa-
yalkenyl chain hydrazides as starting materials. Furthermore, 
this synthetic methodology involves the use of cheap and 
readily available solvents and commercially available reagents, 
giving the desired products in good to excellent yields. The 
mnbidexterily of this synthetic route makes it applicable for 
library synthesis in drug discovery effects. 
2. Materials and methods 
2.L Physical and spectroscopic mcasurenrents 
(9Z, 12R)-l2-Hydroxyoeladec-9-enoic and (9R, 12Z)- 
9-hydroxyoctadee-12-enoic acids were isolated front Ricdocs 
eamnttvttir and Wrightin tincwria seed oils respectively follow-
ing Gunstxne's partition (Constant, 1954). Undeo-1n-enoic 
acid (Purity 98%), (Z)-ocmdec-9-enoic acid (97%) and palmat-
ic acid were purchased from Fluky Chemicals (Buck Switzer- 
land). Ethylaceloacetate and phthalic anhydride were 
purchased from Merck, Mumhai, India. Thin layer Chroma-
tography (TLC) was done on glass plated with a layer of silica 
gel G (Merck, Mumbai, India (1.5mm thickness). Column 
chromatography was carried out on silica gel (Merck, Aenm-
bai, India, 60-120 mesh). IR spectra were recorded on Shilna-
dzu 8201 PC spectrometer and absorption given in cm-1. 'H 
NMR and 11C NMR were recorded in CDCI3 on a Broker 
DRX-400 instrument. The chemical shifts (d) were measured 
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Table I Structue and physicochemical parameters of all newly synthesized compounds. 
Cede Compound Molecular .Molecular Physical MP. 	%Yield 
formula weight state 
la o C2,H,sOzN3 336.44 Colorless - 	75 
oily N IlCtti C—fx— ~~ 
n 	Cx3 
2b CisH2402N, 264.32 Colorless - 	74 
oilN 
xr 	) 
0 	W~ 
2c C&13sOiNa 362.48 Reddish - 	70  
II brown oily 
s 	t  cc CNN 
O~LlS 
Id 
OF! 
C1)H,sO3Ne 378.45 Reddish - 	71 
brown oily 
— 	 I 
CN, 
2e CnH3aO,,N, 378.4 Reddish - 	73 
brown oily 
) s 
DIH 
O11 
3b CI,H,4OJli 328.36 White 85-87 	85 
powder 
xx / ~ 
3c C,al,O)N2 426.52 White 91-91 	82 
potrder 
IM 
O 
3d 	 Ge1htnOaN3 442.52 While 	70-72 70 
OH 	 powder 
KM 
YFN Z 
a 
3e 	 C,,H2OiN2 442.52 White. 	74-76 74 
powder 
IL4 
) s F>I 	\ 
O 
OH 
•M.P.: Melting Point. 
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relative to TMS as an internal standard and quoted in ppm. 
Coupling constants (l) are expressed in Itertz jilt). The mass 
spectra were recorded on SEOL-SX 102/DA-600 mass 
spectrometer. 
2.1.I. Genera) procedure for the preparation off 3-e'itvbHlmted-
11f-pyrazol-.5(4H)-ones 2(a-.) 
Fatty acid hydrazides 1(a-e) previously synthesized in our lab-
oratory (Roof et aL, 2007) were used as the starting material. A 
mixture of 0.01 mat of fatly acid hydranides I(a-e) and 0. mot 
(13 mL) of ethylacetoacemte was heated on paraffin bat!,. 
After sometime the reaction mixture turned into a reddish oily 
syrup. The reaction was continued till all the reactants were 
consumed. After completion of the reaction, the reaction mix-
ture was cooled and worked up with dichlorometbane and 
water. The product was purified by column chromatography. 
All the products were oily in nature and were elucidated on 
the basis of their spectral data. 
2.1.2. General procedure for the preparation of 2-rvbgrilured-
3H-I4-pht),ala-inedinner 3(6-e) 
0.1 mole of fatty acid hydrazides l(h-e) and 0.1 mol ofphthalc 
anhydride in ethanol (5 mL) were taken in a round bottom 
flask and 0.005 or of glacial acetic and was added. Reaction 
mixture was refluxed for 10-12h, and then poured into 
crushed ice, a solid product was precipitated. Al] the products 
were in the form of white powder and were elucidated on the 
basis of their spectral data. The reaction sequences leading 
to the formation of these two novel series of compounds are 
outlined in Scheme I and physiochemical parameters of all 
the newly synthesized compounds are tabulated in the Table I. 
22. Bio)egica1 activity 
2.2.1. .lntibaeteria( studies 
A stock solution of I mg/mL was prepared by dissolving all 
the newly synthesized compounds in DMSO. Filter paper disc 
method (FPDM) (Bauer et al., 1966) was used for testing the 
antibacterial activity of all the target compounds and standard 
doxycychne Media with DMSO was set up as mntrol. On 
nutrient agar all cultures were systematically maintained and 
incubated overnight at 37 °C. At 1000 rpm the culture was cen-
trifuged, pellets were resuspended and then diluted in sterile 
normal saline solution (NSS) to obtain viable 105 efu/mL. 
On nutrient agar plates approximately 0.1 ml. of diluted bac-
terial culture suspension was spread uniformly with the help 
of spreader. Sterile 8 mm discs (Hi-media Pvt. Ltd) were 
impregnated with the test compounds. Antibiotic disc, doxycy-
cline (30 pg/disc Hi-Media) was used as control. The disc was 
placed on the nutrient agar plate. Each plate had one control 
disc impregnated with the solvent. The plates were then incu-
bated for 24 It at 37 °C, and the resulting zones of inhibition 
were measured (mm). 
2.2.2. Antijuogal studies 
The synthesized compounds were dissolved in DMSO. Media 
with DMSO was set up as control. Al! cultures were consis-
tentiy maintained on SDA (sabouraaud's dextrose agar) and 
incubated at 26 °G Spare formation of filamentous fungi 
was prepared from 7 day old culture in sterile normal 
saline solution (8% NaCI) and approximately diluted to obtain 
lbscfu(mL The inoculums of oon-sporing fungi, Cundldo arbi-
caFLr were performed by growing the culture in SD (sabou-
raud's) broth at 31°C for overnight. At 1000 rpm the culture 
was centrifuged, pellets were resuspended and then diluted in 
sterile normal saline solution (NSS) to obtain viable 10' cfuf 
mL. On SEA plates approximately 0.1 mL of diluted fungal 
culture suspension was spread uniformly with the help of 
spreader. Sterile 8 mm discs (Ill-media Pvt. Ltd) were impreg-
nated with the test compounds. Antibiotic disc, nystutin 
(30 pg/disc Ili-Media) was used as control. The disewasplaced 
onto the SDA plate. Each plate had one control disc impreg-
nated with the solvent The plates were incubated at 28 °C 
for filamentous fungi for 72h or more, while for C. ulbicans 
plates were incubated at 37°C for 18-48 h. Antifungal activity 
was determined by measuring the diameters of the inhibition 
zone (mm). 
J- Results and discussion 
3.1. Chemistry 
The present study is based on the synthesis and characteriza-
tion of two novel series of pyrazolone and phthalazindione 
derivatives of long chain fatty acids. The fatty acid hydrazides 
t(a-e) were used as the starting material and they were pre-
pared from the fatty acids following previously reported meth-
od (Rauf et al., 2007). The derivatives of 1,3-disubstituted-IH-
pyraznl-5(4H)-ones Na-a) were syntheswPd by the condensa-
lion of long chain alkyl, alkenyl (internal and terminal) and 
hydrozyal1cnyI carboxylic acid hydrazides 1(a-e) with cthy-
lacetoacerate. followed by cyclizttion. The synthesized com-
pounds were identified on the basis of IR, 'H NMR, "C 
NMR and MS. The structure of compound 2b was confirmed 
by the appearance of an absorption band at 1603 cm 1 due to 
C'N stretch. Another absorption band for 	O was ob- 
served at 1698 em 1 . The absorption band at 2932 cur' was 
observed for aliphatic stretch. The 'H NMR spectrum was 
more informative in assigning the structure. In addition to 
peaks of fatty acid chain, the singlet at 54.18 for two protons 
of pyrazolone ring CH2 was observed along with a singlet at 
51.57 for CH, protons which is directly attached to the ring. 
In I 'C NMR, peaks at 6178.6, 6130.2, 550.8 were observed. 
Further evidence was obtained by recording mass spectrum. 
The mass spectrum showed characteristic molecular ion peak 
which was in accordance with the molecular formula. Similar 
type of spectral data were obtained for compounds 2a, 2c, 2d 
and 2e. 
Similarly, the other novel series of 2-substituted-3H-I,4-
phthalazindione derivatives 3(be) were synthesized by the 
condensation of long chain alkenyl (interim] and terminal) 
and hydcoxyalkenyl carboxylic acid hydrazides I(Ve) with 
phthalic anhydride in ethanol and catalytic amount of glacial 
acetic add was used. Products were in the form of white pow-
der. All the newly synthesized compounds were characterized 
on the basis of IR, 'H NMR, "C NME. and MS. Compound 
3b showed IR absorption bands at 3228 em 1 for N-H stretch, 
at 2925 cm ' fm C-H stretch and at 1595em I for C-0 
%ss ak this 	wPrima rA1Eud. A. et J.; S}auGstl; Gaiegied wetew otuevdkm4 can  dc6w6vn of 1.3. is'u fitrncd-LH.py,azo 5(4Eu)-mt ardl srtrtiNled 
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stretch. The 'H NMR showed a singlet at 68.01 corresponding 
to the N-H proton. Also a multiplet at 87.74-7.89 was oh-
sened for four aromatic protons. In 13C NMR, peaks at 
8171.8, 5165.3, 5139.2, 3134.7, 5130.9, 5129.1. 5128.4, and 
8127.1 were observed. The mass spectrum showed a character-
istic molecular ion peak which was in accordance with the 
molecular formula. Similar type of spectral data were obtained 
for compounds 3c, 3d and 3e. 
3.1.1. The sp crroscopic and analytical dada for the synthesized 
compounds 2(a-e) and 3(b-) are presented below 
3.1.1.1. 	I-(Hexa~ranoyl)d-merhyl-lKp)mazol-5(4H)-one 
(2n). IR (KBr, cal'): 2920 (C-H stretching), 1680 (C0 
stretching), 1592 (C=N stretching). 'H NMR (CDCI3, a0): 
4.12 (2H, s, CH2 ring), 2.25 (2H, t, J = 7.59 Hz, CH2CO), 
1.95 (21!, m, Cf12CH2CO), 1.56 (311, s, C113 ring), 1.22 
(24H, br.s, (CHz)Iz chain), 0.85 (3H, dist.t, CHs). 13C NMR 
(CDCI,, 3dJ: 176.9. 165.4, 127.9, 45.8, 35.6, 33.8, 33.7, 32.9, 
31.8, 31.2, 30.0, 29.9, 29.8, 29.7. 27.4, 27.0, 25.4, 23.8, 22.8, 
14.0. MS (ESI): m/z = 359.500 found (M + Na]', calculated 
[M + Na]* - 401.470. 
3.1.1.2. ]-(Undeo-ld-enoyl)-3-methyl-IH-pyra_ol-5(4H)-arse 
(2b). IR (KBr, an I): 2932 (C-H stretching), 1698 (O 
stretching), 1603 (C=N stretching). 3H NMR (CDC13, by): 
5.82 (III, tdd, Iu-90r, =6wNL Jx-n,.l .,, Jx-Ne-17.10 
Hv CHa = CH), 5.01 (1H, dd, Jaa_)t = 10.3ONz, 
2.00H7, 	H7C - CIH, 	4.91 	(III, 	dd, 
Jura = 16.90H2 Jo n. = 2.00H, HbC = CH), 4.18 
(211, s, CH2 ring), 2.51 (211, t, J = 7.38 Hz, C111C0), 2.06 
(2H, m, CH: = CH-CH2), 1.71 (211, m, CH2CH2CO), 1.51 
(3H, s, C7!3), 1.25 ([OH, br.s. CH,(CH,)5). i3C NMR (CDCI, 
bd: 178.6, 174.0, 130.2, 130.0, 129.9, 50.8, 34.4, 33.9, 31,9, 
30.8, 30.1, 29.7, 27.1, 24.2. 18.0. MS (EST): m/z = 287.121 
found [M + Nal', calculated [M + Na] * = 287.310. 
3./.13. 1-((9'Z) [Octadec-9-eddy!))-3-mctlgd-III-pyraco(-
5(411)-one (2c), IR (KBr, cm): 2924 (C-H stretching), 
1700 stretching, 1598 (C N stretching). 'H NMR (CDC13, 
8H): 5.35 (211, m, CH - CH), 4.20 (214, s, CHz ring), 2.36 
(2H, 1, J = 7.52 Hz. CH2CO), 2.24 (4H, m, 
CH,CH = CHCH,), 2.00 (21-1, m, CH,CH,CO), 1.61 (311, s, 
CH3), 1.25 (20H, br.s, (CH,)te), 0.88 (311, dist.t, CH3). °C 
NMR (CDCI,, &c): 180.1, 165.8. 127.2, 123.1, 122.9, 48.1. 
35.0, 33.1. 31.9, 29.7, 29.6, 29.4, 29.3, 29.2, 29.1, 27.1, 25.3, 
25.0, 24.7, 15.4, 14.1. MS (EST) mfz - 385.381 found 
[M + Na]*, calculated [M + Na]' = 385.471. 
3.1.1.4. 1-((9'Z, IYR)-1Z-Hydroxy-ocladec-9'-enaylJ-J-
rnerhy/-IN-pyraco!-.5 (4H)-one (2d). IR (Ker, cm'): 3400 
(0-H stretching), 2929 (C-IT stretching), 1685 (C = 0 stretch-
ing), 1579 (C = N stretching). 'H NMR (CDCI,, Sn): 5.34 
(2H. m, Cfl = CH), 4,87 (1 H, m, C11OH), 4.H (2H, s, CH2 
ring), 2.27 (211, I. J = 7.47 Hz, CHZCO), 2.21 (IH, m, 
CHOH), 1.96 (4H, in, CH,CH = CRC!!,), 1.85 (211, m, 
CHCH2C0), 1.55 (3H, s, CH, ring), 121 (1811, br.s, 
(CH,J9), 0.80 (3H, dist.l, CH,). '3C NMR (CDCI3, 3d: 
)82.9. 173.9, 133.2, 132.8, 123.8, 72.0, 50.1, 37.4, 36.7. 34.3, 
31.9, 31.7, 30.1, 29.6, 29.5, 29.1, 28.9, 27.3, 25.6, 24.9, 15.9, 
14.1. MS (ESI) n3/z = 401.299 found [M + Na]', calculated 
[M + Na]* = 401.470. 
3.1.1.5. 1-[(9'R. JYZ)-9-Hydraxy-adadx-IYenov/J-3-
melhyl-/H-pyra+ol-5(4H)-one (2e). IR (KBr, car-'): 3391 
(0-H stretching), 2933 (C-H stretching), 1680 (C = 0 stretch-
ing), 1570 (C - N stretching). I H NMR (CDC13, SH): 5.35 
(211, nt, CH = CH), 4.86 (IH, in, CHOH), 4.13 (211, s, CHz 
ring), 2.25 (2H, t, J = 7.50 Ha, CH,CO), 2.19 (1H, m, 
CHOH), 1.95 (4H, in, CHCH = CHCH2), 1.86 (2H, m, 
Cl72CH,CO), 1.53 (3H, s, CH3 ring), 1.23 (181-I, br.s, 
(Cllils), 0.82 (3H, dist.t, CN3). I3C NMR (CDC],, 8c): 
181.9, 176.9, 133.1, 132.5, 123.0, 72.9, 50.4, 38.4, 37.7, 33.3, 
31.8. 31.7, 30.2. 29.5, 29.2, 29.0, 28.6, 27.1, 25.7, 24.6, 15.9, 
14.3. MS (ESI) In/z = 401,302 found [M + Nal+, calculated 
[M i' Na]' = 401.470. 
3.1.1.6. 2-(Unrlec-10'-enayi)-311-1,4-rBtlmdazieGon (3b). IR 
(RBr, co I): 3228 (N-H stretching), 2925 (C-H stretching), 
1599 (C - 0 stretching). 'H NMR (CDCI3, 3,,): 8.01 (IH, s, 
NH), 7.74-7.89 (4H, in, ArH), 5.80 (IH, tdd, Jx-+cn,-6.71 
Hz, Jn-x.=10.90 Hz, Jana-16.92 11z, CH, = CH), 5.01 
(111, dd, 4—,,=10.11 Hz. Jam-nF°2.20 Hz. HzC - CH), 
4.93 (IH, dd, Jnz_n=17.45 Hz, Jur_rrz=2.20 Hz, 
NEC = CH), 2.39 (211, t, J = 7.50 Hz, CH2CO), 2.03 (2H, 
in, CH z = CH-CH,), 1.70 (211, in, CII2CNzC0), 128 (10H, 
br.s, CHZ(CH,S). 13C NMR (CDCI3, Sc): 175.1, 171.8, 
165.3, 139.2, 134.7, 130.9, 129.1, 128.4, 127.1, 124.0. 114.1, 
33.9, 33.8. 29.3, 29.2, 29.0, 28.9, "one signal hidden", 25.1. 
RMS (EST): m/z = 351.333 found [M + Na]`, calculated 
[M + Na]" = 351.353. 
3.1.1.7. 24(Z)-Ociadec-9'-ermylJ-3H-1.4-phIlml2ridiure (3c). 
1R (KBr. cm''): 3232 (N-H stretching), 2922 (C-H stretching), 
1594 (C = 0 stretching). IH NMR (CDCI3 SH): 8.36 (III, s, 
NH), 7.77-7.92 (4H, m, ArS), 5.34 (211, 3u, CH = CH), 2.41 
(2H, t, J = 7.40 Hz, CH,CO), 2.22 (4H, m, 
CH,CH = CHCH2), 1.70 (2H, in, CH2CH2CO), 1.29 (20X. 
br.s, (CH,),h), 0.87 (31I. dish, CN3). 13C NMR (CDC(,, Sc): 
[74.8, 170.1, 167.2, 138.1. 134.9, 133.5, 131.9, 128.1, 127.7, 
118.4, 115.6. 36.6, 34.2, 31.5, 31.2, 30.5, "two signals hidden", 
29.5, 29.2, 29.0, 28.7, 27.5, 26.2, 24.1, 14.1. MS (ES) a,/ 
z = 449.500 	found 	[M + Na]*, 	calculated 
[M + Na]* = 449.510. 
3.1.1.8. 2-((9'Z, IYR)-J.2'-Jlydruxy ocmdec-9'-ermylJ-3H-1.4-
phr8(aeindianz (3d). 3392 (0-H stretching, 3227 (N-H 5tretch-
ing), 2921 (C-H stretching). 1585 (C = 0 stretching). 'II 
NMR (CDCI,, 5H): 8.41 (III, s, NH), 7.34-7.67 (4H, m, 
Ar/i), 530 (2H, m, CH = Cff), 4.21 (111, m, CHOH), 2.54 
(2H, 1, J = 7.79 Hz, CH2CO), 2.19 (III, m, CHOH), 1.80 
(411, in, C/f,CH = CHCH,), 1.65 (2H, m, CH2CH CO), 
1.27 (18H, br.s, (CH), 0.88 (311, dist.t, CHI). '3C NMR 
(CDCI3, 8dJ: 173.1. 168.8, 163.9, 134.9, 133.4, 132.7. 130.1, 
126.7, 123.4, 118.8, 114.7, 72.0. 38.1, 38.0, 37.2, 36.7, 35.1, 
33.9, "one signal hidden", 32.1, 29A, 28.5, 27.6, 24.8, 23.1, 
13.9. MS (EST) mfr = 465.490 found [M + Na]', calculated 
IM + Na]' - 465.513. 
3.1.1.9. 2-f(9R, 32'Z)-9'-fiydroxy ocladec-l7-car ylf-3H-I,4-
pMhalazfnrfione (Je). 3372 (0-H stretching), 3217 (N-H 
stretching), 2918 (C-H stretching), 1591 (C = 0 stretching). 
'H NMR (CDCI,, SH): 8.42 (111, s, NH), 7.29-7.57  (411, in, 
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ArM), 5.480 (2H, m, CH = CM, 4.29 (ILL at CHOH), 2.34 	standard drug for the comparison of the antibacterial activity 
(2H, t, .1 = 7.59 R. CH1CO), 220 (LH, m, CHOW). 1.81 	results. The in vitro antimicrobial screening results are given in 
(4H, m, CH2CH = CHCI/,), 1.71 (2H, m, CH1CH,CO), 	Table 2. Graphic representation of the biological screening re- 
1.25 (18H, br.s, (CH2)9), 0.81 (3H, dist.t, CH3). '3C NMR 	suits is depicted in Fig. 2(A-E) in terms of diameter of zone 
(CDC13, 3c): 174.5, 169.1, 162.6, 134.0, 133.9, 132.5, 131.5, 	inhibition (in mm). The newly synthesized compounds 2(a-e) 
125.7, 124.4, 119.0, 112.9, 71,0, 38.9. 38.1, 37.6, 36.7. 35.8, 	and 3(b-e) have exerted significant inhibitory activity against 
33.0, one signal hidden", 32.1, 30.0, 29.5, 28.4, 26.4, 24.9, 	the growth of the tested bacterial strains. The antibacterial 
14.4. MS (ESI) m(z = 465.600 found (M + Na]', c lculated 	screening results showed that among the tested bacterial 
[M + Na]- = 465.513. 	 strains, good inhibitory results were obtained against E. colt 
and P. aeruginosa as depicted in Fig. 2(C) and (D). Among 
3.2. Biaiogy 	 the tested compounds, 3d and 3e showed more potent inhibi- 
tory activity against both types of bacteria. However, depend- 
AU the newly synthesized compounds were assessed for in vitro 	ing on the nature of the heterocyclic moiety (phthalazindione/ 
antibacterial activity against an assortment of two Glum-posi- 	pyrazolone) and substituents (long alkanoyl/alkenoyl/bydroxy 
Live bacteria, Staphylococcus mucus SA 22, Bacillus vnbIPis 	aIkenoyI chains) attached to it exerted varying in1ti6itory ae- 
MTCC 121, and two Gram-negative bacteria, Eschericbia colt 	Lions. in another set ofexperitnents, all the newly synthesized 
K12, Pmudnmomv aeraginosa. Doxyeychne was used as the 	compounds 2(a-e) and 3(b-e) were also screened for in vivo 
antifungal activity against C. afbicans $OA 109. Nystatin was 
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Figure! (A-ft): Graphic representation of the antimicrobial screening results in terms of diamemr of inhibition zone (in mm) against 
various microbial strains. Fg 2(A-D) shows the antibacterial activity against Bucillus snbrilis, Staphylococcus carom, Ercherkhia coli and 
P.seudanorms neruglno a, respectively, standard used was Doxycyeline. Fig. 2(E) shows the anti£ungal activity against Candide albicans, 
standard used was Nystatin. 
Table 2 In Sn, antimicrobial screening data of compounds 2(a-e) and 3(b-e) 
Tnl 
 
CoiieeutraGo3 B oulm SraphrlococnLc Eviherkh4, Pscid moos Cndida 
sample (pg/n,L) rrbsuis aureur roll Wbw'r'' 
2a 400 - - 10 n? Ii - 
&I0 - - 14 ❑  13 
2b 400 - ._ 14 16 II 
800 15 14 22 19 16 
2c 400 - - 13 13 10 
800 - - 17 19 14 
2d 400 it 10 15 15 14 
800 13 13 22 21 18 
2e 400 IQ II 13 13 13 
800 13 14 19 20 17 
3b 400 - - 14 13 11 
S00 Cl 13 20 16 17 
3c 400 - - 14 - 10 
SW - - 19 14 15 
3d 400 13 II 19 14 13 
800 Ii IS 22 24 19 
3e 400 II II 15 I5 14 
300 16 Is 23 22 20 
Doxycycline 30 (/dim) 20 IS 23 31 
NA 
30 (,tc/dicc) 	NA 	NA 
ANA: Not applicable. 
used as the standard drug for the comparison of the anti fungal 
results. The synthesized compounds showed moderate to excel-
lent inhibitory results for C. albicans as soon in Fig. 2(E). 
3.2.1. S,nucrure-acfiui(y rolationslup (SAR) srudies 
The structure-activity studies showed that depending on the 
nature of the heterocyclic skeleton and its substituent, the new-
ly synthesized compounds 2(a-e) and 3(b-e) exhibit varying 
degree of microbial inhibition. From the antimicrobial screen-
ing results, it has been found that the phdmlazindione deriva-
tives 3(b-e) have shown better activity as compared to their 
corresponding pyrazulone derivatives 2(a-e). Within the same 
heteroc5<Fc series that is either in phthalazindionc derivatives 
or in pyrazolooe derivatives, the inhibitory activity depends on 
the nature of substitnents attached to them. The fn viRO bio-
logical screening indicated that the presence of the hydroxy 
substituerits attached to the heterocyclic moiety as in coin-
pounds (2d, 2c, 3d and 3e) increased their inhibitory activities 
compared to other compounds. Structure activity relationship 
(SAR) studies cleared that, compounds with terminal alkcnoyl 
substituent (2b and 3b) and smaller carbon chain (C10) have 
better inhibitory acurvlty compared with eorupor3ts (2c and 
3c) which have internal alkenoyl substituent and longer carbon 
chain (Ci).  Further, SAR studies show that heterocyclic moi-
ety having alkanoyl substituent (2a) which is analogue of sat-
urated fatty acid and having long carbon atom chain (Cls) 
shows very small inhibitory results. The values of diameter 
of zone of inhibition in mm for all the newly synthesized coin-
pounds are pictorially represented in graphical form in 
Fig. 2(A-E) against B. sub/his, S. outeun, E. co(i, Pscsuoino,as 
aerugiuosa and C. albitans, respectively. The maximum inhibi-
lion was observed in phthalazindione derivatives substituted 
NA 	NA 	Is 
with hydroxy substituent i.e., 3d and 3e against P. aenginosa 
with zone diameter of 14 and 15 mm, respectively (at 400 pgl 
mL concentration) and also with zone diameter of 24 and 
22 mm, respectively (at R0Q pg(mL concentration) as seen in 
Fig. 2(D). The compounds 3d and 3e also show good inhibi-
tory activity against E. rafi with zone diameter of 18 and 
15 mm, respectively (at 400 pg/mL concentration) and with 
zone diameter of 22 and 23 mm, respectively (at 800 pg/mL 
concentration) as depicted in Fig. 2(C). Hence, we summarized 
that higher activity of compounds 2d, 2c, 3d and 3c may be 
attributed to the presence of hydroxy .eohstituents. Also, the 
synthesized compounds with phthalazindione rings substituted 
with hydroxy group (3d and 3e) show excellent activity as com-
pared to p)'mzolunc rings substituted with hydroxy group (2d 
and 2e). Thus, the nature of substhhenis and the heterocyclic 
skeleton of molecules have a strong influence on the extent 
of antibacterial and antifitngal activities. 
4. Conclusion 
To the best of our knowledge these alkanoyl/alkenoyljhydrox-
yalhenoyl pytazolone and phthalaxinditue derivatives of some 
selected fatty acids have been synthesized for the first time The 
salient features of these procedures includes mild reaction con-
ditiens, use of inexpensive reagents and starting material. 
products were obtained in goad to excellent yields. The struc-
ture-activity studies showed that depending on the nature of 
heterocyclic skeleton and its subaotueo[, the newly synthesized 
compounds Na-c) and 3(b-) exhibit varying degree of micro-
bial inhibition. The in vitro biological screening results show 
that compounds having hydroxy subatitrent attached to the 
heterocyclic moiety (2d, 2c, 3d and 3e) were the most promis- 
Mccrtu aite,his ankle in Press as Ahmed A n aL, SynlLSis bieIQSicd snaisingernmbl tnn4 b•in  a[^vvtiva or 1,3di5uHUM¢d-IH-pymol-i(9H1-unn and 2sr6,otM 4 
H.1 4-Phtlialscrin-16&eve .Ctr([urtns[tiv[cy m3on:hip sZCdi¢ )crmal or M.e stud UnF[ni1v- Pdcnre (101  RI, h1@ /ltlh IuL urdiO. 101 L/j1Iw3.=1I1309.003 
ing antimicrobial agents. The maximum inhibition was ob-
served in phthalazindione derivatives substituted with hydroxy 
substitucnt i.e., 3d and 3e. The synthesis will be a valuable 
addition to the synthetic methodology available for the synthe-
sis of heterocyclic derivatives of fatty acids which are useful 
biologically as well as industrially. From these studies it is 
understandable that further derivauVatiion and heterocyeliza- 
tion of these heleeto-analogues of fatty acids tan be served as 
new templates for antimicrobial drug discovery and could 
probably lead to more potent agents in this field. 
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ARTICLE INFO 	 ABSTRACT 
Arnie hictory: 	 Navel series of long chain isoxazole derivatives were designed as inhibitors of Cytoehrome P450- 
Remived22)one 2013 	 14DMl4a-demethylase from Candido a himms and ribosomal subunit of S12 protein from Fsthedtba Received In revised f rm H. The novel compounds (6-10) were synthesized dlmugh 1.3-dipolar cyclaadctidon of nivile oxide to 14 October 2013 	 long chain allrynoic add and alkenyllhydroxyalkcnyl esters and tested for Unit antimicrobial activity by Accepted 21 October 2013 	 disk diffusion assay and MWC by broth mrvo dilution method. After predicting the hidden potential and Available online 27 October 2013 	 p drug-likeness of compounes.ADME1-related dwcdp 
performed 
Cato calculated to predict phumoamoncdtf 
properties. Molecular Cocking studies have been performed m evaluate pmsihle mode of action of 
U-Lplar-rydoaddltien 	 moIcuilea in  active site ofreocptar,Wmpaunds(9 and  10)showed excellent antimicrobial acPvity nearly Am, and 	 equivalent to the control compounds. 
Mode nrzction ®1013 Elsevier Masson SAS. All tights reserved, 
1. Introduction 
The enteric bacterial infections are one of the major factors of 
morbidity in developing countries including Indian sub-continent, 
part of South America and tropical part of Africa [1l.  The common 
gram-positivepatbugensofnasofomial intcctiansareS1uphylococn3s 
aureus which may also account for outbreaks [231. The world's most 
mmmnn and serious infectious diseases like invasive dysentery and 
diarrhea are caused by Fscherichin call 14.5]. AmoxiclRri. mrrfoxadn 
and ciprofloxacin am generally used to treat the infections caused 
by the E col but they have some side effects IS]. The important role 
in the treatucnt failure is played by toxicity and resistance to the 
drugs also []I. Several severe diseases may be caused by gram 
negative and positive bacteria which may lead to huge damage of 
host tissues I8]. More than 90% of the cases of vagiNns are of 
candidiasis, trichomoniasis and bacterial vaginosis [9]. 
AlbrcWarbne: ,t mole refncdvity: W. molecular welghr. MV. moleavlar 
volume; PASS. predicted a,liiry syernum of substances; PM. polar surface area: 
SAR 51urturc—atUviry relationship; MaC. minimal iaubfrory wnrnni-.lion; MPSA. 
meMinllin resistant Stophylrcaaua uureus; Sy Vuphylucurruv nureuc 
• Carrerpandingzuthoc TeL +Y1 9412545345. 
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Present address: MngFandMeaic1IResearch centre. long AbdulavSUnlverslry. 
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upophibdty is the key physicochemical parameter linking 
membrane permeability and hence drug absorption and distribu-
tion with the route of clearance (metabolic or renal) 110.1I). The 
biological activity spectra of these compounds obtained by PASS 
online (bttpciwww.pharmaexperLm)PASSonlinc1indcz.php) esti-
mates the predirtted activity spectrum of a composmd as probable 
activity (Pa) and probable inactivity (Pi) 112.13]. 
Nitrogen and oxygen containing heterocyclic compounds have 
received considerable attention due to their wide range of biolog-
ical and pharmacological activities. Among the family of hetero-
cyclic compounds the five membered isoxazoles and isoxazotines) 
dihydroisoxazulles provide a valuable scaffold in Inedirinal chcln-
istryas well as a useful synthon in organcsynchesis. lsoxazoles and 
isoxazatines have teen reported to possess antitubulin as well as 
anti-inflammatory activity 114,15]. Dihydroisozazole derivatives are 
reported as antinociceptive compounds [161. In addition. imxazo-
line derivatives have played a caudal role in the theoretical devel-
opment of heteracydic chemistry and arc also used extensively in 
organic synthesis 1171.  Also, medicinal activity like anxiolytic ac-
tivity has been reported for isoxazole derivatives [18]. So many 
methodologies existtowards the synthesisofisoxazoles [19,20[ and 
dihydroisnxazoles [211 and most of them endeavor nitrile made 
cycloadditinn as a keystep [22]. The addition of a t,3-d%pnle to an 
aIkenc/alkyne for the synthesis of 5-membered ring is a classic 
reaction in organic chemistry. The general application of 1,3-
dipoles in organic chemistry was first established by Huisgen in 
888 	 A Mmud N d. / Ewopeun Juumel ofMrdiduul CTnnhny 70 (2013J 881-Soy 
1960s 123]. Isoxazole and isoxazoline heterocycles we derived from 
the [3 +2] gtcloaddition of a nitrile oxide to an alkene and alkyne, 
respectively [24]. TheniMle oxide 1,3-dipole is generated in situ in 
Mnkaiyama reaction from the corresponding primary ni[rualkane 
and phenyl isocyanate 125]. Here, vihle oxide is generated by 
dehydration of primary nin-oalkanes. This method is however the 
most useful due to its easy set up as described by Mukaiyama in 
1960 1251, 1,4-phenylene diisoryanate was used as dehydrating 
agent [261. By using 1,4-phenylene diisocyanate, polyurea 
byproduct was obtained which may he removed from product by 
simple filtration because this polyurea byproduct was insoluble in 
the reaction solvent (benzene and tetrahydrofuran). Various bio-
logical applications such as antimicrobial 127]. pesticidal 1281. 
anticancer [29] and antlfungal activities [30] havebeen reported for 
seed oils, long chain alkenaic acids and their derivatives. These 
observations and our interest in the chemistry of heterofatzy acids 
prompted us to synthesize isoxazo(e derivatives of fatty acids with 
different substiment at 4- and 5- positions. For this reason, the 
present strategy for the synthesis of new compounds is aimed in 
the direction of developing new isoxazole derivatives to inhibit the 
growth of gram-positive, gram-negative bacteria and most patho-
genic fungi, After synthesis the compounds were tested for their 
antimicrobial activity by disk diffusion may and MIC by broth 
micro dilution method against bacterial and fungal strains. Also, 
molecular docking studies dies have been performed on Peptide 
defamrylase (PDF) of E. roll and CYP 450.14DM of [andido olhicans 
to evaluate the possible mode of action of the molecules in the 
active site of the receptor. 
2. Results and discussion 
2.1 Chemistry 
The long chain alkynnic acid and alkenoates used as the starting 
materials were prepared from the corresponding long chain alke-
noic acids or Fatty adds. The long chain alkynoic acid (1) was 
synthesized using the procedure of I(znnan et al. 131 ]. The esters of 
fatty acids (2-5) (long chain alkenoates) were prepared by 
refluxing the fatty acid in methanol in the presence of catalytic 
amount of sulfuric add (concentrated). Nitrobutane and 1,4-
phenylene diisocyanate were purchased from Sigma Aldrich. Th e-
thylamine, tetrahydrofiran (THF) and benzene were purchased 
from Merck. Mumbai. Nitrile oxide was generated in situ from 
nitrobutane employing 1.4-phenylene diisocyanate.The 1,3-dipolar 
cyeloadditictz afnitrile oxide to an alekenejalkyne gives an insep-
arable isomeric mixture of dihydr0isaxazole(rsoxd2oIe derivatives. 
This transformation was most effective when excess base (3 
equivalents of triethylamhte)was employedand nitrobutane added 
dropwise over 6-8 h while hearing. After refuxing, the reaction 
was quenched with water. The polyurea (polymer) was removed by 
filtration. Products were purified by column chromatography and 
identified using different spectral techniques. The signals of prod-
ucts in the 1H and 13C NMR spectra were successfully assigned. The 
high resolution mass (electron ionization) spectral studies have 
further confirmed their structures. The reaction sequences are 
outlined in Schemes 1 and 2. 
IR spectrum of compound (6), 5-(rarkcxynetyl)-3- 
propylisoxazole. revealed characteristic bands at 3285 (011 
stretching). 2918 (CH stretching). 1702 (add C=) stretching),1465 
(C=N stretdiing)'H NMR peaks at 12.61 (111, 5, COON), 6.98 (JH. S. 
CH ring), 235 (211, Li =  7.52 Hz, CH2000H), two triplets merged 
together at d 2.18 were observed for four CHz protons alpha to 
isuxazole ring, 1.63 (2H, to CH2CH2C00H), 1.54 (2H, m, 
CH2CH2CH3), 1.28 (1011, brs, CR2 chain), 0.90 (3H, t, J - 221 Hz, 
013). In °C NMR peaks at 17618. 16785. 82.17, B0.80, 4426.35.81, 
NCO 
4 	 + i 1M/6 v 	/~ N^O,  
01 I 	 NCO 
epN.6ry THE 
COOH 
x 
(6) 
Sehrme I. Synthesis of 3.5-hcsubstltu[M Isnzele (61 
N~I CO 
H 	H 
a 	
NO2 + / 
R( 	Rz 
NCO 
(2-5) 	 EtaN, dry CSHc 
N 
(7-10) 
Compounds 	R, R 
$T X ICX,),COOCN, 
3, a CH,(CH.), (CH,),COOCH, 
4,9 CH4CH kCHOHCH, (CH,f~000CH, 
5.10 CN.(CH,). (CHCHOH(CH,),000CH, 
srhane 2. synthesis or 3$AUWnuwrm and 3A.5-trisubsdruted-45-
dit haisoeazroes (7-10). 
32.68, 29.83, 29.68, 2939, 29.01. 27.46. 25.51. 2293. 14.10 were 
observed. The mass spectra showed characteristic riroleeolar ion 
peak in accord with the molecular formula. 
The structure of (7-10) is evident from their spectral data. The 
structure of compound (7) is outlined in Scheme 1 Compound (7), 
5-(carbomethaxyoctyl)-3-propyl-4,5-dihyroimxazole, showed IR 
absorption bands at 2931 nn t (CH stretching). 1740 cm-t fester 
C=0 stretching), 1457 (C=N stretching). The 111 NMR was more 
informative in assigning the structure. Diagnostic peaks for cyclic 
protons were appeared at4.46 (1H. m, Cliz-CH ring), 2.91 (111. dd, 
Hz 	H 
	
H 	(CH1)8C00CH3 
N ° H3CH2CH2C 	N 
Schemed SNWUre of 5{cummeNmtmctyl}3{,mlryl A$ditydraisrta4ole (7). 
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Jxz-n = 16.90 HZ, JNZ na  = 10D0 Hz, CH-Cffz ring), 2.49 (1 H, dd, 
Jxe-x = 16.80 Hz, JNC_xz  = 8.10 Nz, CH-CUE ring), 2.25 (411 two 
triplets partially merged,-CHZC00CH%-CH1CH2CH3).1.60 (6H, m, 
CH2CH2CH3, (CH2)5-CH2-. CHzCH]C000I3), 125 (10H. br.s. CH2 
Chain), 0.92 (3H. t J = 730 Hz, CH3).  In 13C NMR peaks at 17423. 
158.75. 79,97, 5139. 42.01, 3522, 34.01. 29.72, 2932. 29,25. 29.17. 
29.09, 2551, 24.86,19.74, 13.72 were observed. The mass spectra 
showed characteristic molecularion peak in accord with the me-
lecular formula. Similarly other compounds were characterized 
from their spectral data. 
12. )[l silico study 
22.1 Prediction activity speclm for substances (PASS) 
A type of biological effects, toxicity, molecular mechanism and 
drug-likeness of compounds is presented in (Table 1). The high 
drug-likeness of the compounds (Sandia) was determined to be 
0961 and 0.949 respectively which proved the high probability of 
these compounds as drugs. The antihypettensive activity of the 
compounds (9 and 10) predicted the pharmacological effect of 
these compounds. Moreover, itwas shown that the algorithm used 
in PASS can successfully be applied to discriminate the drug-like 
compounds from drug-unlike substances, 
211. ADME and toxicity predicdan 
The MIME-Plat is a 2D plot using calculated ADMEC_PSA}D 
and ADMEL A logp96 properties. The graph was plotted against 
ADMEF-PSA21] vs. ADMEr_A Iogp9g. Blood Brain Barrier (BBB) 
and Human Intestinal Absorption (HIA) plot (Fig. 1) was drawn 
using all the compounds. In BBB plot two compounds (7 and 9) 
were falling outside the 9 ellipse (undefined). Compounds (Sand 
7) are central nervous system inactive compounds and blood brain 
barrier cannot be penetrated by these compounds. So, the chances 
of central nervous system toxicity are low or absent As the com-
pounds (6,8 and 10) fall inside the 99%ellipse, these would be CNS 
active and would be able to penetrate the BBB. In HIA (human in-
testinal absorption) plot all the compounds except (7) have fallen 
inside the 99% ellipse. Hence, these compounds are expected to 
possess good human intestinal absorption. The aqueous solubility 
plays a critical role indie Unavailability of the candidate drug; and 
with the exception of compound (7) having low aqueous solubility 
level (level 1) as referred In (Table 2). all other derivatives are 
having good or optimal aqueous solubility levels. Except com-
pounds (6 and 10), no other compounds showed liver toxicity. Our 
results indicate that all the compounds except (6 and 70) arc non 
toxic to the liver (level 0. Table 2), and thus they experience sig-
nificant first-pass effect. Similarly, all synthesized compounds are 
satisfactory with respect to CYP2D6 liver (with reference to 
Table 2), suggesting that all the compounds are non-inhibitors of 
CYR2D0 (fable 3). This indicates that all the synthesized com-
pounds are well metabolized in Phase-1 metabolism. The cam-
pounds (6 and 10) have ADMET plasma protein binding >S0% and 
compounds (7, 8, 9) have >95%. dearly suggesting that most of the 
compounds have good bioavailability and are not likely to be highly 
bound to carrier proteins in the blood (refer to Tables 2 and 3). 
Finally, an interesting obsewabnn was that the non-hydroxyanalog 
of 3,4,5-himbstituted4.5-dihydroisoxazale, that is. 5-(carbome-
thoxyheptyl)-4-ot4-3-propyt 4,5-dihydroisoxazole (compound 
6), was found to pass the entire ADME7 test All the parameters 
calculated are tabulated in (fable 3). These observations denote 
that all the synthesized compounds can reach the desired targets. 
Toxicity screening of the ligands was performed by using the 
toxicity prediction extensible protocol and the results were tabu-
lated in (Table 4). From these toxicity studies it was found that none 
of the ligands have shown mutagenidry and ligands like (sand 9) 
D ThI 
PASS predicted but notseputted activities (hidden potential) of all the synthesized 
compounds, 
Comp. Activity 0mg 
ikeness 
Pa Pi 
6 Ptra,mrcologlea1 Uric and excretion 0.800 0305 0059 
effect snnwanc 
Anihyperltroive 0217 0.104 
MoiccWor Endothelia receptor 0.134 0.009 
mednnism antagonist 
Endote4n B receptor 0.141 0.010  
antagonist 
E'AuWelin A rerxp[ur 0094 acos 
all tagomur 
Nithcoxidoagop.ist 0.21] 0.173 
Mute cable donor 0A52 0.041 
Angiatensio Mmagonist 0.022 0.020 
Anguncp.slo n recelxor 0.020 0.030 
aotagonist 
Endmtdm converting 0.134 1086 
enflme inhibitor 
7 Phamcaaniogiczl Antihype+tertave DM8 0246 0P84 
cfeee IIricaridIXcrtiun olaa 0.11i5 
sdnulaat 
Molecular Endathelin receptor 0.122 0.013 
nicqunum antagonist 
Ei+doa¢rp+ B receptor 0.123 0024 
antagonist 
Endnthef+nnrereplar 0.083 omo 
antagonist  
Nitric Oxide agonist 0276 cal] 
Mite nod donor e don 0.055 0.036 
Mgieten antagonist 4.020 0.022 
Mgiv¢min 11 rrccpr r 0.810 0.020 
an agon t 
uluggl Mtitiypertemive 0984 0.396 0.019 
offic
a 
coat Uric add excretion 0.198 0.179 
r 'o Anl  
An gatcnsin An receptor OASd 0.042 
avragonh[ 
Molecular Alpba2 atlmrorecep[or 0289 0A54 
me harnan antagonist 
En 	nBreceptor 8136 0019 
antagonist 
Endathelin rc[epmr 0111 0.017 
antagontn 
£ndotheltnhrecepto[ 0070 h015 
antagonist 
Nitric oxide donor 0.075 0.320 
Nitric nerve agm+ict 8262 naafi 
nmB 0.013 Angwhnsin an n,epooI 
Mgictenannrerep[af ONS 0.013 
a 
E
nugomist 
htictelin convc[thna 0.121 0.119 
rnryme tp.h1hHa' 
Pham acoIogiaal Anlilrycertenvrve ¢961 0.302 n.oss 
effect 
Molecular Alpha 2 adrmocecepmr 0.261 0.1168 
meaunism antagontct 
Endothelia creceptor 0.138 0.019 
antagonist 
Endotheliv receptor OA91 DAYS 
snragpoca 
Nitric oxide dams 0.063 0.22 
Endnthelinfireceptor 0.061 0.0ID 
ant ag alt jar 
in rham,cu[aosinl M4hypettu[sive 0.949 0325 0.048 
(Lect  
Molecular Alpha 2edrenanepmr 0243 0.11/9 
mtaanum antagonist 
EndoteMBreceptor 0.129 0021 
antagonist 
Nitric oxide donor 0.076 0.010 
Endmhcfntrceplor 0.086 0.030 
tagonis[ 
Endothelia A Ircep[ur 005] 0.024 
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AaN.TJJeg198 
Fipl. Prc4icuonefdmg absorprion rorhesyntheded emmpaua s considered foran&microbial artir9ry.Discoverysmdio 25 ADMEtDewiplers.2D polarwrface area IPSAMD) 
in As far earn compound is plotted against tbeh corresponding calculated atom-type pamnan caetflrienr (AlagP98). 
Table 
Standard levels ofADMaT desoiplurs firm di,meeiysIodiu 25. 
Aq. Solublity and dmg likeness 	H8f1 	 Cymdirome P,15014DM 	Hepamnmoly 	InteIDnal absorption 
Iwel 	Intensity 	level Intensity 	 Level value 	level value 	level value 
a Ettrcmey low o Very high 0 Nun Inhibitor 	a Nontoxic 	a road 
No, wry low I High I Inhibitor 	1 Toxic 	1 Moderato 
2 Yes. low 2 MedIum Per 2 Poor 
3 Yes. good 3 Inw level % of biding 3 Very poor 
4 Yes. optimal 4 Vny low 0 p0% 
5 No. too soluble 5 Wommg; molloalis with one or mare I :90% 
unk,mwn Al q;P cokmx[torr 
6 Unknown  
have shown carcinogenic characters in female mouse models. No 
ocular irritancy, carcinogenicity and skin sensitization was found in 
national toxicity program (NIT) and food and drug administration 
(FDA) (Table 4). 
223. PhysiioM1smial properties pred(cdon 
In order to achieve good oral drugs we have subjected a series of 
long chain isuarazole derivatives (6-10) for the prediction ofADMET 
and Lipinski's "Rule of live 1321.  The ADMET parameters are a key 
parameter to understand the nature of interaction, between the 
concerned compound and its various targets. 
213.1. pRo and log P. The octant—water partition coefficient (P) 
(also referred to as Kow) is a measure of the propensity ala neutral 
compound to differentiate dissolution in these immiscible phases. 
Poor solubility and poor permeability arc amongst the main causes 
for failure during drug development (331. It is therefore, important 
to determine the physicochemical properties associated with a 
drug. Furthermore, there am hydrophobic binding sires on the 
proteins concerned in drug disposition further adding to the 
importance of lipophilicity. The results obtained are given in 
Tatatc3 
computer aided ADME screening of the novel compowids. 
Xganci{ Enflievel %man 	Aq.SoIubility Hepa1otouirity cPY]n6 Pro 
intestinal level 	Ieyel 	level level 
absurynon 
level  
a 1 a 3 3 0 1 
7 4 3 1 0 0 2 
a 1 0 3 0 0 2 
9 4 l 2 a a 2 
10 1 0 2 1 0 1 
X86: Blood grain Hams, PPg: Plasma Pmrein Binding CV VtDs Cymchmme P450-  
loots enzyme irddbition usingln chemical snucmre as input. 
(Table 5). There also exists a good relationship between log P and 
antimicrobial activity and in this study we have found that com-
pounds having higher log P and lower MIC values are the excellent 
antimicrobial agents. On the other hand the molecules having 
higher MIC values and lower log P values are the least active as 
shown in (Fig. 2). The compounds with log P values close to the 
linear line and have lower MIC values are the most active. 
21.31. "Rule of five" properties. For good oral bioavailability an 
ideal compound should have high oral bioavailability. good intes-
tinal absorption and reduced molecular flexibility 134). All the 
compounds of series (6-10) under investigation possessing less 
number of hydrogen bond donors (<5) and do possess a consid-
erable number of acceptors (d70) as shown in (Table 5). 
As shown in (Table 5), all parameters of the compounds were 
consistent with the rule of 5'. It was reported that a molecule with 
ten or fewer mutable bonds and PSA less than 140 A' might have a 
high probability of good oral bioavailability [351  as an he seen in 
(Table 5), all the compounds fulfilled both of the criteria. 
2133. The molar refractivity (MR j The molar refractivity (MR), 
which represents the size and polarizability of a molecule 
describing steric effects, was calculated (using Chemihaw Ultra 
11.0 software) to explain the activity behavior of the synthesized 
novel molecules. It is obvious from (Table 5). that the higher value 
of molar refractivity favors the activity ratio of compounds (9 and 
III). 
224. Biaarlviry score 
The standard drug scores were compared with calculated scares 
of the synthesized compounds. Suitable modifications were made 
in order to achieve an active moiety. proper bioactivity and drug-
likeness score as defined by Lipinski's rule. The biosctivity score 
for the synthesized derivatives are tabulated in (Table 6). In the 
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series, compounds (9 and 10) showed better GPCR ligand scores  
(0.19 and 0.19 respectively) than the standard drugs riprnlozacin 
- 	- 	- 	- 	- and Huconazole(0,12 and 012 respectively). Therefore, compounds 
2 	a  (9 and 10) can be considered as the lead antimicrobial agents 
"~ among the series 
a a 0 	" 	0 	A o` 	a
° d 23. 1n vita antimicrobial activity 
z ° 	z 	z 	z ° 	z 2.3.1. Antibacterial studies 
o 
_ 
 °4 The newly prepared compounds were screened for their anti- 
bacterial activity against Escherichta enii (ATCC-25922). S aureus, 
Pseudomonas aeruginasa (ATCC-27B53), Slreptococcfs pyogenes and 
Klehsielfu pneumuuiae (Clinical isolates) bacterial strains by disc 
d. diffusion method (36,371. The susceptibility was assessed on the 
° 	= basis of the diameter of zone of inhibition against gram-positive 
5 E 	A 	y and gram-negative strains of bacteria. Inhibition zones were 
t measured and compared with the controls (Table 7). 
g Minimum inhibitory concentrations (MICB) were determined by 
~ c A 	a g 	z broth micro dilution method. The nutrient broth, which contained 
logarithmic serially two fold diluted amount of test compound and 
controls were inoculated with approximately 5 x Ins c.fa/ml of 
actively dividing bacteria cells. The cultures ofthe bacterial strains 
E a z E z E z E z° E 	__ were incubated for 24 h at 37 °C and the growth leas monitored 
visually and spectrophatumetrically. The lowest concentration 
g € 	g (highest dilution) required to an 	growth est die  	of bacteria was p regarded as minimum inhibitory concentration (MIC). To obtain the 
i E z minimum bacterial concentration (MBC), 0.1 ml volume was taken 
N _ from each tube and spread on agar plates. The number ofcfu. was 
fi counted after 19-24 It of incubation at 35 -C MBC was defined as 
= the lowest drug concentration at which 99.9% of the moculums 
E E ` e a 	€ 2 S e 5 were killed. The minimum inhibitory concentration and minimum a c A 8 z 3z 2 z 0 r 8 baetencidal concenhatian ace given in (Table e). 
e m` The investigation of antibacterial screening data revealed that c C 	C all the tested compounds showed moderate to good antibacterial 
n~ 6 -C g 	d activity. Among all the synthesizedcompounds, compound (9) 
z showed highest antibacterial activity (25 µ6/ml) nearly equivalent 
° to standard drug ciprafoxarin. Compounds (9 and 10) showed 
n = good inhibition against S. pyogenes. S. covers and E coil species. In 
` 	' - 
 general, all the compounds were more effective against gram- 
 - - positive bacteria as compared to gram-negative bacteria. yea -~~cai 	C 	3 
233. Anh]ungal assay E E `. 	`g 	`g 	`. 	. The stock solution of compounds was prepared in UMSO at a 
.s P 	2 	P 	gQ concentration o1200 mg(ml. Agar dilution assay and micro dilution 
e 
-c " 
f C z° 9 z° 	z° '~ z 9 z 3 method were used to establish the minimum -inhibitory cmlcen- bauon(MIC) as well as minimumfungicidal concentration (MFC) of 
a ., t`a synthetic derivatives (3839(. The results are presented in (Tables 9 
x E 	9 = 	e and 10). As shown in (Table 9), compounds (6-10) had good anti- 
 z „ z 0 i 0 z q fungal effects against tested clinical species of [andida. Among all 
y b the synthesized Compounds. compounds (9 and 10) showed 
0 	mbo 	a excellent antifungal activity (32 p3/ml) against Candido tropicnlis 
o a t 	 •s e c e and C albicam5, which were resistant to SIucommte and itracona- 
° z 	z 0 z z c 9 	5 sole as well as against standard species of Candidu. 
° E __ 
cc 
e`. 	a 2.4. Molecular madeling 
z 3 The model for Cytochrome P450-14DM of C albicam generated 
° by modeller package using template structure human Cytochrame 
P450-14DM (PDB Id: 3W6) with 39% sequence identify and 54% 
sequence similarity (Fig. 3). The model has only one residue in 
g $ 	- disallowed regions similar to that ofthe template as observedin the 
as 	a 11 	G 	$ 3 Raniachandran plot using Proclieck program (http:J/nihserve[mbi. 
e g, uclaxxlu/SAVESI) (Table it). 
° ° 2 Ramachandran plot analysis showing thepercentage of residues - F o m 	a 	m lying in each of the four different regions of Cytochmme P450- 
992 	 AAbmad a aL(tiiroisxcaJournal a fMn1frinwcnemisny w (2013) 887-900 
TWO 5 
Physiodlmdcal Properties and nsle of five parameters ul syuthtizes compounds. 
Comp. ehcmical formula 	1ipinsN rah ors 	lP5Aa(A°) MSA 	Rotatable bonds No.Nolat1on5 	Gibbs energy lklfmaI1 	hlR hmsfrsmll MV' 
milugP 	MW 	HOD' HBn° 
6 	4cH25NU3 	4758 	267319 0 	4 	52332 	477.58 	12 0 -15018 80.05 290.7 
CyXLsr4O, 	4593 	283354 	1 	4 	58.897 	521.10 	11 0 -220.68 7463 2/93 
a 	C,5NrsNO3 g371 	381.590 	0 	4 	41.903 	74362 	le 1 -12/.49 11263 414.71 
9 	CnHUNne 	YA65 	397.603 	1 	5 	68.131 	743.00 	18 1 -256.75 11409 425217 
10 	CnH3N04 5830 	397.590 	1 	5 	68.131 	74289 	1S 1 -266.75 114.09 422.217 
Comp. 	Henyslow 	Heat offomsIhi/mall 	Hatennl analysis calculated Bolling point Ill  Melting pain[ IHI  IngD (pH 7.4) 	CLOgP 	pR• 
6 	415 	-61662 	C(67.36%). H (9.42%). N (524X), 0(17.95%) 7R.78 451.72 427 	44 4.6 
261 -695.62 C(68293), H (9.57%), N (498%).0(19.063] 78938 541.2 445 AO 47 
8 	126 	-4x09 	C(12.39%), H (11362), N 13.67%). 0(1258%) 879.46 506.85 7.65 	8.1 45 
9 	116 -10056 C (69.421, H I109EAN (14.5), 0 p610%) 9712 554.67 623 6.4 4.6 
10 	136 	-1005.6 	C(69.4a%). H(10.9%} N (352%), n (16.10%) 9712 554.6/ E2 	5.9 4.5 
a code P. the kg? value alobted using cool sspiraliun eivec. 
HED: hydrogen bead donor (expressed as the sum afoul and NH). 
NBA: hydrogen hand acceptor (ezprcaid as the sum of 0 and N atoms). 
a 1FSA: topological pour swfare area (defined as a sum oldie surfaces of polar a10111e In a molecule). 
MSC molaubr surface area  
W. mNemlarvolume. 
14DM (Fig. 4). In the disallowed region, the number of residues is 
also given in brackets with percentage and all the results are 
summarized in (Table 11). 
Molecular ducking studies have been performed on Peptide 
deformylase (PDF) of .E roll and CYP 450 of C albicans to predict the 
probable mode of action. of the molecules in the active site of the 
receptor. The binding of the compounds have been compared with 
the Ciprofoxacin binding site (Fig. 5). 
2.4.1. Molecular docking of the synthesized compounds with S12 
protein of 305 ribosomal subunit of B. coil 
The patent activity of synthesized compounds (6-10) as new 
antimicrobial agents, prompted us to study the docking of these 
derivatives inside the activesite of512 protein nfrihasomal subunit 
of B. Coll, the potential Larger forarmharterial agents. X-ray study of 
305 Ribosomal subunit 512 protein (PDB Id: 196. L Chain) with 
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divergent inhibitors shows that the binding pocket of the enzyme 
includes the following residues, Arge9, Lys 46. Lys 47. and Lys9l as 
shown in the (Figs. 5 and 6). The top score pose was selected for 
each compound and their results were shown in (Table 12) and 
compared with ciprofoxacin. which was redocked with the target 
protein using the same protocol. It was evident from (Figs. 5 and 6) 
that for each compound, the binding site was found to be the same. 
It was interesting to deserve that even though the core structure of 
all the compounds was same. the degree of interaction and binding 
location were found to be different for all the synthesized com-
pounds. The binding sites of the compounds were found to be in 
close proximity to the binding site of Iiprofoxacin as evident from 
(Figs. 5 and 6). The variation in the bioactivity is mainly attributed 
to the difference in their binding pattern. For instance. the bioac-
evity studies showed that compounds (6 and 7) showed cornpa-
rable results with ciprofoxaci against gram-positive and gram-
negative strains of bacteria. It may be due to two oxygen atoms 
from the carbo goctyl side chain of compound (6) which had fast 
hydrogen bonds with a terminal nitrogen atom of ArgR9 (bond 
length 3.26 A and 2.O A) one hydrogen bond with Lys46 (bond 
length 2.77 A). Compound (7) also had three hydrogen bond! 
(Lys9l bond length 3.06 A, Arg89; 3.05 A and Lys46; 3.09 A). In tht 
similar fashion standard ciprofoxadn also interacted with the 512 
protein and made two hydrogen bonds with Lys46 (band length 
2.68 A and 2.98 A) and Lys91 (bond length 2.67 A The compound! 
(8. 9, and 10) showed better bioactivity as compared to standard 
dprnfioxazin. Compound (9) had four hydrogen bonds (twt 
hydrogen bonds with Arg89 having bond lengths 3.24 A and 2.75 A 
one hydrogen blond with Lys46 having bond length of 3.29 A ant 
another hydrogen bond with Lys9l having a distance of 3.02 A). 
Table 
Bkovoyity score of the synaented compounds. 
Camp. Gept Ion modulator Protease Nudear Enzyme 
ligaod channel kuuse inhibitor recepmr Inhibitor 
lgaed 
6 0.03 0.1] -0.43 0.06 -0.12 016 
0.4! 0.06 -038 -005 -0.06 025 
9 0.13 0.05 -0.40 OUR 008 007 
9 019 213 -0.33 0.14 020 020 
10 11,19 1.11 -034 0.13 0.16 0.18 
Gµ 0.12 -0.04 -VA7 -0.19 -0.21 028 
no 0.12 -0.04 -0.07 -0.19 -021 0?8 
Op. =  pr,0axa7n: Flu. - Fluconamle. 
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Table,? 
Mtbactccia1 activity of 3-pzrnliamzciIc and 3-pgyI-4.5-diliydraisoraole 
aed ativcs. 
eompaunds nianumr ofzane ofiMaitiun (mm) 
enm positive bacteria 	cram nepdve bacteria 
S. pya;mer Saurelu 	P. semglnnta K ).ieumote E ran 
6 21.630A 	19.13 a .4 31.230.4 1 V *0.4 25.920.4 
7 20330.3 	10.110A 30.110.4 17.1103 25.1103 
8 223x04 21S*0A 313±04 16510.4 25f(10A 
9 23.2+07 	228104 323 ±0A 19)+03 278106 
10 az a + 64 	2n$+ as 3181 0.4 1393 o5 253+n3 
Standard 230+01 	22.0402 320 k0.3 19.0 f 112 2).0103 
Pmitve conaal (ftznavd): dprndmxadn; negative cunmoI: tM50; antibacterial 
activity measured by the nda Zone Tear (nnic mm). 
In case of ribosomal subunit of 512 protein, the ligand (9) had 
maximum negative Glide score and contributed five hydrogen 
bonds (Fig. G) followed by that of compounds (10 and 8) (Table 12). 
These compounds also showed better bioactivity results as 
compared to standard ciprolloxacin (Tables 7 and 8). 
The S12 protein is necessary for the translational accuracy. This 
ducking study proposes that these synthesized compounds have a 
similar affinity towards the ribosomal submrit of 512 protein of 
E soli as that of the standard cipmfoxadn. Hence, all of these de-
rivatives can easily dock in the active site residue of the 512 protein 
and forma docked complex and as a resu1tprcventthe translational 
acmracy of E. roll. This leads to the inhibition of formation of 
protein necessary for the transcription of E coil and disturbs the 
self-defense mechanism oflhe E cali species. 
2.42. Molecular docking of the synthesized compounds With active 
site of Cytochrome P450-14DM of C olbimns 
The binding site of ket0rnna201e (ligand present in the tem-
plate) is used as the active site in the Cytochrome P450-14DM 
model (Fig. 7). The results show that the overall trend of the 
interartion energies of all the derivatives is in good qualitative 
agreement with the in vitro antifungal activities. 
ligand (6) had no hydrogen bond but possesses 50 hydrophobic 
interactions and show maximum Glide score of -9.92. Whereas, 
ligand (7) had one hydrogen bond in the active site residue at His 
132 and carbomethoxy oxygen of carbomethoxyheptyl side chain 
(bond length 3.02 A), and glide score of -6.01. As shown in IFig. 8), 
compound (8) had no hydrogen bond but 72 hydrophobic in-
reractions and higher binding scare (7.59) as compared to that of 
control 0uconazole (-7.44 kcaI/moI). 
Among all the synthesized compounds, ligand (9) had 
maximum negative Glidescare as well as maximum binding energy 
with the active site of Cytocbrame P450-140M of C. albicam and  
contributed to maximum three hydrogen bonds (Fig. 8), followed 
by that of compound (10) which had two hydrogen bonds 
(Table 13).These compounds also showed betterbioactivity results 
as compared to standard 8uconazole (Tables 9. 10 and 13). Like 
standard drug hucona2ote. in case of compound (9) one of the 
rdbomaChoxy oxygen was forming hydrogen bonding interaction 
with the residues of Cytochrome P450-14DM at Ser 378 (bond 
length 3.22 A) and another with His 377 (bond length 3.24 A). The 
third hydrogen bond was formed between the oxygen atom from 
the hydroxyl group on 2'-hydroxyoctyl side chain and Tyr 64 (bond 
length 3.08 A). 
In case of compound (10), oxygen atom from the dihydroisox-
azole heterocylic ring tomis H-bonding interactions with the resi-
dues Ser 378 (2.R6 A) and another hydrogen bond was formed 
between the oxygen atom of the hydroxyl group on 8'-hydrox-
ycarbomethicsydecylside chainand 5er378 (bondlength 2.86 A) of 
Cytarhrome 450-14DM. It suggests that the affinity of all the syn-
thesized compounds to the potential receptor Cytochrome P450-
14DM may primarily attributed to their hydrogen and nan-
bonding interaction with the apaprotein part of the active site. 
The binding mode of the long chain isuxazole derivatives with the 
active site of Cytochrome P450-14DM provides a reasonable 
explanation for their antifungal activities. The antifungal activities 
of all the compounds are comparable to the control flurunazole. 
These results suggest that the addition of the alkyllcarbozyalkylf 
carbomethoxyalkyVhydroxyalky4)hydroxycarbomethoxy alkyl side 
chainswith 5-10 carbon atoms are optimal for antif ingal activities 
and binding of these inhibitors to the Cytochrome P450-14DM re-
ceptor. The S4 subslte is a hydrogen bond donor and acceptor re-
gion which interacts with the functional groups (carboxyl group, 
carbomethoxy group and hydroxyl group) on the3-prapylisoxazole 
and 3-propyl dihydraisoxaznle ring. To study the effect of sub-
stiments at 3-propylisozaznle and 3-propyl dihydroisoxazole bet-
erocyclic ring on their antifungal activities, the analogs with 
different side chains i.e. alkyl/calbwtyalkyl/carbomethozyahpn/ 
hydroxyalkyl(hydroxycarbomedloxyalkyI were designed and syn-
thesized. The binding mode of the docked molecules to Cyto-
chrome P450-14DM and their corresponding antifungal activities 
suggest that compounds with hydrogen banding donoror acceptor 
substituent like hydroxyl group exhibit higher antifungal activities 
than compounds (sands). 
25. Structure activity relationship (SAR) 
The physicochemical properties MW, MV. MR and king P of the 
compounds (6-10) are presented in (Table 5). The compounds (7.9 
and 10) form hydrogen bonds with the target proteins of C. aficans. 
Correspondingly, an the compounds have hydrogen bond interac-
tion with the 512 protein of E. coil. The structural activity study 
shows that antimicrobial activity is dependent on the oxygen atom 
Tabir9 
MlCZnd MBC a5o1ins u13-pmpyhisoxvnle and 3-pupyl-45darydrolmxazWe dmvatioa. 
Camywnds 	Crampppyae bcRd3 	 rira11111tsactYebdGtefta 
S. pyogenes 	S aureu< 	 P. crmiginosa 	KPneirnomae 	 £ ron 
MIC 	Mwe 	Mtc 	Met 	MIC 	Mae 	MIC 	MC 	MIC 	Man 
50 1011 so 100 IX >I00 50 >100 So 100 
9 50 100 50 >100 100 >100 100 >100 too >100 
25 So 25 loo 25 50 25 loo 25 50 
9 v 50 25 50 25 so 3s 'CO 25 50 
10 25 50 25 ten 50 lib 25 100 25 10(1 
Standard 125 125 635 12.5 125 25 615 25 625 12.5 
MW ip6lmlJ = minimum inNbitary concciitradan. Le the lowest concentration M the compound to initlbit the growth 0inhackinis completely; MBC (yg(ml) = minimum 
ba,Zenilmncenaadnq i.e. tile lovicst 0101enratiop al the ra01pauna [w Kl1ltpgr the haocsi' complerety.rosuve cnntml: dpmaoxadn. 
69i A. Agmud ercL/drop aojoumal ofMN;tvNlrnemisi 	]0(20)3)891-900 
T+Me9 
MVf o odfangl oltiVlry ofan the nmdsexvedLUlnPmushs(6-0)against s!aYNarE speoes or cDnelhdo. 
Camp. Tested Fungi (MIC 00% and MIC pglrn1J 
C albkans 	C tropirelis clihf8om C. parapsimis C. NUUi Cdu6une',is 
MW 	MFC 	MIC 	MFC MIC MEC 	MIC 	MFC MIC MFC MW MEG 
6 >256 	no 	>256 	>256 128 >256 	128 	>256 >256 >256 128 255 
2 >255 	>256 	>256 	no >256 >256 	>256 	>256 >256 >256 >356 >255 
128 256 128 	>256 128 >256 	>256 >256 >236 >256 128 no 
128 	256 	54 	>255 32 256 32 	126 64 128 32 256 
10 128 	>255 	128 	>255 64 128 	32 	>256 128 >256 128 >256 
Flu. >256 	>256 32 	256 8 128 4 32 32 >255 2 >256 
It. >256 	>256 	>256 	>256 0.12 >256 	on 	0.5 06 0.12 >256 no 
Flu. = Fluconamle, IL = Itramnazole. 
Table 10 
In r;nn andfunpal aaunty of all the synthesized compounds (6-m) asalnst dininl species or Ca'ESdd. 
Camp. Tested Elug(MIC 90% and MIt pgMn 
C nibicons 	 C nup;cAiv C. Fm9YYlost C clbironi Clropkdi 
MW 	MFC 	MIC MFC MIC 	MFC MIC MFC MW MC 
6 >256 	>256 	128 >256 256 	>256 >256 >256 >256 >256 
7 >256 129 >256 128 >256 >255 >256 >256 >256 >156 
8 128 	>256 	128 >25X 128 	>25f >256 >256 >256 128 
9 32 256 64 255 125 >256 128 >256 >2i6 >25G 
10 in 	256 	64 >128 118 	>255 >256 >256 >256 >256 
Flu. 8 >256 16 256 0.5 1 R R R R 
It 012 	>256 	1 5256 025 	0.5 R R R R 
Flu = nuconarote, le- Itraccnaate. -=- veeweyn te Ruconamk rod hacorimic. R - resstznc 
of isoxazole heterocyclic ring as well as an the nature of the sub-
stiment (IJydruxyl group, carboxyl group and rarbomethoxy group) 
on heterocyclic ring's side chains. Moreover, these compounds. in 
most of the cases, exhibited favorable calculated SAR parameters: 
rather high nemhol—water partitioncoefficient (log P) and low 
values (below 140 A3) of polar surface area (PSA) that is linked 
closely to higher bioavailability. This fact strongly prompted us to 
study these derivatives as potential new antimicrobial substances. 
The most favorable values of log P and PSA were found fur all the 
compounds due to the presence of isoxazole heterocyclic ring in 
their structures. 
Among compounds (6 and 7), compound (6) showed better 
antibacterial activity compared to compound (7) due to the pres- 
ence of isoxazole ring and carboxyoctyl side chain. In case of 
compound (s), the dihydroisoxazule ring contains propyl, octyl and 
carbomethoxyheptyl side chain. Whereas, in compound (9). dihy-
droisoxa2ale ring is substituted with propyl, hydroxyvctyl and 
carbomethoxyheptyl side chains and in compound (10), dihy-
droisoxazole ring is substituted with ptopyl. pentyl and hydrox-
ycarbomedioxydecyl side drains. The dihydroisoxazole derivatives 
containing hydroxyl group substituted side chains (compounds 9 
and 10) showed better activity compared to isoxazole)dihy-
droisoxazole derivatives containing non-hydroxy side chain (com-
pounds 6, 7 and 8) as they make more hydrogen bonds due to 
presence of hydroxyl group substituted side chains. The presenters 
of hydroxyl groups on alkyl(carbomethoxyalkyl side chains were 
medal in making the stable complexes through hydrogen bond and 
hydrophobic interactions within the active site of the selected 
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Tab Jr 11 
PMhr&amlysis for quality of model ofratl.4 with the template. 
Rmzcbararan plot analysis 
Most AdjnunI Generously Disalowth 
frronw atlo«ea all d 
Lyr P450-140M 	VAX 	IOA% 	19X 	02% CI) 
Template 	92.1% 76% D.o% 03%(I) 
targets in the bacteria and fungi.Thecompaunds(9 and 10) showed 
better docked complex, physiochemical parameter and higher 
binding energy compared to standard drugs ciprafloxacin and 
Ilucnnazole. 
Among all the compounds. compounds (e.9 and 10) have high 
drug-likeness score and high values of high octanoi—water parti-
tion coefficient (log P) indicating these derivatives as better anti-
microbial agent compared to compounds (6 and 7). The Clog P 
values were influenced enough by the presence of the hydroxyl 
group an alkyl/carbomelhoxyalkyl side chains. A good in vitro ac-
tivity of all the compounds was described to their song binding 
energies coupled with a high Iipophific character, which allows an 
optimal penetration into the cytosol. Even though the compounds 
(9 and 10) are endowed with goad interaction energies, an 
increasing hydrophilic character positively affects their ability to 
cross the membrane of the bactena and fungi. The lipophilic 
character of all the synthesized compounds combined With very 
low PSA values may be the main factor ensuring a good level of 
distribution in vivo. PSA values were in the range between 47.903 
and 68.131 A2 (Table 5). 
3. Concussions 
The proposed method for the synthesis of novel long chain 
isoxazole derivatives was simple and all the synthesized com-
pounds obtained in good yield. Prediction of the biological activity 
of these compounds by using the PASS software was successful to 
some extent The report of the study confirms traditional usage of 
these compounds as antimicrobial agents. However, large data 
must be generated through the pharmacognsdc studies before 
going for commercialization, The physicachelnical parameters 
suggested that most of the compounds possessed drug-like prap- 
erties. In general, the results showed there was a dependency  
between biological activity and lipophilicity, where MIC decreased 
with increasing lipophilicity.Thispresettt studyshowed thatall the 
title compounds were exhibiting antibacterial activities. These 
compounds were evaluated against yeast Among the synthesized 
compounds, compounds (9 and 10) showed antimicrobial activity 
against all tested microorganisms which is almost equivalent to the 
standard drugs nprofloxacin and fucamaole. Also, compounds (9 
and 1(I) had antifungal activity against tested clinical species of 
Candido which were resistant toflumnazole as welt as itracnnazele. 
The results of the docking experiments for the newly synthesized 
compounds (6-10), with the 30s ribosomal subunit were found to 
be in accordance with the in vitro antimicrobial activity data ob- 
tained. The binding sites of the compounds were found to be in 
close proximity to the binding site of the standard drug ciprollox-
arin. It was interesting to observe that even though the core 
structure of all the compounds was the same, the degree of inter-
action and binding patterns were found to be different We antic-
ipate that this kind afdocking and aitipathogcmc screening studies 
would help in designing of navel drugs that targets microbial 
protein synthesis. Morenveq the made of action of the long chain 
isoxazole and riihydcouozazn1e derivatives showed that the affinity 
of the lead molecules for Cytochrome P450-I40M was mainly 
attributed to hydrogen and their non-bonding interaction with the 
active site residues of fytochrome P450-14DM protein and binding 
with the home. which was similar to that of azoles antifungal 
agents. The studies presented here provide a new structural type 
for the development of novel antifungal agents 
4. Experimental protocol 
4.1. Physical and spectroscopic measurements 
Anhydrous conditions were achieved by drying flasks and other 
equipments in the oven. Reagents and solvents were afcomtneicial 
grade and were used without buffer purification. Undec-l0-enoic 
and (Z)-ocradec-9-enoic adds were obtained commercially from 
Fluka Chemical (Switzerland). (92, 12R)-12-Hydroxyoctadec-9- 
ennic (Ricinclic) and (9R 12Z)-9-hydrotpycrcts.rieg-12-enoic (Isa- 
ricinolic) acids were isolated from the natural sources, i.e. from 
Rxius comoruuis and Wrighteria BptarYo seed oils, respectively 
following Gonttine s partition method [401 and further purified by 
column chromatography. Thin layer chromatography (TLC) was 
vnit~6sms 
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performed on glass plates (20-5 cm) with a layer of silica gel 
(Merck. Mumbai. India 0.5 mm thickness) and was visualized in an 
iodine chamber. Silica gel (60—so mesh) was used for column 
chromatography. The cluent was a mixture of diethyl ether)ethyl 
acetate and petroleum ether in different proportions for different 
campaunds Solvents were dried and distilled before use. IRspectra 
were obtained by Shimadzu 8201 PC PT4R uses IBr pellet with 
absorption given in cm t.'H NMR Spectra were recorded in CDCI3 
on a Sinker DRX-400 instrument. The chemical shifts (6) were 
measured relative toTMS as an internal standard and are quoted in 
ppm. Coupling constants (5)  are expressed in Hertz (Hz). 13C NMR 
spectra were recorded at the Broker DRX-400 spectrometer in 
(Clz  with CDCI3 (t = 77. 00). 
41 Synthesis of compounds 
42.1. General procedure for the synthesis of long chain ulkyaoic 
acid (1) 
The long chain alkynot acid (1) which is used as the starting 
material was prepared by the previously reported method 131) 
41.7.1. Synthesis of 35-disubstituted isoxazale derivative of long 
chain atkynoic acid (6). 1,4-Phenylene diisocyanate (0.003 cool) was 
added to long chain alkynoic acid (1) (0.001 mol) in dry tetrahy-
drafuran (THF) (2D nrl).Triefhylamine(0.D03 mop was added to the 
meetwo mixture and this was heated to 8U -C Nitcubuton 
(0.003 mol) wag added in portions over a period of 6—B h, and then 
the reaction was heated for additional 2 h. The precipitate was 
observed. After heating, the reaction mixture was cooled. The re-
action was quenched with water (ro6 ml) and then allowed to stir 
at room temperature for 1 h. The polyurea (polymer) was removed 
by filtration and washedwieh THF. The solvent was evaporated on a 
water bath and then worked up with diethyl ether-water. Further, 
product(6) was purified by silica gel column with petroleum ether/ 
diethyl ether as eluent. The characterization data of novel com-
pound (6) are given below. 
10 	 C•2•  
Fig fl The interaction plot (ti8plct) of all the five molecules with the binclq site .,id., of 512 protein The goutI-5 m xespnSs roymllpzervWS (6-10)rperpvety and panel 4 
to cnnwol drug ciprnn Wacin.iM hydrogen bonds and hJu rophobicNletact elu ae shewnwhirb are horning the ligand within Me6mtling acre. 
A Mmod eral l Eumpeonjoumal o) Medirinei (Temshy ]4 (2013) 887-900 	 997 
TzbPe1 
The rgand molmilles with mmlber of mdet,dar imendlnns and the scores for 
enengrb ofbmdmg. 
Coma. hydrogen Hydrophobic Glide 8indiagenergy Iu8(KC1 
bends Interactions ftert (kc1IIMO1) 
6 3(2) 29(7) -1.97 -539 3.95 
7 3(3) in (J) 087 -£40 3,96 
8 4(3) 34(6) -314 -619 4.53 
B 5(4 3118) -125 -5.75 422 
II) 4 (3 2g (10) -0.64 -619 454 
❑prn. 3 (2) 10(3) -150 -5.69 4.17 
The number of residues ini olvM in the hydmzen 0 hydrophobic intercBQnj are 
lnovided in brackets with the total number of [ra1itucdoru the snoknee Is eapeñ-
cin&Thcbinding Ingy and-log IKa) values are caIevlotXr using%Starer The 
more negative is the guile scow, the better is the durkng Gpm: tlproiloncin. 
4212. 5-(Cmbog'oct'q-3-propyflsoxazo!c 	(6). 'Mrfte 	solid; 
MY = 79-80 `C; yield: 80%; IR (KB. mi 1): 3285 (OH stretching). 
2918 (CH stretching). 1702 (C=O stretching], 1465 (C=N stretch-
iug).'H NMR(CDU-j dH): 12.M Siii, s, COON), 698 (lH, s, CHring), 
235 (2H, t, )=7-52 11; CHICOOH), 218 (4H. two triplets merged 
together, (CH2)5-CH2, CH3CH2CHZ). 1.63 (2H. m. CH2CH2COOH), 
1.54 (2H. m, CH2CHZCH3). 1.28 (10H. bcs, CHH chain), 0.90 (3H, t, 
j = 7.21 Hz, Cli3). 13C NMR (COC(2, dc): 176.18, '67.86, 8237. 80.80, 
4426. 35.81, 32.68. 29.83. 29.68, 29.39. 29.01, 27.46, 25.61, 22.93, 
1410. MS (ESI): m(z = 290,210 [M + Na]', calculated = 290.308. 
422. Synthesis of 3,5-disubstimted and 3,45-himbsdmted-45-
dihydroisoxazole derivatives of long chain alkenoates (7-10) 
1,4-Phenylene disocyanate (0.03 mol). nitrobutatic (0.01 mul) 
and long chain alkenuates (2-5) (0.01 mol) were dissolved in dry 
benzene (30 ml). Triethylamine (25-50 drops) was added. The re- 
action mixture became turbid and a precipitate was observed. After 
S h at rellux the reaction mixture was cooled. The reaction was 
quenched with water (=5 ml) and allowed to stir at room tenl- 
perature for 1 h. The pnlyurea (polymer) was removed by filtration 
and washed with benzene. The solvent was evaporated on a water 
bath and then worked up with dierhyl ether-water, Further, the 
products (7-10) were purified by silica gel column with petroleum 
ether/diethyl ether as eluent, All these novel compounds were 
characterized foam their spectral data. 
422.7. 5-(Carbomemoxyucty))-3-propyl-4,S-dihydroisoxazale (7). 
Colorless oily liquid; yield: 85%; IR (KBr. cm-' ): 2931 (CH stretch-
ing), 1740 (C=O stretching). 1457 (C=N stretching). 'H NMR 
(COd 3, 5n):4.46 (IH. m, CH2-CH ring), 3.60 (3H.s. OCN3), 291 (1H, 
dd,JM,-It =16.70 Hz,JW-Or =10.00 Hz, CH-CHZring), 2.49 (IH, dd, 
Jkr-H - 16.80 H2. Jex1 = 8.10 Hz, CH-CHE ring), 2.25 (4H, two 
triplets partially merging, CH2COOCH3, fH2CIi¢H9). 160 (6H, m, 
CH2UhCH3, (Cf12)5-Ui2,. CHZCH2C000113). 1.25 (1OH. bcs, CH2 
Chain). 0.92 (3H, t. J = 7.30. CH,). 13C NMR (CDCI1 dc): 174.23, 
156.75. 7937, 5139, 42.01. 3522. 34.01. 29.72, 2932, 2925. 29.17, 
29.09.25.51, 24.86.19.74,13.72. MS (ES!): m/z- 305.700 (M +Na]', 
calculated = 306343. 
4.2.2.2. 5-(Carbometkoxyheptyl)-4-actyl-3-propyl-4,5-
d9tydroisoxozNe (8). Colorless oily liquid; yield: 83%; IR (KBr, 
cm''): 2928 (CH stretching), 1743 (CO stretching), 1462 (C=N 
stretching). IH NMR(CDC13,dx): 5.26 (2H, At HC-CH ring), 3.59 (3H, 
S. 0-CH3). 254 (2H, t, J = 7.60 Hz, CHXOOCX3). 2.42 (2H, C, 
J = 7.60 Hz CH,CHzCH3).195 (4H, m, H2C-CH-CH-CH),1.70 (2H, 
M. CH2CH2C000H3),156 (2H, in, CH2CH2CH3),1.20 (2011, brs, CH2 
chain), 0.91 (3H, t, j = 7.20 Hz. CH2CHxUHs), 0.81 (311, distt, CH). 
13C NMR (CDCI3, dc): 173.82, 159.24, 80.18, 52.85, 43.01, 35.55, 
34.89, 3128, 30.97, 29.98, 29.86, 29.69, 29.40, 2927. 29.10, 26.67, 
25.38,24.46,22.73,18.89. 13,96 M5 (ESI): mlz= 404,190 IM + Na]`, 
calculated = 404.504. 
4.2.2.3. 5-(Carbomethoxyhepty))-4-((2'R )-2'-hydrnxyoctyl ]-3-
propyl-4,5-dihydroisoxazole (9J. Yellow oily liquid; yield: 80%; IR 
(Rliq cm 1 ):3328(OHstretching),2924(CH stretching),1738(C=O 
stretching), 1447 (Ce N stretching). 111 NMR (CDC13, EH): 5.32 (2H, 
m, HC-CH ring), 420 (18, m, CH-OH), 3,60 (38, s. O-CH31. 2.65 
(2H. t, J = 7.54 Hz, CH2C000H3). 235 (2H. L J = 7.45 Hz. 
CH2CH2CH3), 2.10 (4H. m, H2CHC-CHCH2), 1.80 (111, m, CH-OH), 
1.68 RH, m, CHa[II2COOCH3),1.42 (2H, m, CH2CAZCH3),130 (18H, 
brs,CH, chain),0.95(3H,t.3=7.25 Hz, CH,CH,CH3), 0.87 (3H. distt, 
CH9). DC NMR (CDCI3, bd: t76.41,158.70, 60.01. 72i9. 52.85, 4341. 
39.56. 35.60. 34,84, 29.99. 29.75, 29,51. 29.39. 29.28. 29.01. 27.48. 
25.40.2491, 21.99.19.57.14.00. MS (E51): mfz=420.409 [M + Na]', 
calculated = 420.503. 
4.2.2.4. 5-((e'R)-8'-Hydrnxy(carbomethoxydecyl)J-4-pentyl-3- 
pmpyl-4.5-dihydroisaxaznle (10). Yellow oily liquid; yield: 75%; IR 
(IBr. cm"t):3294 (OH stretching), 2918 (CH stretching).1734(C=O 
stretching). 1468 (C=N stretching). 1H NMR (CDC 3, dn): 534(2K. 
in, HC-CH ring). 4.41 (1 H, m, CH-OH), 3.69 (38, s, 0-CH3), 2.55 
(21, t, J = 7.45 Hz, CHpCOOCH]), 2.29 (2H, t, f = 7.50 H; 
CH2CH2CH3).1,98 (4K, in, HaC1C-CHCH2).172 (111. m, CH-OH), 
1.67(2K, m, CH2CHZ000(H3). 1.90 (2H, m, CH2CH2043). 130(18K. 
br.s, CH2 chain), 0.95 (311, t,J= 7.25 Hz, CH2CH¢H3),0,87 (3H, distt, 
CU;). 13C NMR (COCK, dc):175.413.156.96~ 61.00.73.16.51.87, 42.05, 
39.02. 3490. 34.29, 29,82, 29,69, 29.47, 2937, 2929, 29.00, 2683. 
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24.98, 23.992L90,19.81,13.93. MS (BS[): m1z-420347 (M + Na(+ 
calculated = 420.503. 
43. Prediction of hidden biological potential of the synthesized 
compounds 
The activity of the molecule was predicted, using PASS (Pre-
diction of Activity Spectra for Substances) which estimates the 
probable biological activity profiles for compounds under study 
based on their structural formulas presented in.Metfile or.SDfile 
format using Marvin applet 141 ]. 
4.4. ADME & toxicity studies 
In silica ADME studies were performed by using ADME De-
scTiptms algorithm of Accelnjfi Discovery studio 2.5 in which 
various phaanacokinetic parameters Eke Aq.SoIubdity t421,huinan 
Table 13 
The ligznd molecules with number of molecular inrencdmu and the scores for 
strength ofbinding 
Cylmrmme P650.141M protein 
Molende Hydrogen iyaInatuobiL-  Clide llindmg energy kg(Kr1 
bonds interactions score (YcaI/Nq) 
6 0 50(8) -992 -7.20 528 
7 1 57(11) -Gal -737 5.40 
8 0 72 (17) -595 -7.59 5.56 
9 3 (3) 48 (12) -8.76 -8.56 630 
10 2123 51 t13) -83g -869 631 
Flit 1 22 f7) -626 -7.44 545 
The number orresidues involved in the hydrogen & Irydroplwbic interactions are 
provided in bnrkers with the total number of interaction the molecule is experi-
enthtl The binding metgy and -log (Ke) values are calculated using X-Seore The 
more negadvti is the glide scros, she better is the docking, nu: FluaonaaWc 
intestinal absorption [43], plasma protein binding (PPB) [44]; blood 
brain harrier (BBB) penetration [45(. Cytochrome P450-14DM in-
hibition 1461 and bepatotoxit1ry levels (47] were estimated for 5 
ligands. Obtained results were moss checked with the standard 
levels listed in (Table 2). Toxicity profiling of all the 5 ligands were 
performed by employing toxicity prediction-exfcbsibleprototol of 
Accehys discovery studio 2.5. 
Toxicity profile includes sneering for aerobe biodegradability 
developmental tozioty potentials, AMES mutagentdty, carcinogenic-
ity.andowlar&skin irdtznry 148).7eramgemhtyefeufi ofthe ligands 
were studied by using an online tool, OSBt6 property explorer (49]. 
4.5. Prediction ofphysirochemiml properties 
The octarsol—water partition coefficient ClogP being a measure 
of hydrophobicity(lipophilicity was calculated using Chearliraw 
Ultra 11.0 software (Cambridgcsoft Corporation) [501. The physi-
cochemical parameters including actanal partition coefficients
(miing PJ, MW, HBO, HBA. TPSA. and Rotatable bonds were calcu-
lated using a Molinspirafion server (hltinHen'v.molnspira 
tion.com/rgi-hin(preperties) and ChemAxon (chemicalize.arg). 
4.6. Rioattivify score 
The drugs were also checked for the bioactivity by calculating 
the activity score. All the bioactivity parameters were checked with 
the help of software ChemSketch 11 and Molinspiration drug-
likeness score online (wxnvmolinspiration.com). 
4.7. Antibacterial assay 
The antibacterial activity of the synthesized compounds was 
completed by the disk diffusion method and measured by Halo 
A Aamvd et nL/ Europeoa journal ofMedirmal CRerninry 70 (3019) 88]-D00 	 Ben 
Zone Ten [36.371. The MIC of synthesized compounds against 
bacterial strains was performed by the micro dilution ten and the 
results were observed visually and spectrophotometlica7Iy. 
4.9. Analungal assay 
Bacterial and fungal strains were obtained from microbiology 
laboratory as gift, where these strains were already characterized. 
Sabouraud dextrose agar (SDA), potato dextrose agar (PDA), 
oatmeal, and RPM! 1640 were used for agar dilution and macro-
dilution methadLThe Clinical isolates offing! including C olNfans, 
C tropicudis. and Candido purapeilosis were purified and submltures 
on SC. SCC, and PDA media before testing. To obtain the stock so-
lutions of the compounds, 200 mg/nil of the compound was dis-
solved in DM50. The compounds were diluted in solid and broth 
media to obtain a final concentration from 0.0312 to 256 mg/ml, 
using PDA and RPM( 1640 media. The Inocnhla of the yeasts were 
prepared from Ito 10 days mature colonies grown. 
49. Molecular modeling and docking 
49.1. Modeling of Cytuchrolne P450-14DM from G albicans 
Homology model of Cytdchromc P450-14DM was generated 
using ModelletYv9 package 151). Human Cytorhrome P450-14DM 
protein was chosen as the template (PDB id: 3LDG) which dis-
played 39% identity and 54% similarity with the Sequence of our 
protein. The five best models out of 100 models were shortlisted 
based on the lowest value ofthe Modeller objective function or the 
DOPE assessment score and with the highest GA341 assessment 
score. Finally, the best model was selected using Procheck analysis 
152) and thus the best chosen model has shown the presence of 
only one residue in the disallowed region similar to that of the 
template as revealed by Ramachandran plot 
492 Protein & grid preparation 
The crystal structure of 305 Ribusomal subunit 512 (PDB Id: 
1 JG. L Chain) was retrieved from protein data hank and the 
modeling of Cytoebrome P450-14DM was performed and the best 
model is selected. Proteins are prepared in Schrodinger protein 
preparation wizard including the addition of hydrogen atoms fol-
lowed by minimization and optimization using the OPLS force field 
in the premin option of Schiodinger Glide [53(. The shape and 
properties of the receptor are represented on a grid by several 
different sets of fields that pmvde Progressively more accurate 
scoring ofthe ligand poses. For512 protein, the grid is generated for 
the site containing StreplooryClu whereas for Cylochrame P450-
14DM protein, the binding site of ketoconazole is used as a clue 
for grid generation. 
493. Ligand preparation 
All the ligands were then prepared in Schrodinger Ifgprep 
wizard and predocking preparations were made where hydrogens 
were added followed by minimization and optimization in 
OPLS-2005 force field, finally 10 conformations for each ligand 
were generated and set ready for docking. 
49.4. Docking of ail five !goods on 572 protein end Cytochmme 
P450-74DM 
Docking was performed after preparation of ligand library, 
deletes and the grid in binding site of proteins. Our chosen soft-
vare Glide uses Systematic and Simulation method for searching 
he poses and ligand flexibility. In systematic method it uses in-
:remental construction for searching, and its output G scare is a 
:orvbination ofvarious parameters. The G scam is calculated as: 
C - Score = H bond 3 Lipo t Metal ± Site f 0.13OCoul 
t 0.0654W - BuryP - RotH. 
where: H bond = Hydrogen bonds, Upo = hydrophobic in-
teractions. Metal = metal-binding term. Site - polar interactions in 
the binding site, VdW - Vander-weals forces, Cool = columbic 
forces, Bury P = penalty for buried polar group. Rat B = freezing 
ratable bonds. As each ligand has 10 sterenisomers or conforma-
tions, so each conformation was subjected to extra precision (XP) 
module for detailed docking. 
495. Post docking amilysis 
For analyzing the interaction of docked protein-ligand complex, 
❑eplat program was used to check the polar and hydrophobic 
interaction between the receptor and ligand [54[. PyMOL was used 
in preparation of figures showing protein-ligand complex and also 
in the analysis of ligand-protein interactions 155). X-Score is used 
for calculating the binding energy and -lag (lid)  for each ligand 
[561. 
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(triazolothiadne nucleus) and the hydrmtyl group attached to the FA chain (4c and 4d) were 
found to be the most promising anticancer agents.  
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1. Introduction 
Nitrogen, oxygen and sulfur containing compounds are the 
most common heterocycles which serve as the core component 
of a large number of biochemical materials which are essential 
to fife such as nucleic acids. Oxadiazoles am used as support 
on which pharmacophores are placed to provide potent and 
selective medicines (Somani and Shirodkar, 2009). During 
the past few years, considerable evidence has been accumu-
lated that demonstrates the effiticg of 1,3,4-oxadiazoles 
including insecticidal, analgesic, diuretic, C NS depressant, 
antiviral, herbicidal, antihypertensive, pesticidal activities and 
these are cited in the literature (Deshmukh et al., 2011). 
Oxadiazoles also possess antitubereular (Rone ci al., 2012), 
antimalarial (Mohan et al., 2004), antileishmanial (Rastogi 
et al., 2006) and anticancer (Bondock at a1., 2012) activities. 
The 1,2,4-triazole derivatives possess a broad spatrum of 
activities including antimalarial, anticancer and antitubercular 
(Husain ct al., 2012; Patan or al., 2012) and also have a wide 
range of therapeutic properties like analgesic (Almasirad et al., 
201 I), insecticidal (Tirlapur and Tadmalle, 2011), hypoglyce-
mic (Nath at al., 2011), antiparasitic, herbicidal (Wang ct al., 
2011) and plant growth activities (Agg,uwal at al., 2011). 
The 1,2,4-triazole nucleus is extensively used in medicines 
(Aytaq et al., 2009). Due to ambidentate nucleophilic centers 
i.e. mercapto and amino groups, the 4-amino-1,2,4-trianol-3-
thiones can be considered as excellent starting materials for 
the synthesis of triazoIsthiadiazines. The substituted 1,2,4-
triazolo[3,4-b]-l,3,4-thiadiawne derivatives have been reported 
to possess antimicrobial activity mainly due to N-C-S linkage 
in the skeleton of triazolothiadiazine and also possess antican-
mr activity (Altintop et al., 2011; Badr and Barn, 2011; 
Mohammad at al., 2012; Prokash et al., 2011). These bihetero-
cyclic tdazolothiudiazine derivatives also possess a broad spec-
trum of pharmacological activities (E1-Shehry ct al., 2010; 
Komar at al., 2010). The literature survey (Lrmani and 
Kotresh, 2010; Mohsen, 2012) reveals that there are many 
examples of triaaale fused with pyridines, pyridazines, pyrimi-
dines, pyraxince and triavnes but triazolothiadiazines we not 
very common moieties. 
Earlier works (Sharma et al., 2011; Shaini et al., 2011) 
showed that these heterocycles were synthesized from different 
substituted carboxylic acids and hydrazides (other than long 
chain aikeayljhydroxyalkenyl hydrazides). Literature survey 
(Srivastava et al., 2010) also reveals that a minor change in 
the structure of 1,3,4-oxadiamles, 1,2,4-triazolee and 1,2, 
4-triamlo(3,4-b]-1,3,4-thiadiazines can lead to quantitative 
and qualitative changes in biological activity. Recently (Juhie 
et al., 2012), stearic acid (a saturated FA) analogs having 
1,3,4-osadiazle. 1,2,4-Iriazole and I,2,4-triazo o-[3,4h1l n3, 
4-thiadiawlc were reported as antidepressant and antimicro-
bial agents. Also, the usage of FAs shows an incasing trend 
in the treatment of neuropsychological disorders such as  
depression and schizophrenia (Sinclair at al., 2007; Yamima 
and Belmakmt 2009). Despite this, some of the FAs have been 
found to play a regulatory role in tumor growth progression 
and were reported as effective anticancer agents (Khan cl al., 
2011). Keeping in view the significance, the aforementioned 
facts of long chain alkenyl/hydroxyalkenyl carboxylic acids 
as potential pharmacophores and is continuation of earlier re-
search work in our laboratory on the synthesis of novel series 
of biologically active heterocyclic derivatives or FAs (Farshori 
etal., 2011), we herein report the synthesis of three different 
novel series of biologically important heterocyclic FA analogs. 
And evaluate in vitro anticancer activity against three different 
human cancer cell lines and normal human cells (PHMCs). The 
salient features of the procedure described here are taking 
short reaction time, not requiring elevated temperatures, the 
use of cheap reagents and easily available starting materials. 
2. Experimental protocol 
2.1. Materials and methods 
(Z)-octadec-9enoie add (purity, 97%) and undec-10-enoic 
acid (purity, 98%) were purchased from Fluka chemicals (Swit-
zerland). (9Z, 12R)-12-hydroxyoctndec-9-enoic acid (Ricinolic) 
and (9R, 12Z)-9-hydroxyoctadec-l2-cnoic acid (Isoricinolic) 
were isolated from the natural sources i.e. from Rictma romnm-
nis and Wrightin tinctoriu seed oils respectively, following Gun-
stones partition procedure (Gnnston, (954), general grade 
(GR) of solvents was used for the extraction purposes. Hydtu-
xy FAx were purified by column chromatography and charac-
terized by the spectral data FA esters were prepared by 
refusing the FAs in methanol in the presence of catalytic 
amount of concentrated sulfuric acid. Long chain alkenylf 
hydroxyalkenyl hydrazidc was used as starting material which 
was previously synthesized in our laboratory. All the products 
were purified by column chromatography. When required, sol-
vents were dried and distilled before use. Carbon disulfide, 
potassium hydroxide, pbency1 bromide, hydrazine hydrate 
were purchased from Merck, Mumbai, India. Thin layer chro-
matography (TLC) was performed an glass plates (20 x 5 cm) 
with a layer of silica gel G (Merck, Mumbai, India, 0.55 mm 
thickness). Developing solvents used were the mixture of petro-
leum ether-diethyl ether-acetic acid (75:25:1; viv). Silica gel 
(Merck, Mumbai, India, 60-120 mesh) was used for carrying 
column chromatography. IR spectra were obtained on Shima-
dzu 8201 PC FI-IR using ICBr Pellet with absorption given in 
em-1. III NMR spectra were recorded with Broker DRX 400 
Spectrometer (400 MHz) in CDCh, using TMS as internal 
standard. Chemical shifts (5) are quoted in ppm and coupling 
constants (.f) are given in Hz. 13C NMR spectra were recorded 
with Hruker, DRX 400 Spectrometer in CDCI3 (d = 77.00). 
Mass spectra were recorded on JEOL-SX 1021DA-600 Mass 
Spectrometer. 
2.2. Chereisrry 
2.2.1. Slmthess of novel series of 5-long chain a)keny)J 
b3'drosyyofkenyl-1.3-4-orodia:o1-2-Ihianes, 2(a-0) 
A mixture of 0.01 mot of long chain mk,nyI/hydrazyalkenyl 
hydrazide (Raul et al.. 2007) 1(a-d), 0.01 mol of potassium 
hydroxide and 10 mL of carbon disulfide was refuxed 
(80-90 'C) in 50 mL ethanol for 8 h. The reaction mixture 
was concentrated on water bath, Then cooled to room temper-
ature, acidified with dil. HCI at 0 °C and the solid product was 
separated out. After that the product was filtered and washed 
with cold waver. The solid products 2(a-d) wete then air dried. 
Further, the products 2(a-d) were purified by sit= gel column 
chromatography with petroleum ether: diethyl ether as eluent. 
Tie products were identified by spectral data. 
2.2.1.1. 5-(Dec-9-enyl)-(3H)-1,3,4nmdiazol-2-rh one, 2a. IR 
(KBr, cm '): 3215 (N-H stretching), 2921 (C-H stretching), 
1613 (C=N stretching), 1165 (C=S stretching), 1054 (C-0-
C stretching). 'fl NMR (CDCl , b J: 11).30 (III, s, Nil), 
5.81 (IH, tdd, Jy acn,  =6.48 Hz, J_,= 10.31 Hz, 
Jn-xe=17.24 llz, CHs=Cd), 5.01 (I H, do, J,,-,=10.31 
Hz. Jarne =2.00 H2, H2C CH), 4.92 (IH, dd, 
Jnr-n=1691 Hz, Jne-n2 =2.00 Hz. Hr CCII), 2.69 (2II, t, 
J - 7.50 Hz, CHz  a to ring), 2.01 (2H, m, CH3 CH-CH3), 
1.74 (211, re, Cr1, (i to ring), 1.30 (IOU, br.s, (CHi)5). '3C 
NMR (COCI3, bc): 166.8, 165.4, 123.0, 122.3, 30.9, 30.8, 
30.1, 29.9, 28.5, 27.1, 26.2, 24.2. MS (ESI): m/z = 262.880 
found [M+ Na]`, calculated [M+Na]+ - 263.146. 
2.2.1.2. 	S-(Hepiadec-8-cveyl)-(3H)-1,3,4-oxad!ozol-2-rhione, 
2b. IR (KBr, cnti '): 3218 (N-H stretching), 2925 (C-H 
stretching), (615 (C=N stretching), 1166 (C—S stretching) 
1059 (C-O--C stretching). 'H NMR (CDCI,, 8H):  10.g5 (111, 
s, NH), 5.35 (2H, m. CH=CH), 2.69 (2H, t, J - 7.58 Hz, 
CH,, n to ring), 2.01 (414, re, CH2CHCHCH,), 1.75 
(2H, m, CHy 0 to ring), 1.31 (20H, br.s, (CH,)10). 0.88 (3H. 
dist.t, CHs). '3C NMR (CDCI,, dry:  165.3, 163.2, 126.0, 
125.8, 35.0, 33.9, 31.0. 29.4, 28.9, 28.7, 28.0, 27.3, 26.8, 25.8. 
23.7, 23.4, 23.0, 22.0, 14.0. MS (FS) nom - 362.231 found 
[M4-Na], calculated [1'1+Na]*  - 361.481. 
2.2.13. S-[(8Z, 11R)-11-Hydroxyheptadec4-eny1J-(3H)-
1.3,4-oxadiazol-24d1one, 2c. IR (KBr. mn '): 3398 (0-H 
stretching), 3121 (N-H stretching), 2923 (C-H stretching), 
1625 (C—N stretching), 1159 ((=S stretching), 1056 (C-6-
C stretching). 'H NMR (CDCI3, b,d: L2.34 ((H, s, NH). 
5.47(21-1,m,CH=CH), 3.68 (IH, m, CHOH), 2.68(2H, t,J= 
7.49 Hz, CHz a to ring), 2.28(IH, m, CHOH), 2.04 (4H, m, 
CXyCEIrCHCHJ), 1.72 (2H, m, CH, P to ring), 1.28 (1811, 
br.s, (CH,),), 0.88 (3H, dist.t, CHs). '3C NMR (C Cl,, 8c): 
168.3, 164.2, 133.2, 125.1, 72.0, 37.3, 36.6, 35.1, 31.8, 30.1, 
29.7, 29.6, 29.1, 28.9, 27.2, 25.4, 24.0, 23.4, 14.2. MS (ESI) 
tuft = 376.689 found [M+Na]', calculated [M+Nat+  
377.420. 
2.2.1.4. 5-/(8R, 11ZJ-8-Hydrozyhepradeo-11-eyAJ-(317)-
13.4-oxadiazol-2-thiune. 2d. IR (KBr, cm): 3353 (0-H 
stretching), 3159 (N-II stretching), 2921 (C-11 stretching), 
1619 (C=N stretching), 1152 (C=S stretching). 1051 (C-0-
C stretching). 'H NMR (CDCI, bu):  11.56 (IH, a, NH), 
5.37 (2H, m, CH=CH), 3.59 (IH, m, CHOH), 2.70 (2H, t, 
J = 7.50 H2 CHi  rc to ring), 2.25 (III, m, CIIOH), 2.00 
(4H, m, CH2CH—CHCH2), 1.72 (2H, m, Cl!, 9  to ring), 
1.29 (ISH, br.s, (CH,),), 0.87 (3H, dist.t, CHI). t'C NMR 
(CDCIh, bc): 167.3, 165.8, 133.0, 125.9, 71.9, 37.1, 36.4, 35.1, 
32.8, 31.4, 30.9, 29.9, 28.2, 27.6, 26.9, 25.2, 24.6, 23.1, 14.0. 
MS (ESI) m/c = 376.450 found [M+Na]', calculated 
[M+Na]+ = 377.420. 
2.2.2. S)inthesis of novel series of 4-amino-5-long eliani alkenyl/ 
hydraxyalkenyl-1,2,4-trlarol-3-lhiones, 3(a-d) 
To a solution of 0.01 mol oC potassium hydroxide in 50 mL 
absolute ethanol, 0.01 mot of long chain alkenyl/hydroxyalke-
nyl hydrazide, 1(a-d) and 0.013 mot of carbon disulfide were 
added. The reacliva mixture was stared for 8 h at roam tem-
perature. The reaction mixture was then diluted with 30 ad , 
ether and stirred for additional I h. The potassium salt without 
further purification was used for the next step. 0.02 Mot of 
hydrazine hydrate in 20 mL water was g aduaJ1y added to 
the above potassium salt with constant stirring and then the 
reaction mixture was relluxed for 4 h. During rcduxing, H2S 
gas released and the reaction mixture color changed to light 
pink. The reaction mixture then cooled and acidified with 
cone. HCI. The white solid product was separated out which 
was then filtered and washed with water. The solid products 
3(a-d) were then air dried. The products 3(a-d) were purified 
by silica gel column chromatography with petroleum ether:-
diethyl ether as eluent. The products were identified by spectral 
data. 
2.2.2.1. 4-Aniino-S-(&c9-eny!)-),2,4-uviazol-3-ihrorw, 3ct. JR 
(KBr, cm'): 3228 (N-H stretching), 2924 (C-H stretching), 
1599 (C—N stretching), I L86 (C—S stretching). 'H NMR 
(CDCh, dtt):  11.60 (I H. s, NJ!), 5,79 (IH. tdd, 
JH  erne 
 
= 6.70 Hz, Jwrrz  =10.10 Hz. Jx-xe=17.20 Hz. CHy 
C.W, 5.01 (111, dd, Jr,:-n=  10.10 lIz.  Jn _ne-1.30 Hz, H7, 
(CH), 4.94 (1H, dd, Jn,-a=17.20 Hz, Jfl_e,=1.30 Hz. 
H5C CH), 4.57 (2H, br.s, NH,), 2.74 (2H, t, J = 7.50 Hz, 
CHz  a to ring), 2.02 (2H, m, CH3  CH-CH,), 1.70 (2H, vet, 
CH, p to ring), 1.29 (1011, bes, (Cl1)4). 13C NMR (CDCI,, 
bc): 167.0, 160.5, 139.1, 121.2, 33-7, 31.8, 29.5, 29.4, 28.8, 
27.2, 26.1, 24.8. MS (EST: rn/z = 276.830 found [M+Nu]', 
calculated [M +Na]+ = 277.347. 
2.2.2.2. 4-Amino-5-[(8Z)-1ey1ue1ec8-enyl2l-1,2.4-temctit-3-thi-
one. 3h. 1R (KBr, cm): 3224 (N-H stretching), 2924 (C-H 
stretching), 1595 (C=N stretching), 1179 (C 	stretching). 
'II NMR (CDCI3, br): 11.32 (I H, s, NH), 535 (2H, rn, 
CH=CH), 4.55 (2H, br.s, NH,), 2.75 (2H, t, J = 7.50 Hz, 
Oli, a to ring), 2.03 (411, m, C1I,CH 2HCH2h 1.68 (2H, 
m, CH, p to ring), 1.29 (2013, bra. (CH, 10), 0.88 (3H, dist.t, 
CHs). "C NMR (CUC13, br: 167.3, 165.6, 134.6, 122.1. 
365, 34.1, 30.9, 29.2, 29.0, 28.9, 28.6, 27.4, 26.0, 25.9, 24.6, 
24.1, 23.2, 22.4, 14.2. MS (ESE) mfz = 374.912 found 
[M+Na]', calculated [M+Na]' - 375.508. 
2.2.23. 4-Amino-5-((8Z, l!R)-ll-hydroxyhepladecA-enylJ-
12,4-IritrzoF3-lh7one. 3e. IR (KBr, cm'): 3380 (0-H stretch-
ing). 3214 (N-H stretching), 2924 (C-H stretching), 1622 
(C=N stretching), 1162 (CS stretching). 'H NMR (CDCI,, 
8H): 12.17 (IH, s, NH), 5.41 (2H, ne, CH=CH), 4.51 (2H. br.s, 
Please die this mifdelri press as. ALmad,4ci aL. Syunc&s and anticancer activity oflnvg chain suhsttnttd l,3,4-cxd1aznto2-th!ony124-tria-
2uI-3-tbicuc, and 12 -trio olo [3,4-b -I 3.4-ilwinia1ne derivatives. Ambian fomnal of.. Chemistry. (2014).. 1tttp://dr.doi,orofI0. 1016,' 
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NH2). 3.69 (1H, m, CHOH), 2.70 (2H, t, J = 7.51 Hz,  CHz  a 
to ring), 2.26 (lH, m, CHOH), 2.02 (4H, m, CHs-
CH=CHCIIIJ, 1.67 (2H, m, CH i to ring), 1.29 (18H, br.s, 
(CH2)e), 0.89 (3H, disL.t, CH3). t3C NMR (CDCI3, .c): 
168.0, 163.2, 135.1, 121.9, 71.9, 37.3, 36.2, 34.9, 32.8, 30.1, 
29.9, 29.6, 29.1, 28.2, 2B.0, 27.8, 25.4, 24.0, 13.9. MS (PSI) 
mf. - 392.014 found [M+Nal', calculated [M+Na]' 
= 391.507. 
2.2.2.4. 4-Anibno-5-[(8R, HZ)-8-Ll'drosY1aepradc-ll-enYlJ-
1?.4-rriazol-3-rkione, 3d. IR (KBr, cm 1 ): 3376 (0-H stretch-
ing), 3217 (N-H stretching), 2921 (C-H stretching), 1619 
(C-N stretching), 1164 (C=S stretching). IH NMR (CDCI3, 
Sp.): 12.09 (IH, s, NH), 5.47 (2H, m, CHCH), 4.56 (2H, br.s, 
NH2), 3.68 (1H, m, CHOH), 2.72 (211, t, J = 7.50 Hz,  CH, z 
to ring), 2.27 (111, m, CROH), 2.04 (4H, m, CHe-
CH=CHCHz), 1.69 (2H, m, CH2 p to ring), 1.28 (ISH, bra, 
(CH,),), 0.87 (3H, dist.t, CH3). t'C NMR (CDCI3, or): 
167.8, 164.4, 135.2. 122.5, 70.4, 37.2, 36.9, 34.0, 32.4, 30.1, 
29.8, 29.5, 292, 28.7, 29.0, 27.6, 25.4. 23.5, 14.2. MS (ESI) 
m/z = 392.210 found [M+Na]', calculated [M+Na]+  
= 391.507. 
2.2.3. Synthesis of navel serkes of3-long dial,, alkeny/l 
kydroxyafkcny?6-phenyl-711.1,2.4-!rirate(3.4-bJ-1.3.4-
/Jiiadianines, 4(a-d) 
To a solution of 0.0025 mot of 4-amino-5-long chain alkenyl/ 
hydroxyalkenyl-I,14tri;aol-3-thiones, 3(ad) in 15 mL absolute 
ethanol, 0.0025 mot of phenacyl bromide was added and the 
reaction mixture was retained at 90 °C for 121r an oil bath. 
When all the triuzQ1e was consumed the reaction mixture 
was neutralized by ammonium hydroxide. The product was ex-
tracted with dich1osQmethane: water. The organic layer dried 
over anhydrous sodium sulfate. The solvent was evaporated 
on water bath from the oily product 4(a-d). Further, the prod-
ucts 4{a-d) were purified by silica gel column chromatography 
with petroleum ether: diethyl ether as elnent. The products 
were identified by spectral data. 
2.2.3.1. 	3. (DVn9-enyl)lephenyl-7H-1.2,4-triazolof3,4-hJ- 
1.3,4-lhiadiazine, 4a. IR (KBr, cm): 2923 (C-H stretching), 
1604 (C=N stretching), 1125 (C-N stretching), 652 (C-S-C 
stretching). 'H NMR (CDCI3, OH):  7.55-7.39 (5H, m, ArH), 
5.78 (III, tdd, Ja-0h=672 Hz, J,,-nr = 10.00 H. 1o_& -
17.24 Hy CHi=Cf1), 5.01 (111, dd, Jn-n = 10.12 Hq, 
Jaa _ux = 1.35 H. H7CH). 4.94 (IH. dd. Jn.. n =17.23 
Hz. Jn,-n, = 134 Hz, Hy(rCH), 4.12 (2H, s, Cl!, ring), 
2.75 (2H, t, J = 7.50 Hz, CHa a to ring), 2.04 (211, m, CHz. 
CH-CH,), 1.69 (2H, m, CH, P to ring), 1.28 (1011, br.s, 
(CHa)5). °C NMR (CDCIb, Sea: 168.1, 165.4. 160.8, 134.8, 
1329, 132.5, 131.1, 130.5, 124.8, 122.5, 115.4,36.2, 34.2, 33.9, 
32.8, 32.1, 31.7, 30.9. 29.4, 25.0. MS (EST): m/z = 378.041 
found [M +Na]' , calculated [M+Na]" = 377.459. 
2.2.3.2. 3-[(87)-XeFiadcc-8-entull-fi-phcrYl-7H-1,2,4-triasal-
of3,4-b]-),3.4-thiadiasire, 4b. IR (KB,, cm): 2926 (C-H 
stretching), 1599 (C=N stretching), 1120 (C-N stretching), 
660 (CSC stretching). 'H NMR (COCk, Fn): 7.61-7.40 
(5H, m, ArM), 5.35 (2H, m, CH=CH), 4.09 (2H, s, CHz ring), 
2.67 (211, t, J = 7.54 Hz, CH, x to ring), 2.03 (4H. m, CHI  
CH==CHCH2), 1.64 (211, m, CH2 i to ring), 1.25 (2011, br.s, 
0.87 (3H, dist.t, CHs). "C NMR (CDCI3, Sc):  168.3, 
165.6, 160.5, 134.5, 132.5, 132.0, 131.5, 130.8, 129.7, 125.0, 
122.1, 35.5, 34.0, 32.5, 30.5, 29.0, 28.9, 28.4, 28.0, 27.2, 26.6, 
25.5,24.4.24.0,23.1, 21.4, 14.3. MS (FSr)m/r = 474.971 found 
[M +Na]+, calculated [M +Na]+ = 475.620. 
22.3.3. 3-f(SZ, 11R)-11-H1droxylwpIadec8-enY11-6-Phny(-
7H-1,2.4-triaroiof3,4-bj-1,3.4-thiadi¢ine, 4c. IR (KBr, cm'): 
3360 (0.H stretching), 2922 (C-H stretching), 1513 (C=N 
stretching), 1115 (C-N stretching), 665 (C-S-C stretching). 'H 
NMR (CDCI3, 6td: 7.60-7.35 (5H, in, ArHJ, 5.40 (211, m, 
CH=CH), 4.10 (211, s, CH, ring), 3.62 (111, m, CHOH), 2.72' 
(2H, 4 J= 7.50 Hz, CHr a to dug), 2.28 (111, m, CHOH), 
2.01 (411, m, CH,-CR CHCHI 1.68 (211, m, CHz (1 to ring), 
1.29 (18H, br.s, (CH2)9), 0.87 (311, dist.t, Clfy). '3C NMR 
(CDCI3, dc): 167.0, 164.1, 163.8, 135.1, 132.7, 132.2, 131.4, 
130.1, 123.4, 123.0, 121.9, 112.8, 36.3, 34.8, 33.9, 32.4, 30.3, 
29.9, 29.5, 29.2, 28.7, 28.3, 27.8, 26.6. 24.7, 24.4, 14.2. MS 
(EST) m/z = 492.106 found [M+Na]+, calculated [M+Na]+  
- 491.619. 
2.2.3.4. 3-[(8R, 1)2)-8-Aydraxvltepladen/Yen11j-6-plreny-
7H-1,2,4-lriazolo/3,4-bJ-1,3,4-Nriadiuzine, 4d. IR (KBr, em'): 
3382 (0-H stmtching), 2924 (C-H stretching), 1615 (C=N 
stretching), 1122 (C-N stretching), 667 (C-S-C stretching). tH 
NMR (CDCI1, bH);  7.58-7.35 (SH, m. ArH), 5.37 (2H, m. 
CH=CH), 4.19 (211, s. CHy ring), 3.64 (III, m, CHOH), 2.69 
(211, t, J = 7.50 Hz,  CHa a to ring), 2.28 (111, m, CHOH), 
2.04 (4H, m, CH2CH=CHCH,), 1.65 (211, m, C112 (i to ring). 
1.28 (ISH, br.s, (CH2)9), 0.87 (3H, disLt, CH,,). 13C NMR 
(CDC13, did: 167.8, 166.2, 161.4, 133.2. 132.6, 131.9, 131.5, 
130.6, 129.6, 123.1, 122.5, 70.2, 37.1, 36.5, 32.8, 32.6. 30.3, 
29.8, 29.4, 29.1, 28.5, 28.0, 27.8, 27.2, 25.8, 23.9. 14.1. MS 
(ES!) m/z = 492.110 found [M+Nu]', calculated [M+Na]+  
= 491.619. 
2.3. In vitro anticancer activity 
2.3.1. Blood peripheral monmtuc1ear call isolation 
Fresh blood (2D-15 niL) was kindly provided by blood bank, 
Jawaharlal Nehru Medical College, Aligarh Muslim Univer-
sity, Aligarh. The blood sample was diluted with the same vol-
ume of phosphate buBk saline (PBS). After that, the diluted 
blood simple was carefully layered on Ficull-Histopaque (Sig-
ma Aldrich, USA). The mixture was centrifuged at 400g for 
30 min at 20-22 -C. The undisturbed lymphocyte layer was 
carefully transferred out. The lymphocyte was washed and pel-
leted down with three volumes of PBS twice and resuspended 
RPMI-1640 media (Sigma Aldrich, USA) with antibiotic and 
antimycotic solution (Sigma Aldrich, USA) 10%, v/v feral calf 
serum (FCS) (Sigma Aldrich, USA). Cell counting was per-
formed to determine the PBMC cell number with equal volume 
of trypan blue (Yeap et al., 2007; Yang et al., 1999). 
2.3.2. MIT assay 
The PBMCs/HeIa73ep3 BJMCF 7 cd1 fines were maintained 
in RPMI 1640 (Sigma Aldrich) culture medium supplemented 
with (0% h.t-inactivated fetal cull serum and antibiotic anti-
mycotic solution (Sigma Aldrich). The cells were plated at a 
density of 5'< 103 coils per well in a 96-well plate, and cultured 
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for 241t at 37°C. The cells were subsequently exposed to 
drugs. The plates were incubated for 48 h, and cell prottfera-
lion was measured by adding 20 pL of Mn (Sigma Aldrich) 
dye (5 mgjmL in phosphate-buffered saline) per well. The 
plates were incubated for a further 4 h at 37 °C in a humidified 
chamber containing 5% CO,. Formosan crystals formed due 
to the reduction of dye by viable cells in each well were dis-
solved in 150 pL dimethyl sulfnxide, and absorbance was read 
at 570 nm. The absorption values were expressed as the cell 
viability (%), according to the control group as 100%. The 
concentration required for 50% inhibition of cell viability 
(ICso) was calculated using the software "prism 10". 
3. Result and discussion 
3.1. Che..isrry 
Earlier in our laboratory it has been reported That some other 
1,3.4-oxadiqzoles substituted with fatty add chain possess 
antibacterial activity (Banday or al,, 2010). Otte to the biolog-
ical importance of heterocyclic FA analogs, synthesis of target 
compounds 2(a-d), 3(a-4), 4(a-d) and evaluation of anticancer 
activity were reported in this paper. All reactions are outlined 
in Schemes I and 2. The physicochemical parameters of all the 
newly synthesized compounds are tabulated in Table 1. Three 
novel series of oxadiazoltbiones, 2(a-d); lriqzmthiunw, 3(a-d) 
and triazolothiadizines, 4(a-4) were obtained from the corre- 
sponding unsaturaled/hydroxy unsaturated FAHs, 1(a-d). 
These FAHs were used as starting material which was previ-
ously synthesized in our research laboratory from the corre- 
sponding FAs. The cycl'izqtion reaction of carbon disulfide 
with FAHs gives a novel series of 5-long chain alkenyl/hydro i- 
yalkenyl-l,3,4cxadia ol-2-thiones, 2(a-d). 4-Amino-S-long 
chain alkenyl/hydroxyaTenyl-1,2,4-triazol-3-thiones, 3(a-d) 
were, obtained by reaction of carbon disulfide and FAHs on 
treatment with hydrazine hydrate. Furthermore, biheterocyclic 
derivatives of FAs i.e. 4-amino-5-long chain alkenylfhydroxy 
alkenyl-6-phenyl-7H-1 2 4-triazolo[3,4-b]-1,3,4-lhiadiazi nes. 
4(q-d) were synthesized from corresponding compound 3(a-d) 
and phenacyl bromide by ring closure reaction. The 1,3,¢ 
oxadiazole-2-thiones and 1,2,4-lriaaol-3-thiones may exist in 
thiol-thione tautomeric forms, but in solid stare thione form 
dominates. Such observations am also reported in the  
N—N 
1 N 	N—ml  
31u-0) 	 O rvu, 
Nam 
Scheme 2 Ring closure synthetic pathway of novel series of 
3-long chain alkenyUhydroxyalkenl-6-phenyl-7H-1,2,4-triazol- 
43,4-h1-1,3,4-thindfazines, 44.-d). Reagents and conditions (1) 
PhCOCH,Or, EIOH, re ux (90°C), 12h, neutralization with 
NH4 OH. 
literature (Banday and Rauf, 2009). Structure of compound 
2b appeared in the literature also, (Tohwal et al., 2009) but 
without spectral data All reactions were monitored by using 
thin layer chromatography (TLC) time by lime. Products were 
purified by column chromatography. The structure of all the 
newly synthesized compounds was determined on the basis 
of their Ill, tH NMR, "C NMR and mass spectral dam. Char-
acteristic [M +Na] ion peaks were observed for all the com-
pounds under study. A detailed spectral description for 
compound 2a, 3n and 4a is discussed below. 
IR spectrum of compound S-(dec-9-cnyl)-(3H)-1,3,4-oxa-
diuzol-2-thione, 2a revealed characteristic bands at 3215 cm' 
for N-H stretching, 2921 cm-' for C-H stretching and the 
detection of C=eIN stretchingband at 1613 cm ', C—S stretch-
ing band at 1165 cm I and C-0C strelchin g band at 1054 cm 
for evidence of ring closure of 1,3,4-oxadiuzul-2-thione ring. No 
peak was observed around 2600-2550eni t for the Ihiol 
group, further confirmed the structure of compound 2a. In 
the 'H NMR spectrum of compound 2a, characteristic peak 
was observed for N-H proton at 6 10.30 as singlet, in addition 
to peaks of FA chains. The 13C NMR characteristic peaks for 
compound 2a were observed at 6 166.5. 165.4, 123.0 and 122.3. 
Further evidence for the formation of 2a was obtained by 
recording the mass spectrum which showed the [M+Na]' 
ion peak at m/z 262.880. Similarly, the structures of com-
pounds 2(b d) were confirmed from their spectral data given 
in spectral section. 
RCONHNH,_ 
l(- d) 
P0. ma, W 
N—N N—NH 
RIfH>'SH ~~b,~ R 	S R 	51I R~ 
NHr 	 NH+ 
2(a d) 	 31a-d) 
Scheme 1 Synthetic pathway for two novel series of 5-long chain alkeayl(hydroxyalkenyl-1,3-4-oxadiaznl-2-thiones, 2(n-d) and 
4-amino-along chain alkenylfhydroxyalkenyl-1,2,4-triqznI-3-thioncs, 3(a-d) showing thiol-thione tautomerism. Reagents and conditions: 
(i) CSz, KOH, EtOH, refux (80-90 °C), 8 h, acidification with HCI up to pH 3. (i) CS,, KOH, EtOH, stir, room temperature, S h. (iii) 
Et2O, stir, room temperature, 1 h. (iv) N2H<.2H2O, redux (90 °C), 4b, unification with HCl up to pH 3. 
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Table I Physicochemical properties of all the newly synthesized compounds, 2(a-d), 3(a-d) and 4(a-4). 
S.No. Compound code R Molecular formula 	Physie9 state MI'. ("C) % Yield 	Melee. wt. 
2a C,aHz0N2OS While powder 86-S 90 240.157 
n 
2 3a \/y^ryI  CnllteN<S Rbite powder 84-86 90 251.358 
3 42 n  CmHcaNa3 Brown sticky liquid - 65 354.470 
4 2b C19H34N2OS Whitc pewder 8789 SU 336.492 ,(5N_) 
5 3h C,sH3 NsS White powder 76-77 85 352.519 
6 4b Ca,Ne0N15 Brown sticky liquid - 62 452.631 
, 2e CrE3.N203S Yellmv solid 76-78 80 354.431 
rni 
8 3e C.yHaeN4OS Yellow solid 6244 78 368.518 
9 4c CrFomM4OS Brown sticky liquid - 60 466.630 
on 
10 2d CwHr.N2O2S Yellow solid 75-76 84 354.431 
II 3d /` 	,, C,9H3jN,OS Yellow solid 64-66 80 368.518 
12 dd CirHeoNaOS Brown sticky liquid - 60 468.630 
M.P.: Melting poim. 
	
The structure of compound 4-amirm-5-(dec-9-enyl)-1,2,4- 	for the Ihiol group, further confirmed the thinne structure of 
tria,nI-3-tluonc, 3a was confirmed by the appearance of 	compound 3u. The 'H NMR characteristic peaks were 
absorption bands at 3228 cm l  for N-H stretching, 	observed at S 11.60 as singlet for N-H proton, 5457 as broad 
2924 cm ' for C-H stitching, 1599 cm ' for C--N stretching 	singlet for NHi  protons. The 13C NMR characteristic peaks 
and for C=S stretching, the absorption band appeared at 	for compound 32 were observed at .5167.0,  160.5, 139.1 aad 
1186 cm-'. No peak was observed around 2600-2550 cn ' 	1212. In addition, ev'sdencc for the formation of 3a was 
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obtained by recording the mass spectrum which showed the 
[M+Na]t ion peak at mfz 276.830. Similarly, the structures 
of compounds 3(b-d) were eonfixmed from their spectral data 
given in spectral scctiun. 
The structure of compound 3-(dec-9-enyl)-6-phenyl-7H-
1,2,4-triazulo[3,4-b]-1,3,4-thiadiatinc, 42 was confirmed by 
the appearance of absorption bands at 2923 cm' for C-H 
stretching, 1604eom 1 for C=N stretching, 1125 cm t for 
C-N stretching, 652 cm' for C-S-C stretching. The disap-
pearance of absorption peaks for N-H and CS stretching 
further confirmed the structure of compound 4a. The 'H 
NMR characteristic peaks were observed at b 7.55-7.39 as 
multiplet for five aromatic protons, S 4.12 as singlet for two 
ring protons. The disappearance of 'H NMR peak for N-H 
proton further confirmed the structure of compound 4a, The 
11C NMR characteristic peaks forcumpound 4a were observed 
at h 168.1, 165.4, 160.8, 134.8, 132.9, 132,5, 131.1, 130.5, 124.8, 
122.5, 115.4 and 36.2. Confirmation for the formation of 4a 
was also obtained by recording the mass spectrum which 
showed the [M+Na]` ion peak at m/u 378.041. Similarly, 
the structures of compounds 4(b-4) were confirmed from their 
spectral data given in spectral station. 
3.2. In vitro cytotoxic mnluatian and structure-nctirit~' 
relationship 
Cnntentramn m yM 	 hi vitro cytotoxicity of all the newly synthesized compounds 
Fig. I (continued) 
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(2a-d), (3a-d) and (4a-d) was measured by Mn 13-(4,5-dim- 
ethylthiamlyl-2)-2,5-diphenyltetrazolium bromide] assay 
against a panel of three different human amcer cell lines 
namely; human hepatocellular carcinoma (Hep3 B), human 
breast adenocarcinoma (MCF 7) and human cervical Carci-
noma (HeLa). These cell lines are procured from Cell Reposi-
tory-National Centre for Cell Silence, Pane (India). Normal 
human cells (PBMCs) were also used for the determination 
of cytotoxicity of synthesized compounds. The MTT assay is 
a colorimetric assay for measuring the cellular growth that 
reduces the tetrazolium yellow dye MTT, to its insoluble for-
mazon (purple color) by mitochondrial dehydrogenases of liv-
ing cells. MTT is used to determine the cytotoxicity of 
potential drugs and other toxic compounds. The insoluble pur- 
ple formaxan product is dissolved into a colored solution by 
the addition of a suitable solvent, At certain wavelength, the 
ahsorhance of this colored solution can be measured. The po- 
tency of the drug in causing cell death can be concluded 
through the production of dose-response curves when the pur-
ple fonnzn was produced by untreated control cells. Cones 
of dose-dependent effects of (2a-d), (3a-d) and (4a-d) on cell 
viability or different human cancer all lines (Hep3 B. MCF 
7, HeLa) and normal human cells (PBMCs) am displayed in 
Fig. I. Doxorubicin and 5-fluorouracil were used as standard 
drugs. Experiment was performed in a triplicate. For each of 
the tested drug IC50 was calculated and the results are sumnla-
rized in Table 2. Experiments revealed that there was a sub-
stantial increase in cytotoxicity in cancer cell lines with 
increasing exposure to drug concentration i.e. showing low 
ICen values and our in-house synthesized drugs were not 
showing marked effects on normal human cells (PBMCs) i.e. 
showing high IC30 values. None of the synthesized compounds 
showed cytotoxicity to normal human cells (PBMCs). The 
present study showed that among the three human cancer cell 
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Table 2 Showing anticancer data (IGnn values in pM) of all the syulhesizW drugs and standard drugs against t&ee different human 
cancer cdl lines and normal hummn cells. - 
S. No. Compound codes Hep3 P MCF 7 	- HeLa PBMC 
1 	- M 08.94±15 13.60+2.5 11301153.'. 35.323.3.1' 
2 	- 21i 16.42f 15 19.00±2.5 17.6052.3- 	- 39.1231 
3 2c 09.00 } 1.6 15.90 + 1.6 1290 k 1.3 45.42 14.1 
4 2d I0.I0 t 26 16.83 116 13.30 1 3.3 41.38 + 2.5 
5 3s 69:1010.8 14.00 }0.6 11.IO 12.1 39.1231.6 
6 36 16.60 1 1.2 19.90 t 0.7 18.80 * 1.3 .43.83 f 1.9 
7 3c 09.4B + 1.4 132010.5 .. 16.20+2.4 33.5712.3 
B 3d 09.96 f 2.8 14.50 ± 1.6 .':' 15.82 i 3.1 35.2511.9 
9 4n 	- 07A0 t 2.2 10.30 t M 08.01313 32.78 t 2.9 
10 41, 09.49 t 1.5 11.27 124 10.03 2 1.7 >50 
11 4c 06.50k 2.4 08.59 - 1.5 08.83 f 1.4 >50 
12 4d 0].36±1.6 08.80'-2.1 06.00 i 3.1 39.12'_-3.1 
Daxu' 02.35 ± 1.2 03.12 + 1.7 03.56 f 2.7. 09.23 1 2.6 
5-Fr1' 03,54 t 2.1 04.12 + 2.3 	-( 02.78 t 2.6  08.91 t. 1.9 
Standard drop used for reference 
DDxorabion. 
° 5-FlaoroumN. 
lines tested, Hep3 B cells were found to be sensitive to all the 
tested compounds while HeLa and MCF 7 cells were found 
to be sensitive to some selected compounds. The obtained re-
sults revealed that compound 2a, 2c, 2d, 3a, 3e, 3d, 4a, 4b, 
It and 4d showed remarkable inhibitory activities against dif-
ferent human cancer cell lines and were also comparable to the 
standard drugs. 
On the basis of structure-activity relationships, it could be 
concluded that 1,2,4-triazulc fused with the 1,3,4-thiadiazine 
ring was found to have better antitumor activity than those 
of 1,2,4-Iriazoles and 1,3,4-oxadiuzoles. The structural activity 
study also shows that anticancer activity is also dependent on 
the nature of alkenyl(bydroxyalkenyl FAchain. From ICsa val-
ues a number of correlations can be made. It is apparent from 
the IC so values that, all the tested compounds show modenew 
to good cytotoxicity against different human cancer cell lines. 
For C10  terminal alkenyl FA chain residue which is substituted 
at 5-position of 1,3,4oxadiaxol-2-thione (compound, 2a) and 
at 3-position of 1,2,4-triazol-3-thioue (compound, 3a) leads to 
a remarkable increase in potency against human hepatocellnlar 
carcinoma cells (ICsu  value of 08.94 + 2.5 and 09.20 ± 
1.5 pM, respectively). Incorporation of the 1,3,4.thiadiazlne 
ring with the 1,2,41riazole ring having C10  terminal alkenyl 
FA chain residue at 3-position of 1,2,4-triamb-[3,4-b)-13,4-
thiadiazine (compound, 4a) leads to an increase in cytotoxicity 
against all the three human cancer cell lines ; ICsn values of 
07.40 3 2.2 pM (against Hep3 B cells), 10.30 f 2.7 µM 
(against MCF 7 cells), 08.01 z 1.3 pM (against HeLa cells). In-
crease in carbon chain length (C,r) ofinternal alkenyl FA chain 
residue at 5-position of l,3,4-oxadiazol-2-thione (compound, 
2b) and at 3-position of 1,2,4-viazol-3-thione (compound, 31,) 
leads to high IC50  values i.e. ICs,  value was above 16.42 riM 
against all the three tested human cancer cells. In case of 
1,2,4±riazolo-[3,4-bl-l,3.41hiadiavne ring system, even the 
chain length of the internal alkenyl substituent at 3-position 
(compound, 46) was increased (C„) still it displayed good anti-
tumor activity against all the three cancer cell lines (ICsp value 
of 09.49 t 1.5 gM against Hep3 B cells, 11.27 + 2.4 pM 
against MCF 7 cells and 10.03 t 1.7 pM against Hcla cells), 
this may he due to the fused ring system. Presence of the 
hydroxyl group on alkenyl PA chain residue which is attached 
to 1.3,4-oxadiazol-2-thiou at 5-position (compound, 2c and 
2d) was responsible for an increase in potency against hepato-
cellular carcinoma cells (IC5o values of 09.00 3 1.6 and 
10.10 = 2.6 pM, respectively). Also, in caw of 1,2,4-tria2ole, 
the presence of the hydroxyl group on the alkenyl FA chain res-
idue at 3-position was responsible for increased cytotoxicity of 
compound 3c and 3d against Hep3 B calls (IC50 value of 
09.48 ± 1.4 and 09.96 t 2.8 pM, respectively). For compound 
4c and 4d, there were two reasons for an increase in potency 
against all the three cancer cell lines: the presence of the hydro-
xyl group on the alkenyl fatty acid substituent and the other 
was the presence of fused ring system i.e. incorporation of thi-
adiaziun with the triazole ring (IC50 values of 06.50 3 2.4 4M 
against Hep3 B cells, 08.59 ± 1.5 pM against MCF 7 cells, 
08.83 ± 1.4 pM against HeLa cells and 07.36 3 1.6 pM 
against Hep3 B cells, 08.80 + 2.1 pM against MCF 7 cells, 
06.00 t 3.1 gM against HcLa cells, respectively). These initial 
findings lead to further derivatization of heterocyclic FAS. 
Investigation of feasible mechanists of preventing cancer cell 
lines propagation is in progress. 
4. Con hision 
We described here the synthesis of novel heterocyclic fatty acid 
analogs and in vitro anticancer activity evaluation of synthe-
sized compounds against different human cancer cell lines 
and PBMCs by MIT assay. Anticancer activity results re-
vealed that the synthesi2ed compounds are non-toxic to the 
normal human cells and can be used safely for the treatment 
of cancer without damaging normal cells. The results of cyto-
toxic study also show that, all compounds possess moderate to 
good activity but compounds 4c and 4d were the most prom-
ising cytotoxic agent with ICsa  values below 08.83 f 1.4 pM 
against all the three tested human cancer cells (Hep3 B, 
MCF 7, AeLa cells) due to the presence of the hydroxyl group 
on FA chain and fusel ring system (triazuluthiadiaane 
Pleasecitc, this wrack in press as: Ahmad, A. et al- Synthesis and anticancer aeti•ityof tong chain substituted l,3.4oxadiawl-2-ttnone, 1,2,4-tria-
col-3-thione and 1.2,4 nazolu [3.4-b]-1.3.4ldaBnar dsrwatbaas Arabian Journal of. Chemistry. (2014.3, th[[p://dsdai.org110.1016/ 
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nucleux). From this study, it cu be concluded that the potency 
of drugs depends on the nature of FA chain and the heterncy-
cGc ring sysrem. From these studies, it is comprehensible that 
further derivatization of different heterocyclic analogs of fatty 
acids can serve as new templates for antitumor chemotherapy 
and could probably lead to more active molecules in the area 
of cancer chemotherapy. 
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Abstract The efficient cyclocondensation reaction of 
fatty acrd hydrazides with thioglycolic acid (TGA)/mer-
capto acetic acid and Thin lactic acid under anhydrous 
condition in the presence of catalyst anhydrous ZnC12 in 
dimethyl fonmmide solvent is described. The synthesis 
provides the product, substituted thiazolidinone, in appro-
priate yield. The synthesized compounds were character-
ized by R, 1H NMR, 13CNMR, and mass spectra and these 
compounds were tested for in vitro antibacterial activity 
against the representative group of Cram-positive and 
Gram-negative bacteria such as Pseudumonas aeruginosa 
(ATCC-27853), Fscheric/tia colt (ATCC-25922). Strepto-
coccus pyugenes, and Rlebsiella pneumonia (Clinical iso-
late), Methicillin resistant Staphylococcus aureus (MRSA 
+ve), and also tested for antifungal activity against 
AspergWusftmügaies, Tricbophyron menragrophytes, Pen-
icillium mameffei. Camfida albicans. Minimum inhibitory 
concentration, minimum bacterial concentration, and min-
imum fungicidal concentration were determined for the test 
compounds along with the reference standards used. 
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Abbreviations 
TGA Thioglycolic acid 
TLA Thin lactic acid 
TLC Thin layer chromatography 
DMF Dimcthyl Onmamidc 
DMSO Dinnethyl sulfoxide 
Introduction 
Thiazolidinone derivatives have vast medicinal importance 
in the field of pharmaceutical chemistry (Verma and Saraf, 
2008). 4-Thiazolidinone, a saturated form of thiazole with 
carbonyl group on fourth carbon, has been assumed as a 
magic moiety (wonder nucleus) with all types of pharma-
cological activities such as and-HwVagent (Pareek at al., 
2011), antidiarrheal, anticunvulsant. antidiabetic, antihista-
minic, anticancer, Ca*r channel blacker, PAF antagonist, 
antituben:ular (Dubey at al., 2010), antioxidant, hypo-
glycemic, inhibition of gastric H+ KC-A7Pase, CFTR 
(cystic fibrosis transmemhrane conductance regulator pro-
tein)inhibitor(MaetaI., 2002). antiplatelet-activating factor 
a-antagonist, antifungal (Mis(ry and Dcxai, 2004). and 
antituberculosis activity. 4-Thiazolidinone derivatives also 
have the good antimicrobial activity. Morbidity and mor-
tality are the most common enteric bacterial infections 
mostly in Indian subcontinent areas, tropical part of Africa 
(Qadri of at 2005) and part of South America (Devasia eral., 
2006). The world's most common and serious infectious 
diseases like dysentery and diarrhea (Zhang el al., 2006; 
Shaheen et al., 2004) are caused by Escherichia roll. 
symptoms of these diseases are stomachache, cramps, 
bloating, or tenderness (Yoder et a[., 2006). to spite of these 
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ABSTRACT 
The nucleophilic ring opening of epoxy fatty esters was carried out using the amino-t,2,4-triazole to yield substituted 
derivatives ofU-amino alcohol. The synthesis of the substituted beta amino alcohols has been achieved by refluxing 
equimolar quantities of long chain epoxy esters (epoxy fatty esters) and 4-amino-1,2,4-h'iazole in dieb1ommatbaue to 
yield following compounds, methyl 10-(4'-amino-1',2',4'-iriezole)-11-hvdroxy undecanoate (V), methyl 9-(4'-amino-t', 
2',4'-triazole)-10-hydroxy octadecanoate (VI), methyl 9-(4'-amino-1',2',4'-triuzole)-10,12-dihydroxy octadecanoate 
(Vii), methyl 12-(4'-amino-1',2',4'-triazole)-9,13-dihydroxy octadecanoate (VIII). Bpoxides ofestets of fatty acids were 
obtained by reaction of esters of fatty acids with m-cbhnoperbenzoic acid. All the newly synthesized compounds were 
characterized by lit, 'B NMR, 13C NMR and mass spectrometry. 
Keywords: Triazoic; Epoxide of Ester of Fatty Acid; Ring Opening 
1. Introduction 
fl-Amino alcohols are very important class of organic 
compound and this type of organic moiety is found in 
various biologically active alkaloids and peptides [I]. 
These fl-amino alcohols are synthesized by ring opening 
reaction of epoxides with a variety of elecnophilic and 
nucleophilic reagents trader microwave assisted reaction 
condition as well as at the elevated temperature [2] and 
long reaction time. The ring opening of epoxide has been 
also carried out under mild conditions, but this needs 
expensive catalysts, large excess of reagents and solvents 
[3]. 
In the field of organic synthesis, the epoxides are im- 
portant intermediates, because of the high reactivity of 
their three member oxirane ring [4]. The inherent polarity 
and the maximum strain in the epoxide ring, allows the 
ring to react with a variety of Lewis acids nucleophilic 
reagents, such as amines, alcohols and thiols, to form 
corresponding /3-amino alcohols 1,2-diols [5], and (1-
hydroxysulfides [6], respectively, catalyzed by various 
Lewis acids, fl-Amino alcohols are medicinally very im-
porWnt as they possess antimalarial parasitic activities [71 
and also used in the synthesis of antihypertensive drugs 
[g]. 
Corresponding awhor.  
fl-Amino alcohols are easily converted into many other 
molecules such as amino acids and amino sugars [9]. A 
literature survey revealed that although various epoxy 
ring containing fatty acid esters have been used for the 
synthesis of a variety of olcochemieals [10] yet. Except 
the recent report by the Biswas et ill. [I1], there is no 
report on the ring opening of epoxides of fatty acid esters 
with amino tdazole. Recently, ring opening of terminal 
fatty acid methyl esters with other nucleophilic reagents 
was reported in the literature [121. Keeping in view, the 
above mentioned synthetic and biological properties of 
(J-amino alcohols, we have planned to synthesize these 
derivatives of fatty acids. Therefore, we report here the 
synthesis of substituted fl-amino alcohols, synthesized by 
ring opening reaction of fatty acid epoxides with 
4-atuino-1,2,4-triazole in dichloromethane. 
2. Result and Discussion 
Various heterocyclic compounds from fatty esters bear-
ing terminal or internal double bond were reported as 
potent dipolamphiles. All these compounds were oh-
wined in good yield. In this paper, we report the ring 
opening reaction of epoxy fatty ester with a nucleophile, 
hem, the amino group of the 4-amino-1,2,4-triaxole act as 
nucleophile, to form the substituted fl-amino alcohol 
Copyright © 2013 SciRes. 	 FNS 
